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Abstract 
Ventilator-associated pneumonia (VAP) is a common complicating condition amongst 
patients mechanically ventilated in the Intensive Care Unit (ICU). It is a common 
reason for antibiotics to be administered. The diagnosis of VAP is challenging and 
amongst patients in whom VAP is suspected, approximately a third will have infection 
confirmed. Therefore many patients receive antibiotics for VAP despite the condition 
not being present. Antimicrobial resistance (AMR) is a growing global concern and the 
overuse of antibiotics is an important factor in increasing AMR. The ICU is an 
environment with high antibiotic use and improving antibiotic stewardship is a priority. 
Rapid biomarker-based diagnostics could achieve this by expediting the diagnostic 
process. 
In this thesis I present the findings of a multi-centre validation study of a novel 
bronchoalveolar lavage-based biomarker test. The diagnostic value of the measured 
biomarkers is discussed and the optimum biomarker-based diagnostic test for use in 
VAP is presented. I subsequently present a multi-centre randomised controlled trial in 
which the biomarker-based test is assessed in the clinical environment to determine 
whether it does indeed result in improved antibiotic stewardship. Trial outcomes are 
reported and implications are discussed. 
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Chapter 1. Introduction 
1.1 Definition of ventilator-associated pneumonia (VAP) 
Ventilator-associated pneumonia is hospital-acquired pneumonia (HAP) occurring in 
patients who are undergoing intubation and mechanical ventilation. Conceptually this is 
inflammation of the gas exchange areas of the lung, the parenchyma, caused by an 
infectious agent. Definitions of VAP are difficult since obtaining histological evidence 
of alveolar inflammation (pneumonia) is impractical in critical care patients and there is 
little consensus on histological and clinical definitions. It is for these reasons that 
working definitions and surrogate ‘gold standards’ of VAP diagnosis have been 
surrounded by considerable controversy for decades. 
The histological features of VAP, although considered to be the true ‘gold standard’ of 
diagnosis, lack consensus. Histological evidence demonstrates that VAP has a 
predominance for dependent regions of the lung, is patchy and can be distributed within 
large areas of non-specific alveolar damage resulting in histological evidence of 
pneumonia only being apparent on one or two slices of lung segment, which could 
easily be missed(Rouby et al., 1992).  
In a prospective study of 39 patients who died while receiving mechanical ventilation, 
lung histology was evaluated by four pathologists(Corley et al., 1997). The pathologist 
assessed specimens for pneumonia based on consensus of pathologist opinion and 
according to previously described criteria by Johanson et al(Johanson et al., 1988). 
There was consensus between all four pathologists on diagnosis for 77% of patients (7 
patients with pneumonia and 23 without pneumonia). Six patients judged not to have 
pneumonia by consensus pathologist opinion were reclassified as having mild to 
moderate pneumonia based on the predefined criteria. Interestingly one patient judged 
to have pneumonia due to invasive fungi by consensus of opinion, was not classed as 
pneumonia by criteria due to an absence of inflammation. Fungi are generally 
considered to not be pathogenic organisms in VAP(American Thoracic Society, 2005), 
yet in this study a total of four patients had invasive fungi, one with typical neutrophilic 
infiltration of bronchopneumonia and another with lymphocyte and plasma cell 
inflammation.  
The consensus reached in this study describes the earliest stages of pneumonia as 
beginning in small bronchi with accumulation of neutrophils. Adjacent alveoli become 
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oedematous before complete infiltration and obliteration by neutrophils. This advances 
to macroscopic consolidation or formation of abscess in some cases. In the later stages, 
the infiltrate can be replaced by a myxomatous connective tissue resulting in an 
organising pneumonitis. Macrophages can be identified in the alveolar space scavenging 
debris, with neutrophils remaining in fibroinflammatory tissue. 
Since histological evidence is not routinely available, clinical definitions based on 
collections of signs and clinical investigations make up working definitions of VAP. 
There are numerous criteria, which vary greatly in their complexity and can be divided 
into clinical definitions (have diagnostic utility at the bedside) and surveillance 
definitions (used on a population scale to monitor VAP epidemiology). All definitions 
require the onset of symptoms to be 48 hours after the initiation of mechanical 
ventilation. VAP is often divided into early- and late-onset VAP, although the cut-off 
varies in the literature between 4-7 days(Trouillet et al., 1998; Chastre and Fagon, 2002; 
American Thoracic Society, 2005; Forel et al., 2012) 
The predominant clinical definitions used are those put forward by the American 
Thoracic Society and Infectious Diseases Society of America(American Thoracic 
Society, 2005),the British Society of Antimicrobial Chemotherapy (BSAC) 
criteria(Masterton et al., 2008) and the Association of Medical Microbiology and 
Infectious Diseases Canada(Rotstein et al., 2008). These criteria are based in clinical 
signs and chest x-ray (CXR) findings and are summarised in Table 1. 
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Definition Radiological Clinical Clinical Use of CPIS 
American 
Thoracic 
Society & 
Infectious 
Diseases 
Society of 
America 
New or 
progressive 
CXR 
infiltrate 
And at least 2 
of: 
Temperature 
>38
o
C 
Leucocytosis 
or 
leucopaenia 
Purulent 
tracheal 
secretions 
 Recommend: 
If CPIS ≤6 for 3 
days, early 
discontinuation 
antibiotics 
British Society 
of 
Antimicrobial 
Chemotherapy 
New or 
persistent 
CXR 
infiltrate 
And: 
Purulent 
tracheal 
secretions 
And: 
Increased 
oxygen 
requirement 
Core 
temperature 
>38.3
o
C 
Leucocytosis 
(>10,000/mm
3
) 
or leucopaenia 
(<4000/mm
3
) 
Recommend: 
CPIS to guide 
short-course 
therapy 
Association of 
Medical 
Microbiology 
and Infectious 
Disease 
Canada 
New 
infiltrates, 
progressive 
changes or air 
bronchogram 
on CXR 
And at least 2 
of: 
Temperature 
>38
o
C or 
<36
o
C 
Leucocytosis 
or 
leucopaenia 
Purulent 
tracheal 
secretions 
Decrease 
PaO2 
 Recommended: 
Calculate CPIS. 
If  <6 then 
infection 
unlikely and 
decision for 
antibiotics 
should be 
carefully 
considered 
Table 1: Clinical definitions of VAP. CPIS, clinical pulmonary infection score(Pugin et al., 1991; Singh et 
al., 2000) 
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All three of the above guidelines recommend the use of the clinical pulmonary infection 
score (CPIS) to guide antibiotic use. The CPIS was proposed by Pugin et al as an early 
clinical scoring system for VAP(Pugin et al., 1991). The CPIS was derived in a small 
cohort of 28 patients of whom 13 had VAP. The CPIS criteria are presented in Table 2. 
In the original derivation study, a CPIS >6 identified patients with VAP. The diagnostic 
accuracy of this score will be discussed in a later section. It should be noted that the 
CPIS includes the results of semi-quantitative culture from endotracheal aspirate (ETA). 
Therefore the full score can only be calculated 2-3 days after the day of suspicion. The 
greatest value of a clinical infection score would be to correctly identify patients at the 
moment of suspicion. At this point the results of semi-quantitative cultures would not be 
known and so a modified CPIS is used which excludes the final microbiology criteria.  
Diagnostic feature Score = 0 1 2 
Tracheal secretions Rare  Abundant Abundant and 
purulent 
CXR infiltrate None Diffuse  Localised 
Temperature (
o
C) ≥36.5 and ≤38.4 ≥38.5 and ≤38.9 ≥39 or ≤36 
White blood cell 
count (x10
9
/L) 
≥4.0 and ≤11.0 <4.0 or >11.0 <4.0 or >11.0 plus 
band forms ≥50% 
PaO2/FiO2 (mmHg) >240 or ARDS  ≤240 and no ARDS 
Culture of tracheal 
aspirate (semi-
quantitative 0-+++)  
No growth or ≤+ Growth >+ Culture >+ plus 
same bacteria seen 
on Gram stain 
 
 
The clinical criteria described above are relatively simple criteria that aim to guide 
clinical decision-making on an individual patient basis. In contrast, case-definitions for 
surveillance purposes are more cumbersome. These are generally used for retrospective 
Table 2: The Clinical Pulmonary Infection Score (CPIS)(Pugin et al., 1991). 
    
  5  
analysis of population level data. The two main definitions used are the Hospitals in 
Europe Link for Infection Control through Surveillance (HELICS) criteria which is now 
coordinated by the European Centre for Disease Prevention and Control 
(ECDC)(European Centre for Disease Control, 2010) and the American Centers for 
Disease Control and Prevention (CDC) definition(Horan, Andrus and Dudeck, 2008) 
(Table 3). The CDC criteria have in recent years been superseded by a new diagnostic 
paradigm which will be discussed in a later section. The new criteria no longer define 
VAP, rather a collection of ventilator-associated complications. 
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HELICS Radiological 
Two or more serial CXR or computerised tomography (CT) scans 
suggestive of pneumonia in patients with underlying cardiac or 
pulmonary disease. In patients without pulmonary or cardiac disease one 
definitive CXR or CT is sufficient. 
Clinical 
And at least one of: 
Fever >38
o
C 
Leucopaenia (<4000 WBC/mm
3) or leucocytosis (≥12,000 WBC/mm3) 
Clinical 
And at least one of the following (or at least two if clinical pneumonia 
only (PN4 and PN5 below)). 
New onset of purulent sputum or change in character of sputum. 
Cough, dyspnoea or tachypnoea. 
Suggestive auscultation (rales, bronchical breathing, ronchi or wheeze). 
Worsening gas exchange (eg. O2 desaturation, increased O2 requirements 
or increased ventilation demand). 
Microbiological 
PN1: Positive quantitative culture for minimally contaminated lower 
respiratory tract specimen (eg. bronchoalveolar lavage (BAL) or 
protected specimen brush (PSB)). 
PN2: Positive quantitative culture for possibly contaminated lower 
respiratory tract specimen (eg. endotracheal aspirate (ETA)). 
PN3: Alternative microbiology methods including blood culture, pleural 
fluid culture, needle aspiration from pulmonary or pleural abscess, 
histological examination or positive examination for viruses or particular 
pathogens (eg. Legionella, Mycoplasma). 
PN4:Others including sputum culture or non-quantitative lower 
respiratory tract culture. 
PN5: No positive microbiology. 
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CDC Radiological 
X-ray findings must have at least one of: new or progressive and 
persistent infiltrate; consolidation; cavitation or pneumatocoeles in 
infants ≤1 year. These findings need to be present in two serial x-rays in 
patients with underlying disease or in one x-ray in patients without 
underlying disease. 
Clinical 
At least one of: 
Fever >38
o
C. 
Leucopaenia (<4000 WBC/mm
3) or leucocytosis (≥12,000 WBC/mm3). 
Altered mental status with no other cause in ≥70 years old. 
Clinical 
And at least one of (two if clinical diagnosis only PNU1 (below)): 
New onset of purulent sputum, change in sputum character, increased 
respiratory secretions or increased suction requirements. 
New onset or worsening cough, dyspnoea or tachypnoea. 
Rales or bronchial breathing. 
Worsening gas exchange. 
Microbiology 
PNU1: ‘Clinically defined pneumonia’ in the absence of microbiology 
data. 
PNU2: ‘Pneumonia with common bacterial or filamentous fungal 
pathogens and specific lab findings’. These specific lab findings include 
blood culture; pleural fluid culture; positive quantitative culture from 
minimally contaminated lower respiratory tract sample (BAL or PSB); 
≥5% BAL-obtained cells containing intracellular bacteria on direct 
examination; or histological examination. 
PNU2: ‘Pneumonia with viral, Legionella, Chlamydia, Mycoplasma, and 
other uncommon pathogens and specific lab findings’.  
PNU3: ‘Pneumonia in immunocompromised patients’. Criteria for 
immunocompromised patients are less stringent than for immune 
competent patients. 
 
  
Table 3: VAP criteria used for surveillance. 
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1.2 Epidemiology 
1.2.1 VAP in the context of healthcare-associated infections 
Healthcare-associated infections (HCAI) are a priority for the National Health Service 
(NHS). It is estimated that 300,000 HCAI occur annually and result in at least 5000 
deaths a year(National Institute for Health and Care Excellence, 2014). The estimated 
cost of HCAI is £1 billion per year(National Audit Office and Office, 2000; National 
Audit Office (NAO), 2009) and it has been estimated that a high proportion of HCAI 
could be preventable (up to 70% catheter-related blood stream infections)(Umscheid et 
al., 2011), allowing for a significant resource reallocation. 
The overall prevalence of HCAI from UK and European point prevalence surveys has 
been very similar. The estimated prevalence of all HCAI in England is 6.4%(Health 
Protection Agency, 2011) and in Europe 5.7%(European Centre for Disease Prevention 
and Control, 2012b). In both of these surveys ICU wards have represented a minority of 
patients (2.6% in UK and 5% in Europe) yet have had the highest prevalence of HCAI 
compared to other specialties, with 23% in the UK and 19.5% in Europe. Recent data 
from the USA reports 9% of critical care patients surveyed have a HCAI(Magill et al., 
2014). A point prevalence survey by Health Protection Scotland specifically with 
regards to ICU HCAI reports a prevalence of 5.6% in Scottish ICUs(Health Protection 
Scotland, 2011). 
Respiratory infection accounts for a significant proportion of all HCAI. HAP accounts 
for 23% of HCAI in the UK and 26% of HCAI across Europe. Pneumonia represents 
approximately 50% of HCAI on the ICU(Health Protection Agency, 2011; Health 
Protection Scotland, 2011). 80% of HAP in Scottish ICUs were classed as VAP(Health 
Protection Scotland, 2011). 
1.2.2 Epidemiology of VAP 
The accuracy of defining the epidemiology of VAP is determined by the surveillance 
definition used. As previously described, surveillance case-definitions vary 
considerably to clinical definitions. This has led to a discrepancy between clinically 
observed rates of VAP and those that are reported by national or international 
surveillance systems(Michetti et al., 2012).  
The reported incidence of VAP in clinical studies generally ranges from 9-28%(Chastre 
and Fagon, 2002). Randomised controlled trial (RCT) data from 1998, which measured 
VAP as an outcome measure, reported VAP occurring in 18% of patients undergoing 
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mechanical ventilation(D. J. Cook et al., 1998). Two contemporary epidemiological 
studies, one a global study of 1,873 patients found that VAP occurred in 15.6% of 
mechanically ventilated patients(Kollef et al., 2014) and a European study of 1,735 
patients found that VAP occurred in 14-19% of mechanically ventilated patients 
(depending on age grouping)(Blot et al., 2014).  
Different methods of respiratory sampling can significantly alter the observed VAP rate. 
In a single-centre before-and-after study, diagnosis based on clinical criteria and 
endotracheal aspirate (ETA) was changed to VAP diagnosis based on culture of 
bronchoalveolar lavage (BAL) above a threshold of >10
4
 colony forming units per ml 
(cfu/ml)(Conway Morris et al., 2009). The reported incidence of VAP fell from 18 per 
1000 ventilator days in the ETA period to 9 per 1000 ventilator days in the BAL period. 
The incidence of VAP varies amongst patient groups. VAP is more common in trauma 
patients than other patient groups. In a retrospective analysis using the CDC/National 
Healthcare Safety Network (NHSN) criteria for VAP the incidence in trauma patients 
was 18% and 3% for non-trauma patients(Cook, Norwood and Berne, 2010). This study 
also found that the mortality amongst patients with VAP in the trauma and non-trauma 
groups was 11% and 34% respectively, from which the authors conclude that although 
VAP is more common in trauma patients it may well be of less consequence in this 
patient group. Patients with acute respiratory distress syndrome (ARDS) are a 
particularly challenging group in which to diagnose VAP. In a prospective study to 
determine the incidence of VAP in patients with ARDS, patients meeting inclusion 
criteria for ARDS underwent bronchoscopically guided respiratory 
sampling(Markowicz et al., 2000). VAP was diagnosed on the basis of culture growth at 
specific thresholds for the sampling methods used. VAP occurred in 36.5% of patients 
with ARDS in comparison to 23% of non-ARDS patients. In a further trial evaluating 
neuromuscular blockade in ARDS, VAP occurred in 28.9% of patients but the 
occurrence of VAP was not associated with an increase in mortality(Forel et al., 2012). 
1.2.3 VAP surveillance 
The surveillance of VAP and its relevance to the epidemiology of VAP requires specific 
discussion. A considerable number of interventions have been studied for the prevention 
of VAP and these have shown that VAP rates could be reduced(Lorente, Blot and Rello, 
2007; O’Grady, Murray and Ames, 2012). This has led to a perception that VAP is 
entirely preventable and that VAP rates can be used as an indicator of quality of 
care(Klompas, 2010; Walsh, Morris and Simpson, 2013). However, as described in the 
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previous section, the case definitions used can greatly influence the number of cases. It 
should be noted that infection control teams that are separate to the ICU teams, using 
case definitions that differ from the clinical diagnosis, commonly perform surveillance. 
In the main, case definitions used are the HELICS criteria in Europe and the CDC 
criteria in the USA.  
The CDC/NHSN have reported a steady decline in VAP rates. For comparison, the 
incidence of VAP in trauma patients (expressed as number of VAP cases per 1000 
ventilator-days) was 15.2 in 2004(Center for Disease Control, 2004); 10.2 in 
2007(Edwards et al., 2007); 9.3 in 2008(Edwards et al., 2008); 8.1 in 2009(Edwards et 
al., 2009) and 6.0 in 2010(Dudeck et al., 2011). These observations are in contrast to 
clinically observed VAP rates which in the trauma patient population remains close to 
20%(Michetti et al., 2012). These falling rates raise concerns about the objectivity of 
reporting and the vulnerability of case definitions to pressure to reduce VAP 
rates(Halpern et al., 2012). Surveillance criteria results in a much lower incidence of 
VAP in comparison to clinical case definitions(Skrupky et al., 2012). 
In an effort to improve consistency of surveillance reporting of VAP in the USA, the 
CDC have developed entirely new case definitions, the ventilator-associated condition 
(VAC) which encompassed the new terms of infection-related ventilator-associated 
complication (IVAC), possible pneumonia and probable pneumonia(Klompas, 2013). A 
recent study comparing these criteria to prospective surveillance (with CPIS as 
reference standard), found that VAC identified 33% of prospectively identified VAP, 
IVAC 18% and ‘possible’ or ‘probable VAP’ 17%(Klein Klouwenberg et al., 2014). 
The most common conditions contributing to VAC were pneumonia (including pre-
existing and new onset pneumonia) (28%); volume overload (28%); atelectasis/sputum 
plug (15%); pleural effusion (12%); acute neurological event (12%); new onset 
systemic inflammatory response syndrome (SIRS)/sepsis (extra-pulmonary) (11%); and 
abdominal distension (11%). This study highlights that the new CDC surveillance 
paradigm does not represent surveillance of VAP and is a collection of respiratory 
complications in the ICU. This paradigm shift brings together multiple pathologies, not 
to aid diagnosis or treatment but to improve objectivity of surveillance within a single 
healthcare system (USA). Furthermore there is limited evidence as to whether VAP 
prevention strategies (that led to the idea of using VAP as a quality indicator), can have 
an impact on VAC. A recent study of spontaneous breathing trials (SBT) and daily 
sedation interruption (DSI) found that VAC were reduced per mechanical ventilation 
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episode (not ventilator-days) but pneumonias were not reduced(Klompas et al., 2015). 
This study demonstrated that reducing time on mechanical ventilation reduced the time 
at risk of its complications rather than the prevention of VAP. 
1.3 Microbiology of VAP 
The pathogens implicated in VAP characteristically depend on the time until onset 
(early vs late VAP), the patient group and previous antibiotic exposure. The method of 
respiratory sampling influences the anatomical region tested and confidence that the 
microbiology represents the pulmonary infection rather than respiratory tract 
colonisation (this will be discussed further in Diagnosis). A recent global study of 1,873 
patients enrolled from the USA, Europe, Latin America and Asia Pacific identified 
Pseudomonas aeruginosa as the most common pathogen causing VAP followed by 
Staphylococcus aureus, Acinetobacter species, Klebsiella species, Enterobacter and 
Escherichia coli(Kollef et al., 2014). The predominance of Gram-negative bacilli in 
VAP has been recognised for many years. In a prominent review, the microbiology of 
24 studies demonstrated that Gram negative bacilli comprised approximately 60% of 
pathogens and the predominant Gram-positive pathogen being S. aureus accounting for 
20% of cases(Chastre and Fagon, 2002). P. aeruginosa accounted for 24% of cases, S. 
aureus 20%, Acinetobacter spp. 8%, Enterobacteriacease 14%, Haemophilus spp. 10% 
and Streptococcus spp. 8%. The German Nosocomial Infection Surveillance System 
reported on the 5811 cases of VAP between 2005-2007(Kohlenberg et al., 2010). Gram-
negative bacteria accounted for 59%, Gram-positive 26% and Fungi 12%. The most 
common pathgens were S. aureus (18%), P. aeruginosa (15.7%), Klebsiella spp. 
(10.2%), E. coli (9.8%) and Candida spp. (9.3%). VAP is often polymicrobial occurring 
in 25% of cases in a large scale surveillance study in Asian countries(Chung et al., 
2011), although the rate of polymicrobial positivity has been shown to vary 
considerably between patients who underwent BAL (12.3%) and those who had ETA 
(45.5%)(Fagon et al., 2000). VAP that occurs within 7 days of mechanical ventilation is 
more likely to be due to Enterobacteriaceae, Haemophilus spp, S. aureus and 
Streptococcus spp.(Trouillet et al., 1998). Beyond 7 days of mechanical ventilation P. 
aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia become 
prominent. Furthermore previous exposure to antibiotics and greater level of 
comorbidities are associated with antibiotic-resistance(Trouillet et al., 1998; Depuydt et 
al., 2008).  
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Aetiological patterns may vary between patient populations too. In a comparison of 
trauma and non-trauma patients, there were significantly more VAP cases caused by 
Haemophilus influenzae, Enterobacter spp. and Acinetoacter baumannii in trauma 
patients(Cook, Norwood and Berne, 2010). In the context of ARDS, Gram-negative 
bacilli are more common(Markowicz et al., 2000). 
Newer microbial detection methods are shedding new light on the aetiology of VAP and 
the pattern of transcolonisation to the lungs. Bacterial DNA polymerase chain reaction 
(PCR) detection of bacteria from BAL samples in patients with suspected VAP revealed 
bacteria not previously detected in BAL including Haemophilus spp., Terrahaemophilus 
aromaticivorans, Shigella spp., Pseudomonas fluorescens, Janthinobacterium lividum, 
Streptococcus spp., Gemella spp., Dialister spp., Megasphaera spp., Firmincutes spp., 
Lachnospiraceae spp., Porphyromonas spp. and Prevotella spp.(Bahrani-Mougeot et 
al., 2007). Interestingly for some individuals in that study, known VAP-associated 
pathogens were detected only by PCR and not standard culture, including H. influenzae, 
S. pneumonia and E. coli. 
The role of Candida spp. in the respiratory tract is uncertain. As noted above, it is 
frequently isolated from cultures and expert opinion and clinical guidelines advise that 
it is a colonising pathogen and not implicated in infection unless the patient is 
immunosuppressed(Chastre and Fagon, 2002; American Thoracic Society, 2005). In a 
retrospective analysis of patients with Candida spp. in the respiratory tract from a large 
RCT(Delisle et al., 2008), the presence of Candida spp. on respiratory culture was 
independently associated with hospital-mortality. Furthermore limited evidence does 
suggest that the presence of Candida spp. in comparison to control patients (no 
suspicion of VAP), is associated with increase inflammatory markers including pro-
calcitonin, C-reactive protein and Interleukin-6(Williamson et al., 2011). However this 
issue remains unresolved and as to whether patients should undergo treatment for 
Candida spp. is uncertain(Albert et al., 2014). 
1.4 Pathogenesis 
The critically ill patient on a mechanical ventilator is vulnerable to acquiring 
nosocomial infections. In health the upper airway provides protection to the lower 
airway predominantly by the epiglottis and cough reflex. These barriers are bypassed by 
endotracheal intubation. Furthermore inspired gases are humidified by the upper airway, 
and this process is also circumvented by mechanical ventilation. If gases were not 
humidified, normal respiratory tract function would be severely impaired(Fonkalsrud et 
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al., 1975). It is not only these mechanical changes but also the state of immunity that 
renders the patient vulnerable. Critically ill patients have been shown to have immune 
impairment with dysfunctions in regulatory T cells and neutrophils associated with 2.4 
and 6.9 fold increased risk of nosocomial infection respectively. When these two 
dysfunctions where present in conjunction with monocyte dysfunction, 75% of these 
patients acquired a nosocomial infection (Conway Morris et al., 2013). Patients who 
have suffered a traumatic brain injury are recognised to have a high prevalence of VAP 
and an immune paralysis has been described in association with this type of 
injury(Dziedzic, Slowik and Szczudlik, 2004)  
The predominant mechanism of infection of the lung is by micro-aspiration although 
haematological spread or local infiltrations (from the pleural space) are also relevant 
routes of infection(Estes and Meduri, 1995). In health micro-aspiration can occur while 
sleeping(Gleeson, Maxwell and Eggli, 1997) yet the balance between inoculation and 
host defence is such that pneumonia does not develop. There are changes in the 
critically ill patient in terms of organisms/pathogens and also alterations in host 
immunity.  
Central to this mechanism are the organisms that colonise sites of potential trans-
colonisation, the upper gastrointestinal tract and the oropharynx. Culture-independent 
methods of bacterial detection, using detection of bacterial 16s rRNA by microarray, 
has shown that in healthy subjects the characteristic family of bacteria colonising the 
oropharynx are Streptococcaceae, Lachnospiraceae and Clostridia(Lemon, 
2010).Gastric contents, thought previously to be inhospitable to bacteria, shows a 
diverse range of normal flora, when detected by bacterial 16s rDNA, with 5 
predominant genera of Streptococcus, Prevotella, Rothia, Fusobacterium and 
Veillonella(Bik et al., 2006; Nardone and Compare, 2015). In comparison to healthy 
subjects, hospitalised patients have a predominance of aerobic Gram-negative bacilli 
(AGNB) colonising the oropharynx(Filius et al., 2005). Bacteria demonstrate tissue 
tropism, where tissues support growth of specific bacteria, which is dependent on 
adhesion molecules and tissue factors. For example fibronectin is a factor present in 
salivary fluid that favours Streptococcus spp. binding in the oropharynx(Avila, Ojcius 
and Yilmaz, 2009) and P. aeruginosa favours binding on tracheal epithelium and may 
well be able to colonise the trachea without prior oropharyngeal colonisation(de Latorre 
et al., 1995). A clear relationship between bacteria identified by molecular analysis in 
the oral cavity and the BAL of VAP patients supports the oropharyngeal route of 
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translocation(Bahrani-Mougeot et al., 2007). In relation to colonisation of the stomach 
contents, bacterial growth is influenced by stomach pH. Acid suppression therapy is 
common in critically ill patients as a means of prophylaxis against stress ulceration. 
Raising the stomach pH promotes bacterial growth and allows growth of potentially 
pathogenic AGNB(Bonten et al., 1995). Although clinical studies have demonstrated an 
association between the use of acid suppression and VAP(Messori et al., 2000), other 
studies have not demonstrated a clear gastro-pulmonary route of infection for 
VAP(Bonten et al., 1995). In addition to the physiological changes that promote 
colonisation of these sites by AGNB, the endotracheal tube (ETT) becomes an 
important source of bacteria. Staphylococcus aureus has a particular tendency to adhere 
to the surfaces of invasive devices(Jones et al., 1997). It therefore follows, as previously 
described, that the predominant pathogens implicated in VAP are P. aeruginosa, S. 
aureus, Acinetotbacter species, Klebsiella species, Enterobacter species and 
Escherichia coli(Kollef et al., 2014). 
Infectious inoculate accesses the lower respiratory tract past the endotracheal tube. This 
is possible because the endotracheal tube does not represent a complete barrier between 
the upper and lower respiratory tract. The endotracheal tube balloon that forms the 
tracheal seal is high-volume, low-pressure, designed to reduce the risk of tracheal 
ischaemia and stenosis. When the cuff is inflated multiple folds occur in the cuff that 
allows supraglottic secretions to pass around the cuff(Seegobin and van Hasselt, 1986).  
Once the pathogen has gained access to the respiratory tract, the innate immune 
response to pulmonary parenchymal infection is characterised by a neutrophilic 
infiltration of the alveolar spaces. Lung macrophages, including alveolar and interstitial 
macrophages, are the first line of defence with phagocytic, cytotoxic and cytokine 
release functions(Franke-Ullmann et al., 1996). Mouse studies demonstrate that alveolar 
macrophages (AM) play a central role in the initiation of the early pro-inflammatory 
response releasing cytokines such as interleukin (IL)–1, IL-1, tumour necrosis factor 
(TNF)-, macrophage inflammatory protein (MIP)–2 (mouse analogue of IL-8) and 
chemokine CXCL1(Pittet et al., 2011). AM therefore are implicated in neutrophil 
recruitment and AM depletion is associated with reduced neutrophil 
recruitment(Kooguchi et al., 1998; Pittet et al., 2011). In addition alveolar epithelial 
cells are involved in neutrophil recruitment through the release of potent chemo-
attractants such as IL-8(Harada et al., 1994; Thorley et al., 2007; Craig et al., 2009).  
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IL-1β belongs to the IL-1 cytokine family, which includes 11 different cytokines. IL-1β 
is a highly inflammatory cytokine and the margin for benefit and toxicity in humans is 
narrow(Dinarello, 1996, 2011). Binding of IL-1 to its receptor initiates recruitment of 
the adaptor protein MyD88 to the Toll-IL-1 receptor domain, causes phosphorylation of 
kinases, and NK-κB translocates to the nucleus, resulting in the expression of a range of 
inflammatory cytokines(Dinarello, 2011). IL-1β is therefore tightly regulated by two 
mechanisms. Firstly its action is antagonised by interleukin-1 receptor antagonist (IL-
1Ra), which binds avidly to interleukin-receptor-1 (IL-R1) to block the binding of IL-
1β. There is a second IL-1 receptor, IL-1R2. This does not transduce any action and 
therefore acts as a ‘sink’ for IL-1β and the second mechanism for its 
regulation(Boraschi and Tagliabue, 2013). IL-1 is produced by a wide range of cells 
including dendritic cells, monocytes, macrophages, mast cells, neutrophils, B and T 
cells, endothelial cells, epithelial cells and dying cells(Sims and Smith, 2010). It has 
actions on: dendritic cells, increasing cytokine production; macrophages, increasing 
cytokine production and phagocytosis; and on neutrophils, increasing survival, adhesion 
(and therefore migration), oxidative burst and protease release(Borregaard, 2010; Sims 
and Smith, 2010). IL-1β is produced in an inactive form and requires cleavage by 
caspase-1, which itself is activated by protein complexes termed the 
‘inflammasome’(Netea et al., 2010). Several inflammasomes have been described all of 
which include members of the NOD-like receptor (NLR) family of proteins. Stimuli that 
activate the NLRP3 inflammsome include bacterial RNA, muramyl dipeptide (bacterial 
origin) and danger-associated molecular patterns (eg. uric acid crystals and amyloid-
β)(Jo et al., 2016). The NLRC4 inflammasome complex is activated by intracellular 
flagellin that is independent of toll-like receptor (TLR)-5 binding allowing direct 
activation of the inflammasome by bacteria(Miao et al., 2006). The classical model of 
IL-1β production is that two triggers are needed for its production, the first to trigger 
transcription and the second to induce inflammasome activation(Netea et al., 2010). In 
addition to the importance of inflammasome production of IL-1β, pro-IL-1β can be 
cleaved in a caspase-1-independent manner by neutrophil- and macrophage-derived 
serine proteases including proteinase-3, human neutrophil elastase (HNE) and 
cathepsin-G(Netea et al., 2010; Karmakar et al., 2012). This could be an important 
mechanism of IL-1β production in environments where the neutrophil is the 
predominant cell population. 
Considering the central role that IL-1 has in inflammation, blocking its action using a 
recombinant IL-1Ra (Anakinra), has been used to treat a wide range of inflammatory 
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diseases(Dinarello, Simon and van der Meer, 2012). One of the earliest uses of 
Anakinra was in trials as a treatment for sepsis, but no mortality benefit was 
demonstrated(Fisher et al., 1994; Opal et al., 1997). Interestingly, a recent retrospective 
analysis of previous trial data(Opal et al., 1997), examined patients with sepsis and 
features of macrophage activation syndrome(Shakoory et al., 2016). Macrophage 
activation syndrome (MAS) presents with a cytokine storm, with clinical features 
similar to severe sepsis. MAS can lead to multi-organ dysfunction and has been treated 
with anakinra(Dinarello, Simon and van der Meer, 2012). In this retrospective analysis, 
the presence of MAS was defined as the presence of hepatic and coagulation 
dysfunction. Patients with sepsis and these features of MAS did appear to have a 
survival benefit with Anakinra, with a 28-day mortality of 34.6% in Anakinra group 
versus 64.7% in placebo group(Shakoory et al., 2016). This interesting re-analysis calls 
for the reappraisal of the role of IL-1 blockade in sepsis. 
The ability of the neutrophil to arrive at a site of infection is central to the host defence. 
Neutrophils respond to chemotactic cytokines, chemokines, and IL-8 (or CXCL8) is a 
potent neutrophil chemokine(Mukaida, 2003; Nathan, 2006; de Oliveira et al., 2013). 
IL-8 is produced by a range of cells including monocytes, T cells, neutrophils, natural 
killer cells, endothelial cells, fibroblasts and epithelial cells(Mukaida, 2003). IL-8 binds 
to two seven trans-membrane G-protein coupled (GPCR) receptors, CXCR1 and 
CXCR2, and in addition IL-8 can bind to glycosaminoglycans(Jin, Xu and Hereld, 
2008; Kufareva, Salanga and Handel, 2015). Binding to the GPCR primarily results in 
chemotaxis through the dynamic formation of the cellular actin cytoskeleton resulting in 
cell polarity and cell motility in response to chemotactic gradients. Neutrophils express 
both CXCR1 and 2, and IL-8 is one of only three known chemokines that bind to both 
receptors in the neutrophil (these are IL-8, CXCL-6 and N-acetyl PGP). Many ligands 
bind to CXCR2 but none bind solely to CXCR1(Stillie et al., 2009). CXCR1 and 2 
result in different actions in the neutrophil, which may be concentration dependent. 
CXCR2 activation causes the release of matrix metalloproteinase (MMP)-9 and HNE 
and at low chemokine concentration, is purely chemotactic. At high chemokine 
concentration, CXCR1 activation results in respiratory burst. Both receptors mediate 
chemotaxis, intracellular calcium influx and phagocytosis. IL-8 is released in response 
to a range of insults causing inflammation. IL-8 is released in response to several 
P.aeruginosa derived factors including flagellin, procyanin and nucleoside diphosphate 
kinase(DiMango et al., 1995; Chai et al., 2014; Kim et al., 2014); bacterial products 
such as lipopolysaccharide(Maniar-Hew et al., 2013); environmental factors including 
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hypoxia(Keglowich et al., 2014) and over-stretch of the lung, relevant in the 
mechanically ventilated patient(Kotani et al., 2004). High levels of IL-8 have been 
detected in various pulmonary pathological states including pneumonia(Boutten et al., 
1996; Abul et al., 2001), asthma(Ordonez et al., 2000), ARDS(Aggarwal et al., 2000; 
Mukaida, 2003; Agrawal et al., 2012) and VAP(Conway Morris et al., 2010). 
Interestingly, the IL-8 response to inflammation appears to vary with age(Dalboni et al., 
2013; Maniar-Hew et al., 2013), which is of significance given that this questions the 
relevance of experimental models of inflammation to an increasingly elderly critical 
care population. 
Neutrophils that migrate to the alveolar space are the predominant cell involved in the 
killing of bacteria. They are phagocytes with a armamentarium of bactericidal factors 
which are housed within granules(Faurschou and Borregaard, 2003; Segal, 2005; 
Nathan, 2006). There are five groups of granule: the specific, gelatinase, azurophilic, 
lysosomes and secretory granules(Segal, 2005; Nathan, 2006). Granule contents is 
determined by the stage of cell and granule development and so granules have 
overlapping contents(Faurschou and Borregaard, 2003). The specific and gelatinase 
granules contain lactoferrin, lipocalin, lysozyme, MMP-8, MMP-9 and MMP-
25(Nathan, 2006). The azurophilic granule contains myeloperoxidase (MPO) which 
converts hydrogen peroxide to hypochlorous acid, defensins and the serine proteases 
cathepsin G, HNE and protease 3(Nathan, 2006). Lysosomes contain acid hydrolases 
and secretory granules act as a reservoir of membrane components that may serve to 
replenish the membrane used during phagocytosis(Segal, 2005). The components of 
these granules are used to kill bacteria but also serve other functions. Killing of bacteria 
is primarily within the phagosome, a vacuole within the cell containing the 
phagocytosed particle (eg. bacterium)(Reeves et al., 2002; Segal, 2005). Activation of 
the neutrophil, by IL-8 for example, triggers degranulation whereby the granule 
contents are released into either phagosome or extracellularly(Lacy, 2006; Khokha, 
Murthy and Weiss, 2013). Animal models have demonstrated that mice deficient in 
cathepsin G are susceptible to infection by S. aureus, mice deficient in elastase were 
susceptible to C. albicans(Reeves et al., 2002) and both proteases are necessary for 
resistance against A. fumigatus(Tkalcevic et al., 2000). Reeves et al demonstrated that 
despite the acidic contents of the granules being deposited into the vacuole, the pH 
ranged from 6 to 8(Reeves et al., 2002). This rise in pH is partly due to the movement 
of potassium into the vacuole via the NADPH oxidase, a membrane-bound enzyme 
complex. The hypertonic potassium within the vacuole causes the solubilisation of 
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cathepsin G and elastase previously bound (and inactive) to a sulphated proteoglycan 
matrix(Reeves et al., 2002). This mechanism has called into question the previously 
held paradigm that reactive oxygen species produced by NADPH oxidase are the 
predominant mechanism of bacterial killing(Segal, 2005). 
Granule contents are released into the extracellular matrix (ECM) of which many 
components of the ECM are substrates for the granule contents, in particular the 
proteases(Lacy, 2006). Although breakdown of the ECM is necessary to allow cell 
motility to the infected site, proteases are responsible for wider tissue damage and 
inflammation and so an array of antiproteases are released to neutralise the 
proteases(Williams et al., 2006). However extracellular proteases serve other purposes 
such as cleavage and activation of cytokines(Karmakar et al., 2012). Neutrophils may 
also be able to kill bacteria by production of neutrophil extracellular traps 
(NETS)(Brinkmann et al., 2004). Brinkmann et al demonstrated that activated 
neutrophils produced fragile NETS, which contained HNE, cathepsin G, MPO, 
lactoferrin, MMP-9 and DNA. Neutrophils in which phagocytosis was blocked but 
NETS were still present were able to killing 30% of S. flexneri  and S. aureus. NET 
production or “NETosis” is a form of programmed cell death with this particular 
bactericidal purpose(Brinkmann and Zychlinsky, 2012)..  
Considering this neutrophilic infiltration it is unsurprising that nosocomial pneumonia 
has been shown to be associated with high levels of neutrophilic proteases including 
HNE, MMP-8 and MMP-9 (Hartog et al., 2003; Wilkinson et al., 2012). 
1.4.1 Measurement of cytokines 
There are a number of methods with which to quantify soluble cytokines in fluids. 
These methods are generally divided into enzyme-linked immunosorbent assay (ELISA) 
and multiplex assays. ELISA is based on a double antibody sandwich in which the base 
of a well is coated with an analyte-specific capture antibody that binds the cytokine of 
interest when incubated. Another analyte specific antibody complexed with an enzyme 
then binds to the cytokine and the colour change caused by the enzyme when a suitable 
substrate is added allows detection of the cytokine. ELISA allows quantifiable 
measurement and is highly reproducible and considering the experience that has built up 
since its introduction in the 1970s, it is considered the standard for measuring 
cytokines(Leng et al., 2008). There are, however, a number of limitations to ELISA that 
have driven development of alternative assays. The main limitation is that only one 
cytokine can be measured per assay. Since the inflammatory process involves a large 
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number of mediators, measuring many cytokines is desirable but the repeated aliquots 
required for multiple ELISA can be prohibitive with some low volume clinical samples. 
Furthermore there are cost and time considerations when using multiple ELISA kits. 
To overcome the limitations of ELISA, assays have been developed that allow 
measurement of multiple cytokines in a single assay, by multiplex array. These assays 
use flow cytometry, chemiluminescence or electrochemiluminescence(Zhou et al., 
2010). Chemiluminescence is used in multiplex ELISA assays in which multiple 
specific antibiodies are coated at specific locations on a 96 well plate. A similar set up is 
used in electrochemiluminescent assays where the antibodies are coated on an electric 
wired microplate. The use of flow cytometry is the most common format for multiplex 
arrays and these use proprietary antibody-coated beads that are detected by flow 
cytometry. Cytometric Bead Array (CBA) (BD Biosciences) is one such method. 
Flow cytometry is a laser-based technology that measures (‘-metry’) cells (‘cyto’) in a 
stream of fluid (‘flow’). The basic elements of flow cytometry are the fluidics, optics 
and electronics. The fluidics system is the flow of fluid that transports the sample core 
to interact with lasers. The optics system comprises lasers, lenses and prisms that focus 
the laser on the sample core and detectors that capture emitted and scattered light. The 
electronics systems convert the light signals into an electronic output. The principle of 
flow cytometry is that when a cell or particle interacts with the laser beam in the sample 
core it deflects the laser from its path. Therefore measurement of light in line with the 
laser source (forward scatter) reflects the particle size. Measurement of light at right 
angles to the laser source (side scatter) represents the internal complexity of the cell or 
particle. Markers of interest that are to be measured within or on the cell/particle surface 
can be conjugated, via monoclonal antibodies, with fluorescent dyes, 
flourochromes(Morgan et al., 2004). Flourochromes are molecules that when excited by 
lasers, are raised to a higher energy state. When they return to their resting state they 
emit a characteristic wavelength of electromagnetic energy. These are also detected in 
the side scatter optics elements. 
CBA uses these principles of flow cytometry to measure soluble factors. The 
proprietary CBA beads are 7.5µm in diameter and therefore appear as a single group on 
the forward scatter(Morgan et al., 2004). Beads are dyed and so fluoresce at a specific 
intensity at 650nm when excited by an argon laser and detected in the FL3 channel. 
This allows different beads (eg. beads detecting IL-1 and IL-8) to be distinguished 
despite being the same size. The analyte of interest binds to the antibody-coated bead 
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and is then further complexed with another antibody that is bound to the detector 
reagent. This detector is a flourochrome such as phycoerythrin (PE) (which emits a 
fluorescent signal that is detected in the FL2 channel). The intensity of the FL2 signal is 
therefore proportional to the amount of analyte bound to the bead and so the 
concentration of analyte in solution. 
The main benefit of CBA is the ability to detect a range of analytes in a single assay 
with less biological sample. This has benefits in terms of time and efficiency. 
Furthermore the detection range for the fluorescent signal is wide. There are however 
some limitations of CBA that must be considered. Firstly, unlike ELISA, which 
immobilises the analyte being measured, the reactions in CBA occur in suspension and 
cross-reactivity is a concern. Not only is there potential interaction with different 
reagents but also factors that can cause antibody-antigen interactions causing false 
negative or false positive measurements(Bartels and Ribel-Madsen, 2013). Secondly, 
the limit of detection for IL-1 and IL-8 (as with other flex sets) is reported by the 
manufacturer to be 1.2pg/ml. This is estimated from the median fluorescent intensity of 
the negative control plus 2 standard deviations. Caution should be taken when 
interpreting any values that fall below the lowest point on a standard curve which is 
generally 5-10pg/ml for flex sets. Lastly, good correlations of CBA with ELISA have 
been demonstrated but there is poor concurrence of quantitative values(Elshal and 
McCoy, 2006).  
1.4.2 Sampling epithelial lining fluid by BAL 
The cytokines described above are largely present in the milieu surrounding the cells. In 
the context of VAP, the cytokines are present in the epithelial lining fluid (ELF), which 
is sampled by BAL. 
Performing a BAL will invariably sample both the bronchial area, bronchiolar area and 
the alveolar area. Using digital subtraction imaging techniques, it has been 
demonstrated that the first aliquot of saline remains close to the bronchoscope and 
subsequent aliquots were required to fill the alveolar space(Kelly et al., 1987). For this 
reason it has been advocated that the aspirate of the first aliquot is discarded(Meduri and 
Chastre, 1992). Squamous epithelial cells are used as a marker of bronchial 
contamination and considerably more squamous epithelial cells have been demonstrated 
in the first 20ml BAL aliquot (45.0%) in comparison to the second 50ml BAL aliquot 
(7.6%)(Marquette et al., 1995). Uncertainty over exact anatomical position of BAL 
sampling is inherent in BAL and previous expert opinion has stated that discarding the 
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bronchial wash is unreliable and that ensuring a sufficient BAL volume is used to dilute 
the effects of bronchial sampling and lowering the airways:alveolar material ratio is 
required(Haslam and Baughman, 1999). In fact current national guidelines for 
bronchoalveolar lavage in clinical practice, do not recommend discarding a bronchial 
sample(Meyer et al., 2012; Du Rand et al., 2013).  
A minimum volume of 120mls has been recommended(Kelly et al., 1987) and there is 
variation in recommendations in national guidelines with the British Thoracic Society 
recommending 60-180mls(Du Rand et al., 2013) and the American Thoracic Society 
recommending 100-300mls(Meyer et al., 2012). It should be noted that these volumes 
are not specific to BAL in the ICU (ATS recommendations are in relation to 
investigation of interstitial lung disease).  
In cases of bilateral CXR changes, there is inevitably some uncertainty as to whether the 
BAL has been performed in the correct area. The main concern is the risk of a false 
negative result if the infected area is not sampled. VAP has been shown to be widely 
distributed histologically(Rouby et al., 1992) which may account for the finding that the 
bacterial index of directed BAL and non-directed BAL, even if the non-directed BAL 
was in a different lobe or even the contralateral lung, were not significantly 
different(Pugin et al., 1991). In current UK practice, generally more than one lobe is 
lavaged, volumes >100mls are also only used by approximately 10% of clinicians and 
the median volume being 20mls(Browne et al., 2014). This would lead to the 
conclusion that most ‘BAL’ performed in the UK are in fact bronchial ‘washes’. If an 
adequate BAL is being performed with the necessary volumes (at least 120mls), there 
are safety considerations for performing BAL in more than one lobe in ICU patients. 
Anecdotally the volume of 120mls used in these studies was considered to be high 
volume by many clinicians working within the study sites. 
The ELF sampled by BAL is diluted by the instilled saline during the BAL. One of the 
main uncertainties with BAL is the degree to which the ELF is diluted by the saline and 
therefore to what degree the measured biomarker level truly reflects the biomarker level 
in the ELF(Haslam and Baughman, 1999). Urea is a small molecule (60 Daltons) that 
can freely diffuse across biological membranes. Measurement of BAL and serum urea, 
has been previously used to determine a correction factor for the amount of ELF 
dilution that has occurred and ELF has been shown to be diluted approximately 100 fold 
by BAL using the urea correction method(Rennard et al., 1986). Since urea moves 
freely across membranes, down its concentration gradient, the amount of urea in BAL 
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does increase the longer the saline is allowed to remain in the lungs prior to aspiration 
(“dwell time”)(Rennard et al., 1986). The movement of urea during BAL is complex 
and the rationale for the use of urea may be too simplistic(Ward et al., 1992). In a study 
of healthy volunteers BAL urea concentrations were lower in smokers than non-
smokers, urea increased in BAL fluid between 3 sequential 60ml aliquots of instilled 
saline and significant amounts of intravenously injected radiotracer were found in BAL 
fluid demonstrating the dynamic movements of water and urea during BAL(Ward et al., 
2000). 
1.5 Mortality and morbidity  
1.5.1 Mortality 
Estimating the mortality associated with VAP has proven to be complex. VAP 
complicates the condition that mandated the patient’s admission to ICU. Therefore the 
admission condition and subsequent HCAI may both contribute to the risk of death. 
Separating the respective contributions has proven difficult. Furthermore the adequacy 
of treatment for VAP is inherent in its contribution to the risk of dying and in the 
context of estimating ICU mortality, an increased length of ICU stay results in a time-
at-risk bias as these patients will have a prolonged observation period on 
ICU(Muscedere, Day and Heyland, 2010). Mortality rates are either reported as crude 
mortality rates or as attributable mortality. Attributable mortality is calculated by 
subtracting the baseline mortality for the cohort from the mortality in the VAP group to 
determine the contribution of VAP to the risk of death. Attributable mortality is 
generally expressed as relative risk (RR) or as an odds ratio (OR). Difficulties in 
determining attributable mortality in VAP have led to widely ranging estimates. 
Crude mortality rates have been reported to be between 24-76%(Chastre and Fagon, 
2002). This wide range of crude mortality rates is derived from relatively small studies. 
In a retrospective case-controlled study, 48 patients with VAP confirmed by semi-
quantitative culture, the crude mortality was 54.2% and amongst controls 27.1%.(Fagon 
et al., 1993). Similarly in a prospective cohort study in a community hospital VAP was 
associated with a 45.5% mortality compared to 32.2% amongst patients who did not 
acquire VAP, although this was not case-matched(Ibrahim et al., 2001). High crude 
mortality rates have been reported in association with Pseudomonas spp. and 
Acinetobacter spp. with mortality rates of 73%(Fagon et al., 1993, 1996). In contrast to 
these findings, a case-controlled study in a mixed medical and surgical ICU of 97 
patients and did not find a significant difference in mortality between the VAP and case-
    
  23  
control group(Papazian et al., 1996). Furthermore there was no significant increase in 
mortality when Pseudomonas spp. were the causative pathogens. Trauma patients are a 
group of patients in which VAP is a common complication but there does not appear to 
be an associated increase in mortality(Baker, Meredith and Haponik, 1996; Cook, 
Norwood and Berne, 2010).  
Estimates of attributable mortality also vary widely. High attributable mortality rates 
were reported in a prospective, matched, risk-adjusted cohort(Bercault and Boulain, 
2001). Crude mortality rates were 41% and 14% for the VAP and control groups 
respectively, which equates to an attributable mortality OR of 2.7 (95% confidence 
interval (CI) 1.8-3.1). Interestingly when sub-analysis was performed on VAP caused 
by antibiotic resistant or sensitive pathogens the OR was only significant for the 
resistant group (2.6, 95%CI 1.1-5.8 versus 1.8, 95% CI 0.9-3.9 for the sensitive group). 
In contrast to these high attributable mortality rates, a match controlled analysis 
performed on patients enrolled in a stress ulcer prophylaxis RCT did not find an 
increase in RR in patients with VAP (32.2% (95% CI -20.6-85.1))(Heyland et al., 
1999). 
Pooling RR of mortality for VAP from observational studies in a meta-analysis revealed 
a RR of 1.27 (95% CI 1.15-1.39)(Melsen, Rovers and Bonten, 2009). This analysis did 
however include matched and non-matched observational studies and there was 
considerable heterogeneity between studies (I
2
 69%). Interestingly there was very little 
heterogeneity in the sub-groups of trauma (I
2
 1.3%) and ARDS (I
2
 0%) and in these 
groups no additional attributable mortality was associated with VAP. 
In an alternative approach, a meta-analysis of RCTs of VAP prevention interventions 
was performed(Melsen et al., 2011), the rationale being that if there is an associated 
mortality with VAP then any reduction in VAP rates will result in a reduction in 
mortality. A ratio of relative risk reduction (RRR) of mortality to the RRR of acquiring 
VAP, was used to estimate the attributable mortality. The pooled RRR in mortality was 
0.03 (95% CI -0.03-0.08) (no RCT reported a significant decrease in mortality) and the 
RRR in VAP was 0.33 (95% CI 0.23-0.41). The estimated attributable mortality was 
9%. 
Although the previously described reports attempted to control for confounding 
variables through matching, none of them considered the fluctuating risk of VAP over 
time. In an analysis by Bekaert et al, the authors attempted to overcome the following 
confounding factors: patients need to survive long enough to acquire VAP; patients with 
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VAP are more severely unwell throughout ICU admission, not only on admission; the 
interplay between disease severity and adequacy of treatment over time; and that 
discharge from ICU is a competing risk for ICU mortality(Bekaert et al., 2011). This 
analysis was performed using data from a high quality database in which VAP was 
diagnosed not only by clinical criteria but also respiratory sampling by bronchoscopic 
methods and quantitative culture. This approach estimated a 2.3% increase in hazard of 
ICU death for each day following onset of VAP. The estimated attributable mortality 
fraction at 30 days was 4.4% (95% CI 1.6-7.0) and at 60 days was 5.9% (95% CI 2.5-
9.1). Considering the crude mortality rates at 30 and 60 days were 23.3% and 25.6% 
respectively, this results in an attributable mortality at 30 days of 1% and 1.5% at 60 
days. Although this is a detailed investigation, it alone should not lead the reader to 
conclude that there is no significant associated mortality with VAP. It highlights the 
complexity of elucidating the attributable mortality in complex patients in whom many 
factors influence the risk of death. 
1.5.2 Length of stay 
Unlike the attributable mortality of VAP there is much more consistent signal in regard 
to an associated increased length of ICU and hospital stay. The increased length of ICU 
stay amongst patients with VAP ranges from 4.7-8 days(Papazian et al., 1996; Heyland 
et al., 1999; Ibrahim et al., 2001; Rello et al., 2002; Safdar et al., 2005)The increased 
length of hospital stay ranges from 11.5-23.4 days(Ibrahim et al., 2001; Rello et al., 
2002; Cook, Norwood and Berne, 2010). The highest length of stay was reported in a 
prospective study of trauma patients in which the increased length of ICU stay was 17.8 
days and hospital length of stay was 16.8 days although this was not a case-controlled 
study(Cook, Norwood and Berne, 2010). The prevention of VAP using subglottic 
secretion drainage (SSD) has not only prevented VAP but also reduced length of ICU 
stay(Muscedere et al., 2011). 
1.5.3 Healthcare resource utilistation 
Estimating the cost attributable to VAP suffers the same difficulties of estimating 
mortality in patients with complex disease and the potential for multiple complicating 
diseases. The wide range of differences in healthcare systems further limits estimated 
costs. No detailed reports of the cost of VAP in the UK have been previously published. 
Data from the USA (as in studies described below) estimates cost from a patient, 
provider or insurance perspective. Case definitions of VAP can influence the estimated 
prevalence of VAP, which will also influence estimates of cost. In a retrospective, case-
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controlled study in which patients with VAP were identified if ventilated for ≥2 days 
and met the criteria of the International Classification of Disease, Ninth Revision (ICD-
9) code for VAP (997.31)(Kollef, Hamilton and Ernst, 2012), the estimated cost from a 
hospital perspective (indirect and direct costs) was $99,598 for patients with VAP and 
$59,770 for control patients. These costs are very similar to a previously reported 
provider perspective estimate(Rello et al., 2002).  
In a prospective analysis, Anderson et al estimated the cost of HCAIs from a systematic 
review of the literature from 1985-2005 and then applied these costs to the prospective 
HCAI rates for 32 participating community hospitals(Anderson et al., 2007). With an 
estimated cost of $25,072 per VAP case and median of 2 (IQR 0-4) VAP cases per year 
per hospital, the median cost of VAP per year to the hospital was $50,144. 
Another strategy was to estimated attributable cost in a meta-analysis based on the 
estimated attributable increased length of ICU stay and estimated specific treatment cost 
for VAP. The estimated cost was an additional $13,647 per VAP episode(Safdar et al., 
2005). Similar attributable costs were determined in two retrospective analyses with 
costs of $11,897(Warren et al., 2003) and $15,986(Hugonnet et al., 2004).  
In contrast to these a further analysis from a hospital perspective did not find a 
significant cost associated with VAP(Restrepo et al., 2010). The median costs were 
$76,730 for VAP cases and $41,250 for control cases. Following Medicare 
reimbursements to hospitals the median losses to hospitals were $32,140 for VAP cases 
and $19,360 for control cases, although this difference was not statistically significant.  
1.6 Diagnostic test metrics 
Diagnostic tests aim to correctly detect disease but tests rarely do this with 100% 
accuracy. There are two sides to diagnostic testing; the ability to correctly detect the 
disease in those that have the disease and the ability to correctly detect the absence of 
disease in those that do not have it. The ability of a test to correctly identify disease can 
be illustrated by the following 2x2 table: 
 
 Disease present Disease absent 
Test positive A (true positives) B (false positives) 
Test negative C (false negatives) D (true negatives) 
    
  26  
The sensitivity is the proportion of true positives that are correctly identified by the test 
and is given by the equation: Sensitivity =  A / (A+C) (Douglas G Altman and Bland, 
1994). 
The specificity is the proportion of true negatives that are correctly identified by the test 
and is given by the equation: Specificity =  D / (B+D). 
Sensitivity and specificity approach the diagnostic accuracy from the direction of the 
whether the disease is present or not. In clinical practice, however we generally 
approach from the position of the test result asking: what proportion of positive tests (or 
negative tests), correctly identify patients with the disease (or without the disease)? This 
is given by the predictive values (D G Altman and Bland, 1994).  
The positive predictive value (PPV) is the proportion of patients with a positive result 
who are correctly diagnosed and is given by the equation: PPV = A / (A+B). 
The negative predictive value (NPV) is the proportion of patients with a negative result 
who are correctly diagnosed and is given by the equation: NPV = D / (C+D). 
1.7 Diagnosis of VAP 
The lack of a gold standard and the need for surrogate definitions is a major limitation 
in clinical practice and in research. The clinical features that indicate suspicion of VAP 
are all limited in terms of specificity and none of the sampling techniques used to obtain 
respiratory samples are 100% accurate. The implication of this at the bedside is that 
antibiotics may well be used unnecessarily. In fact amongst patients with suspected 
VAP, pneumonia is confirmed in approximately 40%(Meduri et al., 1994; Hellyer et al., 
2015), although diagnosis based on culture is heavily dependent on sampling technique 
used(Conway Morris et al., 2009).  
Diagnostic strategies are generally divided into two approaches. The first is a “clinical” 
strategy based on clinical findings and generally in conjunction with culture of ETA. 
The benefit of this approach is the ease of obtaining an ETA, which is not a skilled task. 
The main issue is the lack of specificity and therefore the risk of over diagnosis of VAP 
and the potential for overuse of antibiotics. An alternative is an “invasive” sampling 
approach. Respiratory samples for culture are obtained by bronchoscopic methods and 
the diagnosis of VAP is determined by quantitative cultures. The benefit of these 
methods is that the distal site of infection is sampled and so is less vulnerable to 
contamination from upper airway colonisation. The problems with this strategy is that 
bronchoscopy is a skilled task that is not necessarily available, sampling in one region 
    
  27  
of the lung could miss infection in another region and there is some risk associated with 
performing the procedures. 
In this section we will consider the evidence base for the clinical diagnosis and then the 
accuracy of respiratory sampling. 
1.7.1 Clinical diagnosis 
The most widely recognised features of suspected VAP are fever; leucocytosis or 
leucopenia; purulent tracheal secretions and new or worsening CXR infiltrates. These 
form the basis of the clinical and surveillance definitions outlined previously. Several 
studies have examined the accuracy of these clinical features against proven VAP at 
autopsy. A consideration from autopsy studies, particularly in relation to clinical data, is 
that there is a temporal dissociation between the clinical data recorded, the histological 
findings and the episode of suspected VAP. For example clinical data collected just 
before death may not represent the onset of clinical suspicion of VAP and alternatively, 
histological findings at death may not represent the histological findings at the moment 
of suspicion of VAP.  
Torres et al carried out a prospective study of 30 patients who died while receiving 
mechanical ventilation(Torres et al., 1994). Following death, patients underwent a 
protocol of several standardised respiratory sampling techniques followed by lung 
biopsies from the same area that BAL and PSB were performed in, guided by the light 
of the bronchoscope. The protocol was performed in the area that corresponded with the 
maximum CXR infiltrate and on the contralateral side. Histological pneumonia was 
defined as a focus of polymorphonuclear cell accumulation in the bronchioles and 
adjacent alveoli. Using histological evidence of pneumonia as evidence for VAP, fever 
had a sensitivity of 55% and a specificity of 58%; purulent tracheal secretions had a 
sensitivity of 83% and specificity of 33% and CXR infiltrates had a sensitivity of 78% 
and specificity of 42%. Alternative diagnoses for pulmonary infiltrates included 
alveolar haemorrhage, alveolar damage, atelectasis and pulmonary fibrosis. There were 
no significant differences in WCC between the VAP and non-VAP groups. 
A further prospective study of 40 patients who died while on mechanical ventilation 
found poor agreement between clinical features and pneumonia on histology(Kirtland et 
al., 1997). Kappa values describe the level of agreement ranging from 0.00-0.20 as 
slight, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial and 0.81-1.0 as 
almost perfect(Landis and Koch, 1977) Temperature had a kappa of 0.15, worsening 
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CXR 0.04, a reduction in PaO2:FiO2 ratio 0.11 and raised white cell count 0.03. A 
limitation of this study is that clinical data were obtained 48-72hrs before death. 
Since case definitions of VAP are a composite of clinical observations and 
investigations, Tejerina et al determined the diagnostic utility of case definitions against 
histologically proven VAP(Tejerina et al., 2010). In a retrospective analysis of patients 
who had undergone autopsy following death on mechanical ventilation, 253 patients 
were included of which 142 had histological evidence of pneumonia. The clinical 
definitions evaluated were: 
1. ‘Loose definition’ of VAP: a new of worsening CXR infiltrate in the context of at 
least 2 of the following 3 findings: temperature >38
o
C or <35.5
oC; WCC >10,000/μl 
or <4000/μl; or purulent tracheal secretions.  
2. ‘Rigorous definition’ of VAP: the above criteria but all 3 findings required in the 
context of a new or worsening CXR infiltrate. 
3. CPIS >6. 
Of patients who had proven pneumonia, 64% met the loose definitions, only 13% met 
the rigorous definition and 43% had a CPIS >6.The sensitivity and specificity for the 
loose definition was 65% and 36% respectively; for the rigorous definition, 15.5% and 
91% respectively; and for a CPIS > 6, 46% and 60% respectively. 
A further study defined ‘microbiologically active pneumonia’ in the presence of 
positive lung tissue culture and positive histology(Fabregas et al., 1999). Twenty-five 
patients who died while mechanically ventilated were included. A high proportion of 
patients, 92%, had histological evidence of pneumonia in at least 1 lung biopsy but 52% 
of patients had ‘microbiologically active pneumonia’. The sensitivity and specificity for 
a CXR infiltrate was 92% and 33% respectively; for leucocytosis the sensitivity was 
77% and specificity was 58%; for purulent secretions the sensitivity was 69% and 
specificity was 42%. The ATS/IDSA criteria (see Table 1) had a sensitivity of 69% and 
specificity of 75% and a CPIS > 6 a sensitivity of 77% and specificity of 42%. In this 
study 68% of patients received antibiotics in the 48 hours before death. It is possible 
that a proportion of patients without ‘microbiologically active’ VAP could have had 
VAP but were culture negative due to the high levels of antibiotics used in these 
patients. 
These studies demonstrated a low sensitivity and specificity of the CPIS. In the 
derivation study a CPIS > 6 correctly identified VAP with a sensitivity of 93% and a 
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specificity of 100%(Pugin et al., 1991). This has failed to be validated in further studies. 
The CPIS correlates poorly with the bacterial index of pathogens cultured from 
BAL(Schurink et al., 2004) and a score >6 detected significant pathogen growth from 
BAL with a sensitivity of 60% and a specificity of 59%(Fartoukh et al., 2003). In a 
prospective study the diagnostic performance of the CPIS to identify VAP was poor 
with an area under the receiver operator characteristic curve (AUROC) of 0.47 (95% CI 
0.42-0.53)(Lauzier et al., 2008). 
Chest x-ray forms part of all clinical definitions of VAP. In a retrospective analysis the 
last CXR before death was examined against histology proven pneumonia(Wunderink 
et al., 1992). Alveolar infiltrates were present in 80% of patients and air bronchograms 
in 57%. Of patients with ARDS, 53% had asymmetric infiltrates. The presence of either 
a single or multiple air bronchograms identified pneumonia with a sensitivity of 83% 
and a specificity of 58%. A single air bronchogram had the highest specificity at 96% 
but a sensitivity of only 17%. Alveolar infiltrates identified pneumonia with a 
sensitivity of 88% and a specificity of 26%. In the regression analysis a single air 
bronchogram was the strongest predictor of VAP with a RR of 3.19 but this model 
predicted only 64% of VAP. 
Sensitivities and specificities for these clinical parameters are summarised in Table 4
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Reference ↑WC
C 
Fever Purulent 
secretion
s 
CXR 
changes 
CPIS 
>6 
CXR 
change 
AND 2 of: 
Fever  
↑WCC 
Purulent 
secretions 
CXR 
change 
AND 
ALL of: 
Fever  
↑WCC 
Purulent 
secretion
s 
Torres 1994 NS Sn 55%  
Sp 58% 
Sn 83%  
Sp 33% 
Sn 78% 
Sp 42% 
   
Tejerina 
2010 
    Sn 46% 
Sp 60% 
Sn 65%  
Sp 36% 
Sn 15%  
Sp 91% 
Fabregas 
1999 
Sn 
77%  
Sp 
58% 
Sn 46% 
Sp 42% 
Sn 69% 
Sp 75% 
Sn 92%  
Sp 33% 
Sn 77% 
Sp 42% 
Sn 69% 
Sp 75% 
Sn 23% 
Sp 92% 
Pugin 1991     Sn 93% 
Sp 
100% 
  
Fartoukh 
2003 
    Sn 60% 
Sp 59% 
  
Wunderink 
1992* 
   Sn 88% 
Sp 26% 
   
Table 4: Summary of sensitivity (Sn) and specificity (Sp) of clinical parameters used in the diagnosis of 
VAP. *sensitivity and specificity for a range of radiological signs reported in reference, ‘alveolar 
infiltrates’ presented in this table. NS, no significant difference between VAP and non-VAP 
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1.7.2 Respiratory sampling 
Samples from the respiratory tract can be obtained by bronchoscopic or non-
bronchoscopic techniques. Bronchoscopic techniques include BAL and PSB. Although 
a standardised approach to BAL has been reported(Meduri and Chastre, 1992), there is 
considerable variation in practice in the UK(Browne et al., 2014). The use of 
quantitative culture is used to distinguish between culture growth from colonising 
bacteria and from pneumonia. To consider the diagnostic accuracy of these techniques, 
data from human autopsy studies will be considered. 
In a prospective study, 26 patients who died while receiving mechanical ventilation 
underwent PSB immediately post-mortem in the left lower lobe followed by 
thoracotomy and collection of peripheral lung specimens(Chastre et al., 1984). Six 
patients had histological evidence of pneumonia and all of these patients had growth of 
a pathogen at >10
4 
colony forming units per gram (cfu/g) of tissue. The 20 patients 
without pneumonia either had a sterile culture or growth <4x10
3
 cfu/g. The correlation 
of PSB cfu/ml to tissue cfu/g was r=0.57. For patients on antibiotics this was lower 
(r=0.55) and for the 6 patients with pneumonia the correlation was higher (r=0.77). 
Operating characteristics of PSB fluid culture (cfu/ml) were determined to identify 
cases with a tissue culture of >10
4
 cfu/g or histological pneumonia. Using a cut-off of 
>10
3
 cfu/ml for PSB, the sensitivity to detect pneumonia (by histology) was 100% but 
specificity was 60% and to detect tissue culture of >10
4
 cfu/g, the sensitivity was 100% 
and specificity was 61%. Excluding patients receiving antibiotics increased the 
specificity for detecting pneumonia to 87% and detecting lung tissue culture to 76%. 
In a seminal paper, Chastre et al aimed to give a comprehensive description on the 
relationship of histological pneumonia to its microbiology(Chastre et al., 1995). Twenty 
patients who died while undergoing mechanical ventilation underwent immediate BAL 
and PSB before thoracotomy and tissue specimens from corresponding segments were 
collected. In order to reduce confounding factors, patients were excluded if antibiotics 
had been commenced within 3 days of death or if the patient had previously developed 
bacterial pneumonia. Therefore patients only had pneumonia if it was acquired in the 
terminal phase of the patients’ condition. The correlation between tissue cfu/g and 
histology was r=0.79. All patients with moderate to severe pneumonia had a tissue cfu > 
10
4
/g. Segments with mild pneumonia had tissue culture that ranged from sterile to >10
4
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cfu/g. There were strong correlations between PSB and BAL culture and tissue culture 
(r=0.67 and r=0.75 respectively). Operating characteristics were determined for BAL or 
PSB (cfu/ml) to detect significant tissue microbiology (>10
4
 cfu/g). For BAL at a 
threshold of >10
4 
cfu/ml the sensitivity was 91% and specificity was 78%; for PSB at a 
threshold of >10
3
 cfu/ml the sensitivity was 82% and specificity was 77%. 
These papers represent the strongest evidence for the accuracy of invasive sampling and 
the relationship between the BAL/PSB sample and tissue culture and histology. 
However some important limitations must be considered. Firstly these studies have not 
studied a population of suspected VAP. Although pneumonia was evidenced on 
histology, how this corresponds to clinical suspicion is uncertain. By definition these 
were groups of severely ill and terminal patients. Secondly the BAL and PSB thresholds 
proposed by Chastre(Chastre et al., 1995) have been widely accepted but it must be 
acknowledged that these were derived against a tissue culture threshold that does not 
encompass all pneumonia, failing to include mild pneumonia. How clinical features of 
pneumonia differ between patients with mild, moderate or severe pneumonia on 
histology is not known nor is it known whether all patients with some evidence of 
pneumonia at histology receive antibiotic treatment. Clinical outcomes have been 
shown to be different in patients above and below these thresholds(Fagon et al., 1996) 
suggesting this is a clinically relevant distinction. Furthermore managing patients as 
non-VAP if culture growth is below these thresholds and discontinuing antibiotics early 
is not associated with worse outcome and may have benefits in terms of reducing 
antibiotic resistance and reducing antibiotic prescribing(Fagon et al., 1988, 2000; 
Raman et al., 2013). 
Further cadaveric studies that aimed to validate the findings of Chastre et al have failed 
to report the same correlations of tissue culture to histology and the same diagnostic 
accuracy with BAL and PSB(Torres et al., 1994; Marquette et al., 1995; Kirtland et al., 
1997; Fabregas et al., 1999). These studies have generally not controlled for antibiotic 
use or the presence of pre-existing pneumonia but are arguably a more clinically 
relevant population. The tissue culture threshold of >10
4
 cfu/g was found to have a 
sensitivity of 27% and specificity of 66% in one study(Torres et al., 1994) and a 
sensitivity of 11% and specificity of 93% in another (Kirtland et al., 1997) against 
histological pneumonia. In a study by Rouby et al, 35% of patients with histological 
pneumonia were culture negative and 49% of culture positive patients had no 
histological evidence of pneumonia(Rouby et al., 1992). However the use of antibiotics 
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in these studies could have resulted in falsely low or negative cultures(Fabregas et al., 
1996). The sensitivity and specificity of BAL ranged from 11-50% and 45-100% 
respectively; for PSB the sensitivity and specificity ranged from 33-83% and 50-100% 
respectively(Torres et al., 1994; Marquette et al., 1995; Kirtland et al., 1997; Fabregas 
et al., 1999). For blind mini-BAL the operating characteristics were report at a 
sensitivity of 70% and specificity of 69%(Rouby et al., 1994). Endotracheal aspirate 
was evaluated in two studies which reported sensitivity from 69-87% and a specificity 
of 31-92%(Kirtland et al., 1997; Fabregas et al., 1999). 
Table 5 summarises the diagnostic performance of respiratory sampling methods 
reported. 
Reference BAL PSB ETA Blind-BAL/ 
Bronchial aspirate 
Blind PSB 
Fabregas 1999 Sn 39%* 
Sp 100% 
Sn 62% 
Sp 75% 
Sn 69% 
Sp 92% 
  
Kirtland 1997 Sn 11% 
Sp 80% 
Sn 33% 
Sp 63% 
  Sn 22% 
Sp 77% 
Chastre 1995 Sn 91% 
Sp 78% 
Sn 82% 
Sp 77% 
   
Chastre 1984  Sn 100% 
Sp 61% 
   
Marquette 1995 Sn 47% 
Sp 100% 
Sn 56% 
Sp 87% 
Sn 56% 
Sp 86% 
  
Torres 1994 Sn 50% 
Sp 45% 
Sn 36% 
Sp 50% 
 Sn 44% 
Sp 48% 
 
Rouby 1992    Sn 70% 
Sp 69% 
 
  
Table 5: Summary of diagnostic performance of difference respiratory sampling methods. Sensitivity 
(Sn) and Specificity (Sp). Reference criteria used by Chastre et al (1984, 1995) tissue culture of >10
4
 
cfu/g, Fabregas 1999, ‘microbiologically active pneumonia’. Remaining studies use histology proven 
pneumonia.* Sensitivity and specificity for ‘protected BAL’. 
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1.7.3 Clinical versus invasive diagnostic strategy: RCT evidence 
Professional bodies have previously recommend the use of invasive respiratory 
sampling as best practice(American Thoracic Society, 2005) due to the higher 
specificity to exclude false positive cultures from proximal airway colonisation. More 
recently this recommendation has been challenged by a meta-analysis that did not 
support the use of invasive sampling(Berton, Kalil and Teixeira, 2012) and updated 
guidelines no longer recommend invasive sampling(Kalil et al., 2016). It may not be 
surprising therefore, that there is considerable variation in practice around respiratory 
sampling(Koulenti et al., 2009; Browne et al., 2014). Clearly improvement in patient 
outcome is the predominant drive for adoption into clinical practice. There have been 5 
RCTs that have compared bronchoscopic methods to clinical/non-bronchoscopic 
methods. The use of an invasive approach was invariably combined with quantitative 
culture; however these trials differ in whether the control arm included non-invasive 
sampling with quantitative culture or qualitative culture.  
Of the 5 trials, two dominate the discussion, and have conflicting results(Fagon et al., 
2000; Canadian Critical Care Trials Group et, 2006). In a French multi-centre trial of 
413 patients conducted over 31 ICUs, patients were randomised to a treatment 
algorithm of antibiotic initiation or de-escalation based on invasive sampling (BAL or 
PSB) or to a clinical management approach (ETA)(Fagon et al., 2000). In both the 
invasive and the non-invasive groups the decision algorithm recommended antibiotics at 
two decision points, the immediate Gram stain result and later culture results. Cultures 
were positive from PSB in 37% of patients, for 34% of BAL and 86% of ETA. The 
mortality at 14 days was significantly lower in the invasive group over the non-invasive 
group (16.2% vs 25.8%, p=0.022). Furthermore there were significantly more 
antibiotic-free days (AFD) at 14 days in the invasive group over the non-invasive group 
with 5.0 +/- 5.1 and 2.2 +/- 3.5 respectively (p<0.001). Fourteen per cent of the invasive 
group did not receive any antibiotics up to 28 days in comparison to only 2 patients in 
the non-invasive group. There was no significant difference in ICU or hospital LOS or 
duration of mechanical ventilation. 
In this trial, considering only those with negative cultures, 85% in the invasive group 
and 60% of the clinical group did not receive antibiotics. This degree of antibiotic 
stewardship in light of negative cultures is not reflected in other trials(Ruiz et al., 2000; 
Solé Violán et al., 2000; Canadian Critical Care Trials Group et, 2006). The algorithm 
used in the trial reflects best practice of de-escalation or discontinuation of antibiotics 
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following culture results. Furthermore the mortality difference could be explained by 
the fact that the invasive group had fewer patients receiving inappropriate antibiotics 
that failed to treat the cultured pathogens (inadequate treatment in 24 patients (11%) in 
the non-invasive group versus 1 patient in the invasive group). 
The adequacy of treatment of VAP is inextricably linked to outcome and so any trial 
intervention must ensure that treatment adequacy is not a confounding factor. A large 
multi-centre trial conducted in Canada went some way to accommodate for this 
confounding factor ensuring that all patients got broad-spectrum empiric 
antibiotics(Canadian Critical Care Trials Group et, 2006). Seven hundred and forty 
patients from 28 ICUs were randomised in a 2 by 2 factorial design RCT. Factorial 
RCTs randomise on two levels to two interventions that are felt not to interact. In this 
trial the levels of randomisation were invasive sampling with BAL and quantitative 
culture versus clinical diagnosis and ETA; the second level was randomisation to 
monotherapy or combination therapy. This trial had important exclusions that limit its 
generalisation into routine practice. Patients were excluded if colonised with S. aureus 
or Pseudomonas spp., if allergic to the trial antibiotics (ciprofloxacin or meropenem) or 
if they had received the trial antibiotics prior to randomisation (within 24 hours for 
ciprofloxacin and within 7 days for meropenem). The protocolised antibiotics resulted 
in equally high degree of adequacy of treatment in both groups (89% in BAL group and 
89.5% in clinical group). 
In contrast to the French trial, which showed a considerable difference in positivity rate 
of microbiology culture, this trial found that BAL was positive in 60% of cases and 
ETA was positive in 52% of cases. There was no significant difference in mortality at 
28 days with a relative risk reduction of 1.01 (95% CI 0.75-1.37). There was no 
difference in duration of mechanical ventilation or length of ICU or hospital stay. 
Furthermore there was no significant difference in number of days alive and without 
antibiotics between the BAL group and ETA group (10.4 +/- 7.5 and 10.6 +/- 7.9 
respectively). However at day 6, 74.6% of the ETA group and 74.2% of the BAL group 
were receiving antibiotic therapy, which suggests that opportunities for discontinuation 
of antibiotics in the context of negative cultures were not taken. The authors do state 
that the decision to continue antibiotics in the context of a culture growth of <10
4
 cfu/ml 
was, pragmatically, left to the treating physician. In addition the diagnosis of VAP was 
adjudicated retrospectively and the authors do state that any potentially pathogenic 
organism regardless of the number of cfu/ml was considered as a positive culture. 
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Three smaller single centre RCTs have also been carried out. Sanchez-Nieto et al 
reported a pilot study of 51 patients who were randomised to either invasive sampling 
by BAL and PSB with quantitative culture or ETA with quantitative culture(Sanchez-
Nieto et al., 1998). The use of quantitative culture in the control arm does not 
necessarily represent standard care. This study also reported high rates of positive 
culture, occurring in 67% of BAL, 58% of PSB and 67% of ETA. Although the trial 
was not powered at 51 patients to detect a mortality difference, there was no significant 
difference in mortality between the two groups. There was also no significant difference 
in LOS and duration of mechanical ventilation. The number of antibiotic days was not 
measured but there were more antibiotic modifications in the invasive group over the 
non-invasive group although whether this lead to fewer antibiotic days or more targeted 
therapy was not reported. 
The trial by Fagon et al highlights the potential value different diagnostic methods 
could have on antibiotic prescribing. In a trial by Ruiz et al, patients were randomised to 
either invasive or non-invasive management(Ruiz et al., 2000). In this trial antibiotics 
were continued if cultures were negative but clinical suspicion of VAP remained. The 
duration of antibiotic therapy was the same for both groups (12 +/- 4 days in the non-
invasive group and 13 +/- 4 days in the invasive group). There was no difference in 
mortality, ICU LOS or duration of mechanical ventilation. Again the rates of positive 
culture were similar in both groups with 51% in the non-invasive group and 60% in the 
invasive group. Surprisingly all PSB performed had a positive culture and 50% of BAL 
had a positive culture.  
In another single-centre RCT, 91 patients were randomised to either invasive or non-
invasive sampling(Solé Violán et al., 2000). The rate of culture positivity for the 
invasive group was 44% in comparison to 76% of the ETA group. There was no 
significant difference in mortality, ICU LOS or duration of mechanical ventilation. 
Although there were more antibiotic modifications in the invasive group over the non-
invasive group (33% vs 12%), the number of antibiotic days was not reported. In fact 
the authors state that antibiotics were not altered following negative cultures. 
The 5 RCTs are summarised in Table 6. 
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Reference Sample 
size 
Trial 
arms 
Primary 
outcome(s) 
Mortality Antibiotic 
management 
Fagon 
2000 
413 BAL/PSB 
vs clinical 
+ ETA 
Mortality at 14 
days 
AFD at 14 days 
 
Mortality 
difference -9.6 
(-17.4 - -1.8) 
P=0.022 
AFD difference  
2.8 (1.9-3.6) 
P<0.001 
CCCTG 
2006 
740 BAL vs 
clinical + 
ETA 
28-day 
mortality 
Relative risk of 
death in BAL 
vs ETA group:  
1.01 (0.75-
1.37) 
NS 
Days alive 
without 
antibiotics:  
BAL 10.4+/-7.5 
ETA 10.6+/-7.9 
Ruiz 2000 76 BAL/PSB 
vs ETA 
30-day 
mortality 
Mortality ETA 
46%, BAL 
38% NS 
Duration of 
antibiotics  
ETA 12+/-4 
BAL/PSB 13+/-
4 
Sanchez-
Nieto 
1998 
51 Quantitati
ve 
ETA/BA
L/PSB vs 
quantitati
ve ETA 
(QEA) 
Crude mortality BAL/PSB 
mortality 46%, 
QEA mortality 
26%  
NS 
Antibiotic 
modifications: 
BAL/PSB group 
42% 
QEA 16%. 
Solé 
Violán 
2000 
91 Quantitati
ve culture 
BAL or 
blind 
BAL vs 
clinical + 
ETA  
Mortality 
Antibiotic 
change 
Mortality: 
Quantitative 
22.2% 
Qualitative 
20.9%  
NS 
Narrower 
spectrum change 
in 10 patients in 
quantitative 
group vs 3 in 
qualitative 
group 
  
Table 6: Comparison of trials evaluating invasive sampling in comparison to non-invasive sampling. QEA, 
quantitative ETA 
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In a Cochrane review, the use of quantitative versus qualitative cultures was reviewed 
for clinical outcomes(Berton, Kalil and Teixeira, 2012). This review is as much a 
review of invasive versus non-invasive sampling. This meta-analysis concludes that 
there is insufficient evidence in terms of 28-day mortality (risk ratio 0.91, 95% CI 0.75-
1.11), length of ICU stay (risk ratio 0.58, 95% CI -0.51-1.68) or antibiotic changes (risk 
ratio 1.53, 95% CI 0.54-4.39) to suggest that an invasive strategy is superior over a non-
invasive strategy. However it is important to note that this review did not include the 
findings of Fagon et al(Fagon et al., 2000) regarding antibiotic reductions because no 
other study measured AFD. The authors highlight that to confirm the risk ratio 
reduction in mortality suggested in this meta-analysis of 9% would require a trial of 
7500 patients. It is therefore futile to make further attempts to demonstrate a mortality 
difference. There are however other relevant outcomes, and in the context of VAP 
antibiotic stewardship endpoints are important.  
The CPIS was used in a RCT as a strategy to improve antibiotic stewardship in patients 
with new CXR infiltrates on a surgical ICU(Singh et al., 2000). Patients with a CPIS > 
6 were excluded from the study and they received treatment for pneumonia (despite the 
same group previously showing that only 50% of patients with CPIS > 6 had 
pneumonia(Singh et al., 1998)). Patients with a CPIS ≤6 were randomised to receive 
either standard care (10-21 days of antibiotics) or ciprofloxacin for 3 days followed by a 
reassessment of CPIS at day 3 and discontinuation of antibiotics if the CPIS remained 
below 6. This study showed a reduction in antibiotic use in the CPIS-guided early 
discontinuation arm, a reduction in antibiotic-resistant pathogens, and a reduction in 
ICU length of stay, while maintaining equivalent outcomes in terms of mortality. There 
are several limitations to this study. Firstly only 58% of the patients were mechanically 
ventilated and it is important to highlight that the CPIS has not been derived or 
validated in a non-ventilated population. Secondly this study excluded patients with a 
CPIS of > 6 at screening and so does not really address the clinical problem of the 
overuse of antibiotics in patients with suspected VAP as it can be presumed that a 
significant proportion of those patients would not go on to have confirmed VAP. 
Although this study did result in a reduction in antibiotics, it highlights the extent of 
overuse of antibiotics for suspected VAP. A strategy of invasive BAL sampling and 
discontinuation of antibiotics following negative culture is likely to have a greater 
impact on reduction of antibiotics(Luyt, Chastre and Fagon, 2004). 
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1.8 Prevention of VAP 
The pathogenesis of VAP has been previously discussed (section 1.4) in terms of the 
changes in bacterial colonisation of oropharynx, subglottic area, sinuses and 
gastrointestinal (GI) tract and then subsequent translocation to lower respiratory tract. 
Altering this process could prevent VAP. The ability to reduce VAP rates through 
preventative measures has had a significant effect on how this HCAI is perceived, with 
a growing sense that this is an entirely preventable disease(Klompas, 2010). Since VAP 
occurs in the context of critical illness which is associated with immune 
dysfunction(Conway Morris et al., 2013), the ability to completely prevent this 
condition seems unlikely. Strategies can be considered as general approaches, strategies 
to prevent aspiration, strategies to prevent contamination of respiratory equipment and 
strategies to reduce colonisation. 
1.8.1 General measures 
Strategies to prevent VAP must be embedded in an environment of good hygiene 
practices to reduce the spread of HCAI by healthcare workers. The importance of hand 
hygiene in the reduction of HCAI is widely accepted(Pittet et al., 2000). Similarly a 
general approach to minimise or avoid intubation and mechanical ventilation is 
important to avoid the specific intervention that is implicated in this HCAI. Patients are 
generally sedated while mechanically ventilated, for comfort. At a point when it is felt 
that the patient has recovered sufficiently to attempt to breathe on their own and 
ultimately be extubated, the sedation is either reduced or stopped and the patient 
undergoes a ‘spontaneous breathing trial’ (SBT). Protocolised daily sedation 
interruption (DSI) to the point that the patient wakes with an assessment made of 
whether sedation should be restarted, in comparison to clinician-guided management of 
sedation, resulted in significantly reduced duration of mechanical ventilation and ICU 
stay(Kress et al., 2000). In a further RCT, SBT were undertaken in conjunction with 
DSI(Girard et al., 2008). In the control group sedation practice was left to the discretion 
of the clinician, to maintain a level of arousal felt appropriate to the patient. An 
assessment was made on the safety of performing a SBT and if appropriate the SBT was 
undertaken. Decisions to extubate based on the success of the SBT were left to the 
discretion of the clinical team. In the intervention arm, sedation was stopped each day 
and if patients tolerated being awake, a SBT was undertaken. There were a greater 
number of ventilator-free days, shorter duration of ICU stay, shorter duration of hospital 
stay and reduced risk of death in the first year in the intervention arm.  
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In a meta-analysis of weaning protocol interventions, protocolised weaning was 
associated with a 25% (95% CI 9-39%) reduction in the mean duration of mechanical 
ventilation(Blackwood et al., 2011). In a recent non-randomised study, SBT and DSI 
were implemented to determine the impact on VAC(Klompas et al., 2015). The study 
found that VAC and IVAC were reduced per episode of mechanical ventilation (rather 
than in ventilator-days) with an OR 0.63 and 0.35 respectively. While this study did not 
prevent ‘VAP’, it does support the concept that time off the ventilator reduces the time 
at risk of the complications of mechanical ventilation. 
With a similar purpose of minimising time on mechanical ventilation, non-invasive 
ventilation (NIV) has been used to assist in extubation from mechanical ventilation. 
NIV provides bi-level positive airway pressure via a tightly fitting facemask or hood. 
Two meta-analyses of randomised trials and quasi-randomised trials of NIV in 
comparison to invasive weaning strategies(Burns, Adhikari and Meade, 2006; Burns et 
al., 2009) have demonstrated a benefit in patients who have undergone weaning via 
NIV with a reduction in mortality (RR 0.55, 95% CI 0.38-0.79), VAP (RR 0.29, 95% CI 
0.19-0.45), ICU LOS (mean difference 6.27 days, 95% CI 3.78-8.77), hospital LOS 
(mean difference 7.19 days, 95% CI 3.58-10.80) and invasive mechanical ventilation 
(mean difference 7.81 days, 95% CI 4.31-11.31)(Burns et al., 2009). The trials included 
in the meta-analyses were relatively small ranging from 21 to 90 participants and the 
majority of trials only included patients with chronic obstructive pulmonary disease 
(COPD). While it is unknown whether these findings can be generalised to a general 
ICU population, it does again support the concept that avoiding mechanical ventilation 
reduces its complications. 
1.8.2 Prevention of aspiration 
Aspiration of either oropharyngeal or gastric contents is implicated in the pathogenesis 
of VAP and strategies to prevent this are important(Estes and Meduri, 1995). In an 
observational study of patients nursed both in a supine position (0
o
) or at a 45-degree 
semi-recumbent position, a technetium (Tc)-99m sulphur colloid was instilled into the 
stomach via a nasogastric tube(Torres et al., 1992). Bronchial secretions were sampled 
at intervals between 0 and 300 minutes. Radioactivity was measured in counts per 
minute (cpm) and there were higher cpm in the supine group over the semi-recumbent 
group, which rose steeply between 240 and 300 minutes in the supine group. In a RCT, 
patients were randomly assigned to being nursed in a supine position (0
o
) or in a semi-
recumbent position (45
o
)(Drakulovic et al., 1999). The primary outcome measure was 
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clinically suspected VAP and the trial was powered to show a 50% risk reduction by the 
semi-recumbent position requiring 182 patients. A secondary endpoint was 
microbiologically confirmed VAP which could be confirmed by a pathogen in either an 
ETA or by a bronchoscopic method (PSB or BAL). The trial was stopped at its interim 
analysis after randomisation of 90 patients due to a significant risk reduction in the 
semi-recumbent position group in clinically suspected VAP of 76% and 
microbiologically confirmed VAP at 78%. A significant limitation of this trial was the 
potential for bias, in that the primary endpoint of clinically suspected VAP is highly 
subjective and the trial had no means of blinding. One key issue with the external 
validity of this trial is that patients are rarely nursed completely supine but generally 
with some degree of elevation. In a further RCT patients were randomised to nursing at 
10
o 
elevation (supine) or 45
o
 elevation (semi-recumbent) and the degree of bed elevation 
was monitored(van Nieuwenhoven et al., 2006). The primary endpoint was confirmed 
VAP by criteria based on culture from BAL fluid. In this trial of 221 patients, one of the 
key outcomes was the feasibility of nursing patients at a 45
o
 position. In the supine 
group bed elevation was 9.8
o 
± 3.9 on day 1 and at day 7 was 14.8
o 
± 7.1
o
. In the semi-
recumbent group the bed elevation was 29.2
o
 ± 10.3
o
 on day 1 and 26.5
o
 ± 8.2
o
 on day 
7. In this trial there was no significant difference in confirmed VAP between the two 
trial arms. Although the exact degree of bed elevation is unclear, patients are almost 
universally nursed with some degree of elevation and an elevation of 30
o
 is widely 
recommended(Lorente, Blot and Rello, 2007) with little controversy since this is a 
simple measure to implement. 
Secretions above the ETT cuff are able to leak past the cuff, reaching the lower 
respiratory tract(Seegobin and van Hasselt, 1986). The ETT cuff is the predominant 
barrier and the pressure of this has to be sufficient for it to function in this regard. In an 
observational study of 83 patients primarily investigating the value of subglottic 
suction(Rello et al., 1996), the investigators found that antibiotic use and subglottic 
suction was preventative against VAP. There was a trend towards patients with cuff 
pressures of <20cmH20 to be at greater risk of VAP (RR 2.57, 95% CI 0.78-8.03) and in 
a multivariate analysis of patients who were not on antibiotics, a cuff pressure of 
<20cmH2O was independently associated with VAP (RR4.23, 95% CI 1.12-15.92).  
Once the ETT cuff is inflated there is a space between the vocal cords and the top of the 
cuff and in this subglottic area secretions can accumulate and be aspirated into the 
airways. This area cannot be suctioned by conventional methods and so specialised ETT 
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are used that have a suction port to this space. The clinical benefits of subglottic 
secretion drainage (SSD) have now been evaluated in three meta-analyses(Dezfulian et 
al., 2005; Muscedere et al., 2011; Wang et al., 2012). The first meta-analysis of 5 RCTs 
incorporating a total of 896 patients showed that SSD was associated with a relative risk 
reduction of VAP of 0.51 (95% CI 0.37-0.71)(Dezfulian et al., 2005). In the sensitivity 
analysis, excluding a single trial that caused the heterogeneity in the group, SSD 
reduced duration of mechanical ventilation by 2 days (95% CI 1.7-2.3 days) and length 
of ICU stay by 3 days (95% CI 2.1-3.9). This meta-analysis was updated in two further 
meta-analyses. In the meta-analysis by Wang et al of 10 RCTs, SSD was associated 
with a RR reduction of 0.56 (95% CI 0.45-0.69), reduced duration of mechanical 
ventilation by 1.55 days (95% CI -2.40 - -0.71) and prolonged time until VAP by 3.9 
days (95% CI 2.56-5.24)(Wang et al., 2012). Similar to Dezfulian et al, the main effect 
appears to be on reducing early VAP rather than late VAP. In the meta-analysis by 
Muscadere et al, the risk ratio for VAP was similarly lower in the SSD group at 0.55 
(95% CI 0.46-0.66) in a meta-analysis of 13 RCTs with no heterogeneity (I
2
 
0%)(Muscedere et al., 2011). In this meta-analysis, not only was there an increased time 
until onset of VAP and shorter duration of mechanical ventilation, but also a reduced 
length of ICU stay (-1.52 days, 95% CI -2.94- -0.11). SSD represents a preventative 
strategy with one of the strongest evidence bases for its use. It is now recommended in 
VAP prevention guidelines(NICE, 2008; Institute for Healthcare Improvement, 2012) 
but despite this it is not widely used in UK ICUs(Baldwin, Gray and Chequers, 2014). 
1.8.3 Prevention of contamination of equipment 
Patients who are mechanically ventilated bypass the natural humidification process of 
the upper airways. Inspired gases must be humidified to allow normal respiratory tract 
function and prevent respiratory secretions becoming tenacious, which could have the 
potentially catastrophic consequence of ETT occlusion. Inspired gases can be 
humidified by two methods, the first of which is heat humidification (HH), which 
passes gases over a reservoir of heated water and in addition may have a heated coil in 
the inspiratory limb of the circuit to prevent condensation. The second method is a heat 
and moisture exchanger (HME). This is a filter placed at the ETT that has a hygroscopic 
salt (calcium or lithium chloride) that absorbs the patient’s water vapour during 
expiration and then releases it on inspiration, thereby conserving the patient’s own 
moisture and heat. While humidification is essential there is also concern that 
humidification can act as a source of contamination and result in VAP. In two early 
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trials of HME and HH, patients in the HME groups had occlusion or partial occlusion of 
the ETT, which led to the death of a patient in one trial(Martin et al., 1990; Roustan et 
al., 1992). A number of RCTs conducted since that have not found a signal for harm 
from HME use(Dreyfuss et al., 1995; Boots et al., 1997; Hurni et al., 1997; Kirton et 
al., 1997; Kollef et al., 1998; Memish et al., 2001; Thomachot et al., 2002; Hess et al., 
2003; Lacherade et al., 2005; Lorente et al., 2006). As with many VAP trials, a number 
of RCTs are limited by diagnostic definitions, and outcomes based on clinical 
definitions are inherently at risk of bias. In a single-centre RCT of 164 patients in which 
VAP was defined based on BAL and PSB culture, no difference in VAP rates or in 
pharyngeal colonisation was found between HH and HME groups(Dreyfuss et al., 
1995). Furthermore in a multi-centre RCT of 369 patients, with a similar rigorous 
definition of VAP, no difference in VAP rates was found between HH and 
HME(Lacherade et al., 2005). A meta-analysis of 8 RCTs found that VAP was lower in 
the HME group with an OR of 0.69 (0.51-0.94).  When sub analyses were performed 
this was only significant in patients ventilated for greater than 7 days and in patients 
with a clinical diagnosis of VAP but not a microbiological diagnosis of VAP(Kola, 
Eckmanns and Gastmeier, 2005). In a further large meta-analysis of 33 trials, of which 
27 were in adults, 25 were parallel design and 8 were a cross-over design, no difference 
was found in outcomes of pneumonia, airway occlusion or mortality between HH and 
HME(Kelly et al., 2010). In subgroup analyses there was no difference in just adults or 
paediatric cases or between hydrophobic or hygroscopic HME filters.  
Suctioning of respiratory secretions is critical in the care of ventilated patients. Open 
suction units require disconnecting the patient from the ventilator to introduce a single 
use suction catheter. This has a number of disadvantages including disruption to 
ventilation, loss of positive end expiratory pressure (PEEP) and exposure of healthcare 
workers to respiratory secretions. Closed suction units are placed in the circuit and 
allow suctioning without disconnection from the ventilator. Despite concerns that closed 
suction units could become contaminated and therefore be a risk factor for VAP, a 
meta-analysis did not find an increased risk of VAP between either method of 
suctioning(Subirana, Solà and Benito, 2007). 
Since inspired gases are humidified, the condensate in the ventilator circuit runs the risk 
of becoming contaminated. For this reason it was practice in the 1980’s for circuits to 
be changed every 24 hours to prevent contamination, however this frequency was found 
to be a risk factor for VAP in comparison to changes every 48 hours(Craven et al., 
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1986). This may be due to increased manipulation of the circuit and therefore the risk of 
contaminated secretions entering the bronchial tree via the lumen of the ETT. Several 
studies have investigated the interval that the circuits should be changed at. In an 
observational study that used circuit changes at 2-day intervals, 7-day intervals and 30-
day intervals, each for 1 year, the highest VAP rate was in the 2-day interval period at 
11.88 cases per 1000 ventilator days and 3.34 and 6.28 per 1000 ventilator days in the 
7- and 30-day interval periods respectively(Fink et al., 1998). In two RCTs one using 
HH(Kollef et al., 1995) and another using HME humidification(Lorente et al., 2004), 
routine 7 day changes were compared to no routine changes. Ventilator circuits were 
changed at the discretion of clinicians if faulty or visibly soiled. In both trials there were 
no significant differences in rates of VAP between the two trial arms, suggesting that 
routine changes are unnecessary and costly. In the trial by Kollef et al, patients 
receiving circuit changes every 7 days had 247 circuit changes at the cost of $7410 in 
comparison to the group with no routine changes, which had a total of 11 circuit 
changes costing $330(Kollef et al., 1995).  
1.8.4 Prevention of colonisation: oral intubation 
The preventative steps outlined so far aim to prevent aspiration of a pathogen. 
Preventative measures are also aimed at reducing colonisation with potential pathogens 
so as to reduce the bacteria at the sources of infections. The potential sites of 
colonisation are the sinuses, the oropharynx and the gastrointestinal tract. Patients can 
either be intubated via the nasal or oral routes. Nasal intubation has the advantage over 
oral intubation in that it is better tolerated in patients on less sedation and it removes the 
risk of patients biting the ETT. The main disadvantage however, is the risk of 
developing infective sinusitis, which could result in infective secretions bypassing the 
ETT. Reports are conflicting on the significance of nasal intubation as a risk factor for 
VAP. In a trial of 111 patients randomised to either nasal or oral intubation, sinusitis 
was diagnosed based on portable x-rays being performed of the head(Salord et al., 
1990). X-ray was performed before intubation, at day 3, day 7 and each week until 
extubation. Maxillary sinusitis occurred in 1.8% of the oral intubation group and in 43% 
of the nasal intubation group. This trial did not measure the influence on VAP. In a 
larger trial of 300 patients, patients were randomised to oral or nasal 
intubation(Holzapfel et al., 1993). Patients were followed up for clinical signs of 
sinusitis including purulent nasal discharge and pyrexia. CT scans were performed 
every 7 days or if there were clinical signs of sinusitis. If an air-fluid level was present 
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on CT, a transnasal puncture was taken for culture. VAP was diagnosed based on 
microbiology data from PSB sampling. This trial did not find a significant difference in 
the rates of sinusitis (which were 19% in the nasal group and 17% in the oral group) or 
in VAP (11% of the nasal group and 6% in the oral group). Despite the inconsistency in 
the evidence, oral intubation is widely recommended in guidelines(Lorente, Blot and 
Rello, 2007). 
1.8.5 Prevention of colonisation: oral antiseptics 
The use of oral biocides, such as chlorhexidine, to reduce oropharyngeal colonisation is 
another strategy that has been widely investigated. The use of chlorhexidine oral care 
has become almost ubiquitous and has been recommended in national guidelines(NICE, 
2008; Institute for Healthcare Improvement, 2012). Meta-analyses are conflicting and 
this requires a reassessment of these recommendations. In a meta-analysis by Chan et 
al, 11 RCT of oral decontamination were analysed(Chan et al., 2007). These included 4 
trials of oral antibiotics and 7 trials of oral antiseptics. There was no significant 
difference in incidence of VAP associated with oral antibiotics but there was with oral 
antiseptics with a RR of 0.56 (95% CI 0.39-0.81). In contrast to this, a meta-analysis of 
7 RCTs of chlorhexidine did not demonstrate a significant reduction in VAP (RR 0.70, 
95% CI 0.47-1.04)(Chlebicki and Safdar, 2007). The trials included in these meta-
analyses incorporated trials in cardiac surgery patients and general/mixed ICU patients. 
The distinction between these two groups of patients is crucial in the emerging 
controversy surrounding this area. Cardiac surgery patients are generally mechanically 
ventilated for 24-48 hours whereas general ICU patients are often ventilated for longer 
periods. In a further meta-analysis of trials of the oral antiseptics chlorhexidine or 
povidone-iodine, the total risk ratio was 0.67 (95% CI 0.50-0.88) in favour of oral 
antiseptic(Labeau et al., 2011). In the subanalysis, however, this was only significant in 
the cardiac surgery population with a risk ratio of 0.41 (95% CI 0.17-0.98). In the mixed 
ICU population the risk ratio was 0.77 (95% CI 0.58-1.02) and in the surgical/trauma 
population the risk ratio was 0.38 (95% CI 0.13-1.10). In this meta-analysis, two RCTs 
in cardiac surgery patients accounted for 37% of patients in the meta-analysis(DeRiso et 
al., 1996; Houston et al., 2002). Trials in this area are limited by inconsistent definitions 
of VAP and other methodological limitations. De Riso et al carried out a double-blinded 
placebo-controlled trial of 350 patients in a cardiac ICU(DeRiso et al., 1996). The 
diagnosis of VAP was based on clinical findings and radiological signs. The duration of 
mechanical ventilation was not reported but the duration of ICU stay was 7.9 and 8.5 
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days in the chlorhexidine and control groups respectively. They demonstrated a 
reduction in all respiratory infections by 69%, which included criteria for VAP and 
tracheobronchitis. When subdivided between upper and lower respiratory tract 
infection, there were no significant differences. The trial by Housten et al(Houston et 
al., 2002) also has a significant influence on the meta-analyses including 561 cardiac 
ICU patients. The authors report that few patients received more than two doses of 
chlorhexidine because of early extubation, however the average duration of mechanical 
ventilation is not reported, although clearly it was short. This trial did not find any 
difference in VAP rates between the two arms. Another large RCT in cardiac ICU, 
randomised 991 patients to chlorhexidine or placebo(Segers et al., 2006). The mean 
duration of ICU stay was only 1.2 days. The primary endpoint was all nosocomial 
infections, which were significantly lower in the chlorhexidine group than the control 
group (19.8% vs 26.2%, absolute risk reduction 6.4%, 95% CI 1.1-11.7%). Lower 
respiratory tract infections, based on CDC criteria, were reduced with an absolute risk 
reduction of 6.5% (95% CI 2.3-10.7%). 
Trials in a mixed ICU or surgical/trauma ICU setting have resulted in inconsistent 
results. In a trial of 385 patients from general ICUs from 5 hospitals in the Netherlands, 
patients were randomised to either chlorhexidine, chlorhexidine and colisitin, or 
placebo(Koeman et al., 2006). BAL was encouraged for diagnosis but not mandated and 
VAP definition was based on clinical and radiological criteria. The trial was stopped 
early due to meeting stopping criteria for superiority of chlorhexidine over placebo. The 
daily risk of VAP was reduced by chlorhexidine by 65% (hazard ratio (HR) 0.352, 95% 
CI 0.160-0.791) and by chlorhexidine and colistin by 55% (HR 0.454, 95% CI 0.223-
0.925). A number of other studies of lower methodological quality support this 
finding(Fourrier et al., 2000; Seguin et al., 2006; Özçaka et al., 2012). In contrast 
however, other trials did not find a significant benefit from oral chlorhexidine, although 
a number of them have methodological limitations(Grap et al., 2004; Fourrier et al., 
2005; Tantipong et al., 2008; Panchabhai et al., 2009; Scannapieco et al., 2009; Berry et 
al., 2011). 
Two recent meta-analyses of chlorhexidine in non-cardiac surgery patients have 
produced very different findings from the earlier meta-analysis. In a meta-analysis of 16 
trials, cardiac surgery patients accounted for 51% of patients in the population(Klompas 
et al., 2014). There was significantly less VAP in cardiac patients receiving 
chlorhexidine (RR 0.56, 95% CI 0.41-0.77). In the non-cardiac patients the reduction in 
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VAP was not significant (RR 0.78, 95% CI 0.60-1.02) and the point estimate was higher 
in blinded studies (RR 0.88, 95% CI 0.66-1.16). In terms of mortality there was a non-
significant trend towards increased mortality in non-cardiac patients receiving 
chlorhexidine with a RR 1.13 (95% CI 0.99-1.29). Price et al performed a meta-analysis 
to determine the role of selective decontamination of the digestive tract, selective 
oropharyngeal decontamination and topical chlorhexidine in the prevention of death on 
the general ICU population(Price, Maclennan and Glen, 2014). Although both SDD and 
SOD were associated with a reduction in mortality, chlorhexidine was associated with a 
significant increase in risk of death with an OR of 1.25 (95% CI 1.05-1.50). These two 
recent meta-analyses raise concerns over the widespread use of chlorhexidine outside of 
the cardiac surgical population. 
1.8.6 Prevention of colonisation: selective decontamination 
Selective decontamination of the digestive tract (SDD) and selective oropharyngeal 
decontamination (SOD) are two further approaches to reduce colonisation and thereby 
reduce the risk of VAP and HCAI more generally. This is the administration of topical, 
non-absorbable antibiotics, and in the case of SDD also a short (4 day) course of broad-
spectrum antibiotic (eg. cefuroxime) to eradicate aerobic bacteria which are potentially 
pathogenic and so leave the gut colonised with anaerobic bacteria. In early animal work 
Van der Waaij et al found that mice who had been given antibiotics to eliminate gut 
flora remained resistant to colonisation by orally ingested E. coli, P. aeruginosa and K. 
pneumoniae(Van der Waaij, Berghuis-de Vries and Lekkerkerk-van der Wees, 1971). 
Furthermore if the healthy mice were contaminated with the flora of SDD-treated mice, 
they too became resistant to colonisation. The GI tract of these mice were colonised 
with anaerobic bacteria and it was concluded that the resistance to colonisation stemmed 
from this. The concept of selective decontaminaton of Gram-negative aerobes was first 
tested in ICU in a group of trauma patients(Stoutenbeek et al., 1984). In this historical 
case control study, patients received systemic antibiotics until they were free of all 
potential pathogenic microorganisms. The mouth was decontaminated with 2% 
polymyxin E, 2% tobramycin and 2% amphotericin. The gut was decontaminated with 
polymyxin E, torbramycin and amphotericin. In the control group, 86% of patients had 
oropharyngeal colonisation by Gram-negative potentially pathogenic microorganisms 
(PPM) by day 15. In terms of intestinal colonisation, the pattern in the control group 
was that rates of E. coli colonisation remained constant but colonisation with other PPM 
aerobic Gram-negative bacteria increased, in particular P. aeruginosa, Proteus spp., and 
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Acinetobacter spp. In the SDD cohort, oropharyngeal colonisation decreased rapidly 
and was significantly lower by day 2. In the intestine, colonisation with E. coli 
decreased and colonisation with PPM aerobic Gram-negative bacteria was significantly 
reduced and occurred in only 14% of patients within 2 weeks. The authors found that 
the total infection rate decrease by 16%. 
Although the initial description of SDD involved the use of systemic antibiotics for a 
short period in addition to non-absorbable antibiotics, the systemic component is often 
not used. SOD refers to the use of non-absorbable oral antibiotics only. The full SDD 
regimen is aimed at reducing the pool of Gram-negative aerobes and therefore aims to 
reduce any HCAI. SOD on the other hand is predominantly focusing on reducing VAP 
There have been 8 meta-analyses evaluating the trial evidence of SDD and SOD in 
terms of reducing VAP, HCAI and mortality(Vandenbroucke-Grauls and 
Vandenbroucke, 1991; Selective Decontamination of the Digestive Tract Trialist’ 
Collaborative Group, 1993; Kollef, 1994; Chan et al., 2007; D’Amico et al., 2009; 
Silvestri et al., 2009; Pileggi et al., 2011; Price, Maclennan and Glen, 2014). These 
meta-analyses generally contain a range of definitions of respiratory tract infections 
including VAP and tracheobronchitis and therefore report reductions in respiratory tract 
infections (RTI) rather than VAP per se. Generally these meta-analyses have shown a 
consistent reduction in RTI(Selective Decontamination of the Digestive Tract Trialist’ 
Collaborative Group, 1993; Kollef, 1994; D’Amico et al., 2009; Silvestri et al., 2009; 
Pileggi et al., 2011; Price, Maclennan and Glen, 2014). A Cochrane review of 36 RCTs 
including 6914 patients found that there was a greater reduction in RTI with SDD that 
included systemic antibiotics, with OR 0.28 (95% CI 0.20-0.38), in comparison to 
topical antibiotics only with a OR of 0.44 (95% 0.31-0.63)(D’Amico et al., 2009). The 
meta-analysis by Chan et al is an outlier in that it did not find a reduction in VAP for 
SOD(Chan et al., 2007). The meta-analysis was of oral decontamination only and so 
included SOD and oral antiseptics. In the 4 trials of SOD included there was no 
reduction in VAP with a relative risk of 0.69 (95% 0.41-1.18). This meta-analysis was 
more robust in terms of ensuring that a definition of VAP was used rather than any RTI. 
In terms of antibiotic stewardship the distinction between VAP and RTI may be less 
important since patients are likely to receive antibiotics for either and so a reduction in 
RTI remains an important outcome. 
In addition to a greater reduction in RTI, the use of the full SDD regimen was also 
associated with a reduction in mortality with an OR of 0.75 (95% 0.65-0.87)(D’Amico 
   
  49 
et al., 2009). The number needed to treat (NNT) for the mortality benefit was 18. 
Silvestri et al performed a meta-analysis of trials that used the full SDD (ie. including 
systemic antibiotics) and found that there was a mortality benefit with SDD (OR 0.71, 
95% CI 0.61-0.81)(Silvestri et al., 2009). The subgroup analysis suggested the 
reduction in mortality was in late deaths rather than early deaths (OR 0.58, 95% CI 
0.45-0.77), and also found a greater reduction when all patients in the ICU received 
both non-absorbable enteral and systemic antibiotics (OR 0.59, 95% CI 0.42-0.82). 
Furthermore, in the recent meta-analysis by Price et al, there was a significant mortality 
benefit for SDD with an OR 0.73 (95% 0.64-0.84) and a smaller benefit with SOD with 
an OR of 0.85 (95% CI 0.74-0.97)(Price, Maclennan and Glen, 2014). This mortality 
benefit has not been demonstrated in other meta-analyses(Vandenbroucke-Grauls and 
Vandenbroucke, 1991; Selective Decontamination of the Digestive Tract Trialist’ 
Collaborative Group, 1993; Kollef, 1994; Chan et al., 2007; Pileggi et al., 2011).  
A number of high quality trials of SOD and SDD have been included in the meta-
analyses. De Jonge et al conducted a trial in two ICUs, with identical patient 
populations, within a single institution with each ICU randomly assigned to SDD or 
placebo(de Jonge et al., 2003). The design was adopted to avoid cross contamination of 
flora between SDD and placebo patients. Their primary outcomes were colonisation by 
resistant strains of microorganisms, ICU- and hospital-mortality, and the trial included 
934 patients. Both ICU- and hospital-mortality were reduced in the SDD group (relative 
risk 0.65, 95% CI 0.49-0.85 and 0.78, 95% CI 0.63-0.96 respectively). There was no 
overall difference in resistance in colonising organisms between the two groups 
although there was increased resistance in Gram-negative organisms in the control 
group. It should be noted, however, that resistance in this population was generally low 
with vancomycin-resistant Enterococcus (VRE) in 1%,and no cases of methicillin-
resistant S. aureus (MRSA).  
In another large Dutch trial, 5939 patients were randomised in a cluster-randomised, 
three arm trial of SDD, SOD and placebo(de Smet et al., 2009). A cluster-randomised 
approach was used again to avoid cross contamination of flora between trial arms. In 
terms of the primary endpoint of 28-day mortality, there was a reduction in the risk of 
death in both the SOD and SDD arms with an OR of 0.86 (95% CI 0.74-0.99) and 0.83 
(95% CI 0.72-0.97) respectively. This corresponds to a NNT to save one life at 28 days 
of 34 for SOD and 29 for SDD. This trial also found that antimicrobial resistance was 
low generally with no increase in resistance in the SOD and SDD groups. In fact in a 
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subsequent analysis of the data, there were fewer ‘highly resistant organisms’ in the 
SDD group in comparison to the SOD and placebo group, which may appear counter 
intuitive(de Smet et al., 2011). Furthermore there was less colonisation of the 
respiratory tract with highly resistant organisms in both the SDD and the SOD groups in 
comparison to placebo (OR 0.58, 95% CI 0.43-0.78 and 0.65, 95% CI 0.49-0.87 
respectively). 
Despite the substantial evidence to support the use of SDD and SOD, it is not widely 
accepted(Walden, Bonten and Wise, 2012; Cuthbertson et al., 2013). One of the issues 
is that much of the evidence in support of SDD comes from the Netherlands(Bergmans 
et al., 2001; de Jonge et al., 2003; de Smet et al., 2009), which has low levels of 
endemic resistance. In contrast, trials from other countries have found inconsistent 
results. A reduction in respiratory tract infections was found in two Spanish 
trials(Sánchez García et al., 1998; de La Cal et al., 2005), a Belgian trial(Verwaest et 
al., 1997) and an international trial(Stoutenbeek et al., 2007). No benefit in reducing 
respiratory tract infections was found in other trials(Gastinne et al., 1992; Hammond, 
1992; Wiener et al., 1995). In many of these smaller RCTs no mortality benefit was 
detected although these would be underpowered to detect such an effect(Gastinne et al., 
1992; Hammond, 1992; Wiener et al., 1995; Verwaest et al., 1997; Sánchez García et 
al., 1998; de La Cal et al., 2005; Stoutenbeek et al., 2007).  
Concern regarding emergence of antibiotic resistance is a major barrier to the uptake of 
SDD and SOD. Although resistance has not been associated with SDD in large trials(de 
Jonge et al., 2003; de Smet et al., 2009), there are trials which have found notable 
increases in resistance(Sánchez García et al., 1998). In a meta-analysis of 35 trials with 
resistance outcomes, when comparing SDD or SOD to control, there was no significant 
increase in MRSA (OR 1.46, 95% CI 0.90-2.37) or VRE (OR 0.63, 95% CI 0.63-
1.02)(Daneman et al., 2013). Amongst Gram-negative bacilli there was no difference 
between SDD/SOD and control in aminoglycoside- or fluoroquinolone-resistance but 
there was a reduction in resistance to polymyxin-E or B (OR 0.58, 95% CI 0.46-0.72) 
and in third-generation cephalosporin resistance (OR 0.33, 95% CI 0.20-0.52). It should 
however be noted that this meta-analysis is heavily influenced by the large Dutch trials. 
In determining the effect of SDD/SOD over time, there was an increase in the 
prevalence of VRE for each month of trial duration in the SDD/SOD group with an OR 
1.2 per month (95% CI 1.1-1.3). In a 5 year observational study of a single German ICU 
that routinely performed SDD, 4,597 isolates were compared against 46,346 isolates 
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from reference ICUs that did not routinely perform SDD(Heininger et al., 2006). There 
was no difference in MRSA in the SDD ICU and aminoglycoside-resistant P. 
aeruginosa was lower compared to the reference ICU. There was, however, an increase 
in VRE, aminoglycoside-resistant E. coli and aminoglycoside-resistant K. pneumoniae. 
In a Spanish observational study in a single ICU over 5 years, the Enterobacteriaceae 
resistance to antimicobials in the SDD regimen was stable and Pseudomonas spp. 
resistance to the SDD regimen antibiotics reduced(Ochoa-Ardila et al., 2011). There 
was a significant increase in P. aeruginosa resistance to ceftazidime, which was not 
temporally related to the increase in cephalopsporin use in the SDD regimen. There was 
an increase in imipenem resistance amongst Pseudomonas spp. associated with an 
increase in imipenem use. Overall there was not a significant increase in antimicrobial 
resistance over the 5 year period. 
1.8.7 Prevention of colonisation: stress ulcer prophylaxis 
Gastrointestinal (GI) bleeding is a recognised complication of being critically ill and 
acid-suppressive therapy is used to raise the stomach pH, which renders pepsin inactive 
and inhibit finbrinolysis of clot(Fennerty, 2002). The consequence of raising pH, 
however is that there is increased colonisation of stomach contents, which could act as a 
source of pathogens that will cause VAP(Bonten et al., 1995). GI bleeding is generally 
reported as ‘overt bleeding’ when frank blood, melaena or ‘coffee grounds’ are reported 
or as ‘clinically significant bleeding’, when there is a fall in blood pressure, a drop in 
haemoglobin or the need for a blood transfusion. In a seminal multi-centre cohort study, 
Cook et al followed up 2252 patients in whom they encouraged physicians to withhold 
stress ulcer prophylaxis (SUP)(Cook et al., 1994). Of these, 100 patients had overt GI 
bleeding and 87 of these were receiving SUP. Only 33 patients, out of the whole cohort, 
had ‘clinically important GI bleeding’ (1.5%, 95% CI 1.0-2.1). Respiratory failure and 
coagulopathy were identified as risk factors for GI bleeding and mortality was 
considerably higher in those with GI bleeding. Within the group of patients who are at 
risk of GI bleeding and in whom SUP is appropriate, there is the need to weigh up the 
effectiveness of different drugs against the risk of promoting VAP. In a RCT of 1200 
patients in a blinded, placebo-controlled trial of sucralfate (a complex of aluminium 
hydroxide and sulfated sucrose that forms a physical barrier to protect gastric mucosa) 
versus ranitidine (a histamine H2-receptor antagonist that reduces gastric acid 
production) there were fewer clinically important GI bleeds in the ranitidine group with 
a RR of 0.44 (95% CI 0.21-0.92) although the event rate was still low (1.7% in the 
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ranitidine group and 3.8% in the sucralfate group)(D. Cook et al., 1998). There was no 
significant increase in mortality for VAP between the two groups. A number of meta-
analyses have been carried out in this area which support the finding that ranitidine 
provides superior SUP over sucralfate(Cook et al., 1996; Messori et al., 2000; Huang et 
al., 2010). The meta-analyses also demonstrated that ranitidine was associated with a 
higher incidence of VAP.  
ICU practices are likely to have changed considerably since the earlier trials of SUP. In 
particular the use of early enteral feeding and the use of proton pump inhibitors (PPI) 
are in far more widespread use now. To determine the role of enteral feeding in SUP, 
Marik et al performed a meta-analysis of RCTs of histamine H2-receptor blockers 
(H2RB) versus placebo and grouped patients into those with or without enteral 
feeding(Marik et al., 2010). In this analysis H2RB SUP was found to reduce the risk of 
GI bleeding with an OR of 0.47 (95% CI 0.29-0.76). This effect was only observed in 
patients who were not receiving enteral feeding and there was no benefit for those who 
were enterally fed (OR 1.26, 95% CI 0.42-3.7). Furthermore the risk of VAP was not 
significant when considering all patients (OR 1.53, 95% CI 0.89-2.61) but for the 
subgroup of patients who were fed enterally the OR was 2.81 (95% CI 1.20-6.56). In a 
historical observational study of two 15 month periods in which SUP was used for the 
first 15 months and no SUP was used for the second, no difference was found in 
incidence of GI bleeding, VAP or mortality(Faisy et al., 2003). 
Proton pump inhibitors (PPI) (a parietal cell gastric proton pump blocker that reduces 
gastric acid) are increasingly used as first line SUP despite little evidence to support 
their use(Daley et al., 2004). A meta-analysis of 7 RCTs including 936 patients found 
there was no difference between PPI and H2RB with a risk difference of -0.04 (95% CI 
-0.09-0.01)(Lin et al., 2010). This was associated with moderate to high heterogeneity 
(I
2
 66%). In the sensitivity analysis, removal of one trial reduced the heterogeneity (I
2 
26%), and the effect remained non-significant. There was no difference in risk of VAP 
between PPI and H2RB either (risk difference 0.00 (95% CI -0.04-0.05). Despite the 
limited evidence for the use of PPI, their use has increase not only within the ICU but 
also amongst non-ICU patients(Heidelbaugh and Inadomi, 2006). There is no evidence 
base for the use of SUP in non-ICU patients and PPI use is associated with increased 
rates of HAP(Herzig et al., 2009) and with community-acquired pneumonia(Sarkar, 
Hennessy and Yang, 2008). In a large scale pharmacoepidemiological study of 35,312 
patients mechanically ventilated for more than 24 hours and receiving either a PPI or a 
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H2RB, PPIs were associated with a greater risk of GI bleeding (OR 2.24, 95% CI 1.81-
2.76), pneumonia (OR 1.2, 95% CI 1.03-1.41) and Clostridium difficile infection (OR 
1.29, 95% CI 1.04-1.64)(MacLaren, Reynolds and Allen, 2014).  
Although these data do not provide conclusive evidence that enteral feeding is sufficient 
to protect against GI bleeding, it does suggest that it may be sufficient. These data also 
highlight that SUP is not without risk and it is used for the prevention of an infrequent 
complication of critical illness. The role of SUP needs to be reassessed in light of 
changing ICU practices. 
1.8.8 VAP prevention bundles 
Grouping the prevention strategies already discussed into ‘bundles’ of care has become 
widespread. VAP prevention bundles have not been tested in randomised trials and so 
are subject to the biases of non-randomised studies. When multiple interventions are 
delivered together as a bundle it is difficult to determine the contribution of individual 
components of the bundle. The Institute for Healthcare Improvement (IHI) has been a 
major driving force with its VAP prevention bundle(Institute for Healthcare 
Improvement, 2012). The bundle includes elevation of the head of the bed to between 
30 and 45 degrees; DSI and SBT; SUP; deep venous thrombosis (DVT) prophylaxis; 
and daily oral care with chlorhexidine. Notwithstanding recent data that suggest the use 
of chlorhexidine is inappropriate, one can appreciate that this bundle is not solely aimed 
at prevention of VAP and reflects more a ‘ventilator care bundle’ by including DVT 
prophylaxis, which is not used for VAP prevention. In an observational study to 
determine the association between the occurrence of VAP and the use of the IHI bundle, 
630 patients were followed up until the occurrence of VAP(Croce et al., 2013). Overall 
compliance with the bundle averaged 77% and compliance with individual components 
ranged from 70.5-92.5%. There was no difference in bundle compliance between 
patients who developed VAP versus those who did not and in regression analysis, 
bundle compliance was not associated with prevention of VAP. 
As part of the highly influential Michigan Keystone ICU project (see high profile paper 
on prevention of catheter-related blood stream infection(Pronovost et al., 2006)), an 
intervention to improve compliance with VAP prevention measures was implemented in 
127 ICUs, including 550,800 ventilator-days(Berenholtz et al., 2011). The VAP 
prevention bundle included: SUP; elevation of head of bed; DVT prophylaxis; DSI; and 
SBT. This study reported significant reductions in VAP from a median of 5.5 cases per 
1000 ventilator-days at baseline to zero at 16-18 months, which was maintained at 28-
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30 months after intervention. There are significant limitations of this study. Primarily 
the study was not randomised and so was vulnerable to bias. The case definition of VAP 
was based on the CDC surveillance criteria, which has subjective elements such as CXR 
changes and the characteristics of sputum. Furthermore, cases of VAP were identified 
by hospital “preventionists”, a group of specialists familiar with the CDC criteria and 
therefore felt to be less at risk of bias. However an alternative interpretation is that these 
individuals would be most vulnerable to bias in a non-randomised, non-blinded study. 
In a European observational study in which VAP was diagnosed based on clinical and 
microbiology data by an independent adjudicator, the reduction in VAP rates was much 
more modest, falling from 15.5% to 11.7% after the implementation of a bundle(Rello 
et al., 2013). The bundle comprised: oral care with chlorhexidine; handwashing; 
maintenance of ETT cuff pressure; sedation control measures; and not changing 
ventilator circuits regularly. Compliance with all 5 elements was only 20% and for 
individual elements compliance ranged from15-34%. While this result could be 
interpreted as suggesting that greater compliance could obtain an even greater reduction 
in VAP, it may well also suggest there is a significant effect from carrying out a non-
randomised intervention. 
1.9 Treatment of VAP 
1.9.1 General considerations 
Different diagnostic strategies, clinical versus invasive, result in different rates of 
VAP(Conway Morris et al., 2011). There is the potential that a clinical strategy over-
treats patients with suspected VAP with antibiotics or alternatively that the invasive 
strategy under-treats patients. In an invasive/microbiological strategy the assumption is 
that if the culture growth is below the threshold (10
4
 cfu/ml for BAL, for example), it 
represents colonisation. There have been a number of reports describing that patients 
with culture growth below the threshold for VAP have equivalent outcomes to the 
baseline ICU population and that there may even be some benefit in with-holding 
antibiotics in these circumstances, in terms of reducing antibiotic resistance(Fagon et 
al., 1996; Raman et al., 2013).  
Another possibility is that the patients have bronchitis rather than VAP. Ventilator-
associated tracheobronchitis (VAT) is an area of controversy. There are varying clinical 
definitions used without a gold standard diagnosis. It has been previously defined as 
patients with fever, raised inflammatory markers and purulent tracheal secretions 
without CXR changes(Nseir et al., 2014) or based on total sputum load from 
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endotracheal secretions(Palmer, 1995). Trials of antibiotic therapy for VAT are of low 
quality and firm conclusions are unable to be drawn from them(Nseir et al., 2008; 
Palmer et al., 2008). Recent observational data do suggest improved outcome and 
reduced progression to VAP with adequate antibiotic therapy(Martin-Loeches et al., 
2015). 
The adequacy of treatment for VAP is fundamental to the outcome. In a prospective 
study of 107 patients Iregui et al demonstrated that a delay in appropriate antibiotic 
therapy (defined as ≥ 24 hours) was associated with a greater hospital mortality at 
69.7% in comparison to the mortality rate in those with appropriate treatment at 28.4%, 
although the median time for initiation of antibiotics for appropriate therapy was 12 
hours(Iregui et al., 2002). Initial delay in appropriate antibiotic therapy was an 
independent risk factor for hospital mortality (OR 7.68, 95% 4.5-13.09). Luna et al 
demonstrated a similar outcome, in a prospective study of 508 patients(Luna et al., 
2006). The mortality rate with appropriate antibiotic therapy was 29.2%, with 
inappropriate therapy (antibiotics that did not provide sufficient coverage of pathogens) 
the mortality was 75% and for those with a delay in appropriate antibiotic therapy the 
mortality was 58.3%.  
The consequences of inappropriate therapy are considerable as are delays in treatment. 
Therefore guidelines advise initial antibiotic therapy should be started promptly and aim 
to provide coverage of likely pathogens. Since infection with a multi-drug resistant 
(MDR) pathogen could lead to inadequate coverage, initial therapy is based on the risk 
of MDR pathogens(American Thoracic Society, 2005). Risk factors for MDR pathogens 
include previous antibiotics, prolonged mechanical ventilation (> 7 days), higher 
number of comorbidities and admissions from another healthcare facility(Trouillet et 
al., 1998; Rello et al., 1999; Depuydt et al., 2008; Parker et al., 2008). 
The American Thoracic Society guidelines for the treatment of VAP(American 
Thoracic Society, 2005) recommend that patients with early-onset VAP and without 
risk factors for MDR pathogens should have coverage for Streptococcus pneumoniae, 
H. influenzae, methicillin-sensitive S. aureus and antibiotic-sensitive Gram-negative 
bacilli. The recommended antibiotics are: ceftriaxone; levofloxacin, moxifloxacin or 
ciprofloxacin; ampicillin/sulbactam; or ertapenem. 
Considering patients with late-onset disease or risk factors for MDR pathogens, 
antibiotic coverage should also include cover for P. aeruginosa, K. pneumoniae, 
Acinetobacter spp, MRSA, and Legionella pneumophila. Combination therapy is 
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advised with (a) an antipseudomonal cephalosporin (cefepime, ceftazidime) or 
antipseudomonal carbepenem (imipenem or meropenem) or -lactam/-lactamase 
inhibitors (piperacillin-tazobactam); (b) an antipseudomonal fluoroquinolone 
(ciprofloxacin or levofloxacin) or an aminoglycoside (amikacin, gentamicin or 
tobramycin); and (c) linezolid or vancomycin. 
In prospectively validating these guidelines, the guidelines accurately predicted the 
organisms for patients classed as having late-onset VAP or risk factors for MDR 
pathogen, correctly identifying 92% of pathogens(Ferrer et al., 2010). However its 
prediction of pathogens for patients classed as having early-onset VAP or no risk factors 
for MDR pathogens was only 50%, with 10 patients (26%) having a potentially resistant 
pathogen. In a prospective, multi-centre cohort study aimed at improving compliance 
with the ATS antibiotic recommendations for patients at risk of MDR pathogens, 303 
patients were included, of whom 129 received compliant treatment and 174 did not(Kett 
et al., 2011). They found that 34% of compliant patients died in comparison to 20% of 
non-compliant patients (p=0.004) and the survival benefit of non-compliant therapy did 
not vary with key potential confounding factors such as duration of mechanical 
ventilation, VAP (as opposed to HAP), age >60, severe sepsis or APACHE 2 score, 
although the compliant group did have significantly higher APACHE 2 scores and more 
met criteria for severe sepsis. It should also be noted that the coverage of identified 
pathogens was similar in both the compliant and non-compliant groups at 81% and 85% 
respectively. 
This study calls into question the previously accepted view that infections should be ‘hit 
hard and fast’. It suggests that there is a potential detrimental effect of multiple classes 
of antibiotics being used. In a quasi-experimental study, Hranjec et al challenged the 
traditional view of antibiotic prescribing(Hranjec et al., 2012). In this before-and-after 
study, an aggressive approach to antibiotics was used in a single surgical ICU for 1 year 
during which, when infection was suspected, appropriate cultures were taken and 
empirical antibiotics were started. Antibiotics were stopped if cultures were negative. In 
the following year the ICU adopted a conservative approach. If infection was suspected 
appropriate cultures were taken but antibiotics were not started until objective evidence 
of infection was found. Physicians could start antibiotics empirically at their discretion 
if the clinical situation required such an approach. The incidence of infection was 
similar between the two time periods with 26.0 infections per 1000 patient-days in the 
aggressive period and 27.2 infections per 1000 patient-days in the conservative period. 
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There was a significant difference in the time from onset of fever to initiation of 
antibiotics, with a median of 11 (IQR 3-14) and 24 (IQR 9-44) hours for the aggressive 
and conservative periods respectively. The duration of treatment was significantly 
shorter in the conservative group (12.5 days versus 17.7 days) and the appropriateness 
of initial antibiotic therapy was higher in the conservative group (74% vs 62%). The all-
cause mortality rate was 27% during the aggressive period versus 13% during the 
conservative period (p=0.015). A sub-group analysis was performed on patients with a 
mean arterial pressure (MAP) of <60mmHg and despite the time from blood culture to 
initiation of treatment being a median of 20 hours (IQR 8-39) in the conservative group 
in comparison to a median of 4 hours (IQR 3-12.5) in the aggressive group, the 
mortality was still lower in the conservative group at 26%, in comparison to the 
aggressive group (66%). 
1.9.2 Duration of treatment 
There are surprisingly few data on the appropriate duration of antibiotic therapy for 
VAP. Updated guidelines recommend 7 days of antibiotics(Kalil et al., 2016). Expert 
opinion has previously recommended that a longer duration of therapy, 14-21 days is 
used for patients with multi-lobar involvement, malnutrition, cavitation, Gram-negative 
necrotising pneumonia or isolation of P. aeruginosa or Acinetobacter spp(Chastre and 
Fagon, 2002). Duration of antibiotic therapy in trials varies from 9-15 days(Brun-
Buisson et al., 1998; Betrosian et al., 2008; Chastre et al., 2008).  
In a prospective study of 27 patients with VAP confirmed by semi-quantitative culture 
from BAL, Dennesen and colleagues monitored clinical signs and ETA cultures for 
resolution of disease(Dennesen et al., 2001). Resolution was by a return to ‘normal’ in 
temperature, leucocyte count, PaO2:FiO2 and no more than 1+ of bacterial growth from 
ETA cultures. There was a fall in mean log cfu/ml of 5.4 on day 0 to 1.4 on day 15. 
Patients colonised with P. aeruginosa did not achieve eradication with appropriate 
antibiotic therapy and so ETA culture is an unreliable metric of resolution for this 
pathogen. The mean time to resolution of all parameters was 9 days and the mean time 
for resolution of clinical parameters only (ie. excluding colonisation criteria) was 6 
days. The median duration of treatment was 13 days (range 7-14). 
Duration of therapy was tested in an RCT of 8 versus 15 days of therapy(Chastre et al., 
2003). One hundred and one patients with confirmed VAP following BAL and who 
received empiric therapy within 24 hours of BAL, were randomly assigned to receive 8 
or 15 days of therapy. The choice of antibiotics was left to the discretion of the clinical 
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team, although empiric treatment had to include an aminoglycoside or flouroquinolone 
and a broad-spectrum beta-lactam. The mean duration of mechanical ventilation before 
VAP was 13.4 days in the 8-day group and 13.8 days in the 15-day group, suggesting 
that this was predominantly a study of late-onset VAP patients. They demonstrated non-
inferiority for 8 days of treatment in comparison to 15 days in their primary outcome 
measures of mortality (18.8% for 8-day and 17.2% for 15-day) and pulmonary infection 
recurrence rate (28.9% for 8 day and 26% for 15 day). The 8-day therapy group had 
more AFD than the 15-day group, with a mean of 13.1 (SD 7.4) versus 8.7 (SD 5.2) 
respectively. In the sub-group analysis, patients with non-fermenting Gram-negative 
bacteria (GNB) had a recurrence rate of 40.6% in the 8-day group and 25.4% in the 15-
day group, with a between-group risk difference of 15.2% (95% CI 3.9%-26.6%). There 
was, however, no difference in mortality in this subgroup. A further trial of 8 versus 15 
days of treatment in patients with early on-set VAP similarly found non-inferiority with 
an 8-day course(Capellier et al., 2012). 
1.9.3 Monotherapy versus combination therapy 
Combination therapy is recommended in guidelines for patients with late-onset VAP 
and risk factors for MDR pathogens(American Thoracic Society, 2005; Kalil et al., 
2016). The predominant reason for this is to provide sufficiently broad empiric therapy 
to cover antibiotic-sensitive GNB, MDR GNB and MRSA. In addition, antibiotics have 
shown in vitro synergism when used in combination(Hallander et al., 1982). 
Furthermore, using antibiotics in combination may reduce resistance to individual 
antibiotics(Drago et al., 2005).  
A meta-analysis compared -lactam monotherapy with -lactam and aminoglycoside in 
combination in trials of patients with severe infections(Paul et al., 2004). There was no 
difference in mortality between the two groups with a RR of 0.90 (95% CI 0.77 – 1.06). 
A sub-analysis of patients with GNB infections (and specifically P. aeruginosa 
infection) also had no benefit from combination therapy. Furthermore there was an 
increase in nephrotoxicity in the combination therapy group.  
In a further meta-analysis of monotherapy or combination therapy for GNB 
bacteraemia, 17 studies were included in which only 2 were prospective RCTs(Safdar, 
Handelsman and Maki, 2004). Only 2 cohort studies found a mortality benefit with 
combination therapy and the overall summary OR was 0.96 (95% CI 0.70 – 1.32). In 
contrast to the previously described meta-analysis, there was a significant mortality 
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benefit in patients with P.aeruginosa infection with combination therapy (OR 0.50, 
95% CI 0.30 – 0.79). 
In the context of VAP, no difference in the resolution of clinical parameters was found 
between combination and monotherapy(Damas et al., 2006). In a 2x2 factorial design 
RCT, monotherapy and combination therapy(Heyland et al., 2008) as well as diagnostic 
strategies for VAP were compared(Canadian Critical Care Trials Group et, 2006). 
Patients were randomised to receive meropenem and ciprofloxacin or meropenem alone. 
As previously discussed, this trial excluded patients colonised with P. aeruginosa or 
MRSA, since clinicians may feel unable to give monotherapy to a patient colonised 
with P. aeruginosa and the antibiotic choice does not provided sufficient cover for 
MRSA. The overall 28-day mortality rate was 18.7% and the risk ratio of death at 28-
days was 1.05 (95% CI 0.78 – 1.42). There was no difference in secondary endpoints of 
duration of MV, ICU or hospital death. However there was a significantly higher rate of 
adequate therapy in the combination therapy groups over the monotherapy groups 
(93.1% and 85.1% respectively). In a subgroup analysis of patients with Pseudomonas 
spp, Acinetobacter spp and MDR GNB, the difference in adequacy of therapy was more 
pronounced (84.2% in combination group and 18.8% in monotherapy group). In this 
sub-group there was a trend towards improved outcome with combination therapy. 
In a retrospective analysis, 183 episodes of VAP caused by P. aeruginosa were 
examined based on monotherapy or combination therapy(Garnacho-Montero et al., 
2007). These authors similarly found that rates of adequate therapy were considerably 
higher when combination therapy was used (90.5% for combination therapy and 56.7% 
for monotherapy). Mortality was 72.5% amongst patients with inadequate therapy in 
comparison to 33.6% in those with adequate therapy. In multivariate analysis, adequacy 
of treatment was an independent risk factor for death, rather than monotherapy or 
combination therapy.  
1.10 Antibiotic resistance and the need for improved antibiotic 
stewardship 
1.10.1 The scale of the problem 
Antibiotics are arguably the greatest discovery of modern medicine. They have greatly 
reduced mortality from infectious disease and allowed medical advances such as 
transplantation and joint replacements. The rise in antimicrobial resistance (AMR) has 
reached a critical level and is a global concern. The World Health Organization (WHO) 
has described it as one of the top three threats to human health and warns of a return to a 
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pre-antibiotic era in which we do not have the means to treat infectious disease(World 
Health Organisation, 2014). 
Determining the scale of the problem of AMR globally is difficult. The WHO has 
attempted to give a description of the global burden using existing data from 
surveillance programmes, as well as national and institution-based data(World Health 
Organization 2014). Not all countries have formal surveillance programmes and so the 
WHO data are limited in this regard. Furthermore surveillance programmes do not 
necessarily capture all AMR. For example the European Antimicrobial Resistance 
Surveillance Network (EARS-Net)(European Centre for Disease Prevention and 
Control, 2012a, 2014) performs surveillance on 8 bacteria of importance: E. coli, K. 
pneumoniae, P. aeruginosa, Acinetobacter spp, S. pneumoniae, S. aureus, Enterococcus 
faecalis and Enterococcus faecium. Only data from invasive isolates (from blood and 
cerebrospinal fluid) are included. If we consider that the prevalence of bacteraemia in 
the intensive care unit is 15%(Vincent et al., 2009), then surveillance of these positive 
cultures reflects only a fraction of treated infections and antibiotics being prescribed. 
Notwithstanding the limitations of the data presented in the WHO report, it does 
demonstrate a worrying situation with resistance amongst common pathogens (E. coli, 
K. pneumoniae and S. aureus), being greater than 50% in many member states.  
In Europe, resistance to Gram-positive bacteria has been relatively stable(European 
Centre for Disease Prevention and Control, 2012a, 2014). In contrast to Gram-positive 
bacteria, Gram-negative are intrinsically more resistant and are often implicated in 
HCAI. The rise in resistance amongst these pathogens is alarming. E. coli is the 
commonest cause of bloodstream infection and in Europe the mean rate of full 
susceptibility to all antibiotics was only 39.5%(European Centre for Disease Prevention 
and Control, 2012a). The prevalence of resistance to aminopenicillin was 57.1% and to 
third generation cephalosporins was 12%(European Centre for Disease Prevention and 
Control, 2014). 71-100% of resistant isolates to 3
rd
 generation cephalosporins were 
attributable to extended-spectrum beta-lactamases (ESBLs). Although the mean 
prevalence of carbapenem resistance was <0.1%, the emergence of carbapenem 
resistance is a particular concern. 
K. pneumoniae is a pathogen of importance in HCAI as a frequent cause of bloodstream 
infection and pneumonia. Its rising AMR is a serious public health concern particularly 
due to the rise of carbapenem resistance. More than a third of isolates are resistant to 
one antibiotic under surveillance(European Centre for Disease Prevention and Control, 
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2014). Resistance to 3
rd
 generation cephalosporins was present in 28% (of which 85-
100% were ESBLs), with the corresponding figures for flouroquinolones 27.4%, 
aminoglycosides 23.1% and carbapenems 7.3%. Resistance to a combination of 3
rd
 
generation cephalosporins, fluoroquinolones and aminoglycosides was present in 
19.6%. Resistance to these antibiotics have all increased since the previous 2012 
report(European Centre for Disease Prevention and Control, 2012a). 
P. aeruginosa is an intrinsically resistant organism and is an opportunistic pathogen in 
hospitalised patients and a major pathogen in VAP. P. aeruginosa is intrinsically 
resistant due to the limited permeability of its outer membrane, efflux pump 
mechanisms and its ability to rapidly acquire resistance(Li, Zhang and Poole, 2000). 
63.9% of isolates in Europe were fully susceptible in EARS-Net 2012 report and 
resistance rates have largely fallen in the 2014 report(European Centre for Disease 
Prevention and Control, 2012a, 2014). Resistance to piperacillin was 16.9%, 
ceftazidime 13.1%, fluoroquinolones 19.4%, aminoglycosides 14.8% and carbapenems 
18.3%. Resistance to 3 or more classes of antibiotics occurred in 13.3% of 
isolates(European Centre for Disease Prevention and Control, 2014). 
With low numbers of virulence factors, Acinetobacter spp is implicated in HCAI 
infections in the immunocompromised patient. Resistance in Acinetobacter spp varies 
widely across Europe with high rates of resistance in countries in the east and south of 
Europe. Resistance to fluoroquinolones was 29% in Denmark and 95.3% in Greece. 
Carbapenem resistance was zero in the Netherlands and 93.2% in Greece(European 
Centre for Disease Prevention and Control, 2014).  
Gram-positive resistance shows a more stable picture in Europe. Resistance in S. 
pneumoniae has remained relatively stable with most countries reporting penicillin non-
susceptibility below 10%. Macrolide resistance is higher than penicillin resistance and 
ranged from zero in Cyprus to 48% in Romania(European Centre for Disease 
Prevention and Control, 2014). 
S. aureus has been a pathogen of intense political pressure in the UK since 2000. At its 
peak resistance was at 40% in 2000 and is now at 11.3% in the UK(Livermore, 2012; 
European Centre for Disease Prevention and Control, 2014). Preventative measures 
such as MRSA eradication therapy, hand hygiene measures and infection control 
measures have been credited with this decline. Average resistance across Europe is 
17.4% with trends decreasing in Belgium, France, Germany, Ireland, Italy, 
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Luxembourg, Portugal and the UK but increasing trends in Denmark and 
Slovenia(European Centre for Disease Prevention and Control, 2014). 
Enterococcus spp. are common gut colonisers of low virulence which have arisen as 
important pathogens in nosocomial infection(Health Protection Agency, 2011; 
European Centre for Disease Prevention and Control, 2012b). High-level 
aminoglycoside resistance in E. faecalis in Europe has seen a significant increase, 
occurring in 28.8% of isolates. Vancomycin resistance in E. faecium (VRE) is on 
average 7.9% which is considerably different to the USA where VRE is >80%(Arias 
and Murray, 2012). 
There is a geographical variation in antibiotic resistance across Europe with a north-
south and east-west gradient, with more resistance in southern and eastern countries. 
Countries such as Italy, Bulgaria, Romania and Poland have some of the highest rates of 
antibiotic resistance. Causes of this geographical variation are unclear but antibiotic 
consumption and infection control practices have been suggested as reasons(European 
Centre for Disease Prevention and Control, 2012a, 2014). The ECDC carries out the 
European Surveillance of Antimicrobial Consumption (ESAC) project(European Centre 
for Disease Prevention and Control, no date). There is considerable variation between 
European countries in antibiotic consumption. Antibiotic consumption is expressed as 
defined daily dose (DDD), which is an assumed average maintenance dose per day for a 
drug used in adults and expressed as DDD per 1000 inhabitants per day (DID). The 
lowest rate of consumption is found in the Netherlands at 11.8 DID and the highest in 
Greece at 34.0 DID. Data from non-EU eastern European countries show antibiotic 
consumption ranging from 15.3 DID in Armenia to 42.3 DID in Turkey(Versporten et 
al., 2014).  
These data give a European perspective but AMR is a global public health concern. In 
the USA surveillance of HCAI, predominantly in the ICU, is conducted through the 
National Healthcare Safety Network (NHSN), which monitors rates of HCAI and AMR. 
The pathogens of concern are similar to Europe with 82% of pathogens belonging to the 
following groups: S. aureus, Enterococcus spp., E. coli, coagulase-negative 
Staphylococci, Candida spp., Klebsiella spp., P. aeruginosa or Enterobacter 
spp(Sievert et al., 2012). Resistance amongst pathogens isolated from central line-
associated bloodstream infections (CLABSI) was high. Vancomycin resistance amongst 
E. faecium was 83.6%; carbapenem resistance amongst Klebsiella spp. and P. 
aeruginosa was 14.2% and 26.8% respectively; and carbapenem and multi-drug 
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resistance amongst A. baumannii was 64.6% and 69.7% respectively. Although the 
percentage resistance had been largely stable when compared with previous periods 
(2009-2010 vs 2007-2008), there was a 54.3% increase in E. coli extended-spectrum 
cephalosporin resistance and a 25.3% increase in A. baumannii resistance to 
carbapenems. 
Data from the Asia-Pacific region similarly demonstrate concerning levels of Gram-
negative resistance with Enterobacteriaceae susceptibility to ampicillin/sulbactam 
being only 41.4% overall for the region, cefotaxime only 68.0%, ceftriaxone 67.7%, 
ciprofloxacin 64.4% and levofloxacin 67.3%(Hsueh et al., 2010). Resistance was 
particularly high in India and China. Furthermore a high proportion of E. coli and K. 
pneumoniae were ESBL producers with rates as high as 59.1% in China and 61.2% in 
India. A prospective surveillance study of AMR in respiratory pathogens in HAP and 
VAP carried out in Asia is valuable considering this is a major reason for antibiotic use 
(and considering that the EARS-Net only reports blood and CSF cultures)(Chung et al., 
2011). MDR isolates occurred in 60.7% of S. aureus and in 44.7% of K. pneumoniae. 
Carbapenem resistance was 27.2% for P. aeruginosa and as high as 56.9% in China. 
MDR rate for P. aeruginosa was 42.8% and extensively drug resistance rate was 4.9%. 
Acinetobacter spp had a very high rate of imipenem resistance at 67.3%. These are 
alarming rates of resistance in pathogens that cause HCAI in the most vulnerable group 
of hospitalised patients. 
1.10.2 Antibiotic consumption and resistance 
The link between antibiotic consumption and antibiotic resistance is widely 
accepted(Davies, 2011; Centers for Disease Control and Prevention, 2013). Bacteria 
produce a massive array (millions) of small organic molecules of which a small 
proportion have been identified and used as antibiotics(Davies and Ryan, 2012). Many 
of these small molecules are resistance factors that are necessary for the survival of 
bacteria. Many bacteria have efflux pumps that are a common mechanism of antibiotic 
resistance. These mechanisms have been evolutionarily selected in bacteria since the 
industrial revolution with the increased heavy metal wastes that have been discarded in 
the environment, which bacteria handle using efflux pumps(Davies and Davies, 2010). 
The antibiotic era has applied an evolutionary selective pressure on bacteria to produce 
resistance factors at an accelerated rate. 
Mechanisms of resistance are complex and beyond the scope of this thesis but exposure 
of bacteria to antibiotics clearly results in increasing resistance(Drago et al., 2005). In a 
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clinical context, antibiotic exposure is linked to increased antibiotic resistance. In an 
outpatient setting, large-scale, Europe-wide, surveillance data have demonstrated 
significant variations in antibiotic prescriptions, with the lowest rate in the Netherlands 
at 10 DDD per 1000 inhabitants daily and the highest rate in France at 32 DDD per 
1000 inhabitants daily(Goossens et al., 2005). There was a strong correlation between 
antibiotic use and antibiotic resistance (Spearman correlation for pencillin use and 
pencillin resistance 0.84 (95% CI 0.62-0.94)). Data from US surveillance of ICUs 
between 1994 and 2000 examined susceptibility of Gram-negative bacilli(Neuhauser, 
2003). Overall there was a 10% chance of an infecting organism being resistant to a 
single antibiotic. There was a decrease in ciprofloxacin susceptibility by 10% over the 
period studied, which coincided with an increase in fluoroquinolone use. In fact the 
selective pressure of antibiotics can occur rapidly and one of the most alarming 
resistance patterns is the emergence of carbapenem resistance. In an observational study 
of 523 patients admitted to an ICU environment in which imipenem was widely used, 
imipenem-resistant Gram-negative bacilli resistance in intestinal flora, as measured by 
rectal swabs, increased from 5.6% in week 1 to 58.6% in week 2(Armand-Lefèvre et al., 
2013). Conversely studies in which antibiotic usage had been limited found a fall in 
antibiotic resistance(Rahal et al., 1998; Singh et al., 2000; Geissler et al., 2003; Cook et 
al., 2006). 
1.10.3 The need for antibiotic stewardship 
As antibiotic resistance increases, the discovery pipeline for new antibiotics is drying 
up. Most large pharmaceutical companies are no longer investing in their anti-infectives 
division(Boucher et al., 2013) Bringing a drug through research and development can 
cost $800 million, which is a major disincentive for companies(Infectious Diseases 
Society of America, 2004). For an antibiotic, once brought to market, it will have its use 
restricted for a small number of patients and is likely to obsolete itself with its increased 
use. Compare this to development of drugs for chronic conditions or disease prevention, 
which millions of people will take each day for the rest of their lives. In a report from 
2004, of all drug R&D programmes from the world’s largest pharmaceutical and 
biotechnology companies registered with the United States Food and Drug 
Administration (FDA) database, only 6 out of 506 drugs were antibiotics(Spellberg et 
al., 2004). None of these had novel mechanisms. A recent report suggests that there has 
been little improvement in this area, with two antibiotics developed since 2009 and at 
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the time of the study 7 were in development but still a falling trend in R&D for 
antimicrobials(Boucher et al., 2013). 
In addition to the urgent need for antibiotic drug development, there is a need to 
conserve the effectiveness of antibiotics that are in current use. Antibiotic stewardship is 
the judicious use of antibiotics to preserve their future effectiveness and involves 
optimising therapy for individuals; prevention of overuse, misuse and abuse; and 
minimising development of resistance at an individual and community level(Davies, 
2011). An important limitation to improving antibiotic stewardship lies in diagnostics. 
Diagnosis of infection has in the main remained unchanged since the development of 
the Gram stain in the 19
th
 century. Since microbiology culture takes up to three days to 
provide results, many patients will receive antibiotics based on clinical suspicion. This 
has implications in the outpatient setting when decisions regarding antibiotic 
prescription must be made on clinical suspicion. In the hospital setting it is of great 
importance that antibiotics are de-escalated or discontinued in the face of microbiology 
evidence. The need to develop novel rapid diagnostics to improve antibiotic stewardship 
is one of the challenges put forward in the 2011 report by the UK Chief Medical Officer 
on antimicrobial resistance(Davies, 2011). 
1.11 Rapid diagnostics 
Novel methods to rapidly detect infections can be divided between culture-independent 
molecular techniques to detect the pathogens and biological markers, biomarkers, that 
act as surrogates for detecting pathogens. 
1.11.1 Molecular diagnostics 
The three main techniques of molecular detection are polymerase chain reaction (PCR), 
matrix-assisted laser desorption ionisation-time of flight spectrometry (MALDI-TOF 
MS) and peptide nuclei acid-based fluorescence in situ hydridisation (PNA FISH). 
MALDI TOF MS and FISH are able to detect pathogens in small numbers directly from 
the clinical specimen, eliminating the time taken for them to the cultured to visible 
colonies. MALDI TOF MS has been shown to have high concordance with traditional 
blood cultures (greater than 90%) and rapidly identifying pathogens in less than 3 
hours(Beal et al., 2013; Dodemont et al., 2014). Detection of pathogens in respiratory 
cultures by FISH has also been shown to be high with a sensitivity of 94% and 
specificity of 88%(Koncan et al., 2015). The FISH assay returned results in 
approximately 10 hours. Although MALDI TOF MS and FISH can detect pathogens 
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against large databases, they cannot detect resistance genes. PCR on the other hand has 
the ability to detect resistance genes but does have other limitations. Firstly PCR 
techniques detect a limited range of pathogens predetermined by the panels used and so 
can only detect pathogens in those panels(Ost et al., 2010; Rios-Licea et al., 2010; 
Lacroix et al., 2015). PCR is extremely sensitive to detecting bacterial DNA, which is 
both a strength and a weakness. Studies generally report high sensitivities for PCR 
when compared to traditional culture but often lower specificities, often due to detection 
of bacterial DNA when culture is negative(Dickson et al., 2014; Lacroix et al., 2015; 
Vincent et al., 2015). Since PCR detects bacterial DNA, it will amplify the signal for 
non-viable bacteria as it will for live bacteria. The limitation of this is that it could lead 
to the overuse of antibiotics. The advantage of this could be in circumstances when 
there is a high index of suspicion of infection but the culture is negative. This could be 
due to the use of antibiotics or that the bacteria are difficult to culture. This has lead to 
the idea of ‘salvage microbiology’(Farrell et al., 2013). The use of this ‘salvage 
microbiology’ approach is understandable if the suspected infection is in a usually 
sterile location. The role of PCR in the respiratory samples is much more challenging 
because this is not a sterile site and the challenge for PCR will be to distinguish between 
viable and non-viable and infection and colonisation. In a large multi-centre 
observational study samples of blood, respiratory secretions (ETA and BAL) and sterile 
site fluid were obtained to compare culture with a novel technique of PCR followed by 
electrospray ionisation-mass spectrometry (PCR/ESI-MS)(Vincent et al., 2015). The 
benefit of using ESI-MS after the PCR is that it allows detection of pathogens against a 
huge database of 800 pathogens. Again this study demonstrated an extremely sensitive 
assay that detected 228 positive pathogens in blood where only 68 were positive by 
culture. Amongst the respiratory tract samples, the discrepancy was not as large with 
117 positive PCR/ESI-MS and 68 positive cultures (sensitivity 84% and specificity 
53%). 
Another approach to molecular detection is the detection of volatile organic compounds 
(VOC) that bacteria produce. Bacteria produce a characteristic signal of VOC that can 
be detected by gas chromatography and mass spectrometry (GC-MS)(Bos, Sterk and 
Schultz, 2013). VOCs are detectable in the exhaled breath of patients on mechanical 
ventilation and so have the potential to distinguish those with high bacterial burdens 
associated with infection. So far studies have been small proof-of-concept studies(Bos 
et al., 2014; Chiu et al., 2014; Filipiak et al., 2015; Fowler et al., 2015). In a single ICU 
derivation study mechanically ventilated patients, who were predominantly acute brain 
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injury patients, exhaled breath condensate was analysed by thermal desorption/gas 
chromatography/time-of-flight mass spectrometry(Fowler et al., 2015). VAP was 
confirmed by semi-quantitative culture of blind-BAL samples. A clear separation in 
signal was observed between patients who were infected and those that were not. 
These molecular methods hold significant promise in particular exhaled breath 
condensate analysis, that would allow for a minimally invasive method of detecting 
infection. 
1.11.2 Biomarkers for bacterial infections 
Biomarkers have the potential to meet the need for rapid diagnostics if they can act as 
accurate surrogates of infection while being able to be measured faster than routine 
microbiology cultures. For bacterial infections the most widely investigated is 
procalcitonin (PCT). PCT is a precursor to calcitonin and has been recognised to be 
released in response to bacterial infections(Assicot et al., 1993; Dandona et al., 1994). It 
was hoped that this could therefore be a marker to distinguish infective SIRS (sepsis) 
from sterile SIRS. However it has been shown to be raised in situations of sterile SIRS 
too(Carsin et al., 1997).  
The accuracy of PCT to discriminate sepsis from sterile SIRS has been the subject of 
three meta-analyses. The first of these was to determine its value in surgical or trauma 
patients(Uzzan et al., 2006). Unfortunately this meta-analysis used any definition of 
sepsis and therefore is limited by the lack of a rigorous standard. Twenty-five studies 
were included, many of which were small and sample sizes ranged from 15-405 
patients. Among the studies included, the sensitivity of PCT to distinguish sepsis from 
SIRS ranged from 42-97% and the specificity was 48-100%. The summary diagnostic 
accuracy of PCT had an OR of 15.7 (95% CI 9.1-27.1). The Q* value is a single 
summary statistic of the receiver operating characteristic curve (ROC) and is the point 
where the sensitivity and specificity are equal. The Q* for the study described was 0.78 
(95% CI 0.71 – 0.84).  
A further meta-analysis used inclusion criteria for trials that incorporated a rigorous 
definition of sepsis, but excluded trials with too narrow case mix, such as studies of 
abdominal sepsis(Tang et al., 2007). This meta-analysis included 18 studies of which 14 
were phase 2 diagnostic studies (diagnostic studies in patients with or without the 
disorder) and 4 phase 3 studies (real-life performance in patients suspected of having 
the disorder). A total of 2097 patients were included. Considering the 14 phase 2 studies 
the diagnostic OR was 7.79 (95% CI 5.86-10.35) with a Q* value of 0.73. Adding in the 
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4 phase three studies introduced significant heterogeneity (I
2
 86.1%) and the overall 
result was similar with a Q* of 0.72. Furthermore, on inspection of the funnel plot the 
authors determined that there had been a publication bias and that missing studies were 
likely to fall to the left of the summary estimate, suggesting that the summary estimate 
was an overestimate of the effect.  
Although the ROC curves for PCT between these two meta-analyses were quite similar, 
the authors drew quite contrasting conclusions with Uzzan et al suggesting the 
diagnostic value was high and Tang et al concluding the diagnostic value was low. A 
more recent meta-analysis aimed to update this area and also to overcome the 
shortcomings of these meta-analyses with respect to the reference definition of sepsis 
and the heterogeneity of studies(Wacker et al., 2013). 30 studies with 3244 critical care 
patients were included. The authors reported pooled sensitivity and specificity. The 
pooled sensitivity was 77% (95% CI 72-81%), the pooled specificity was 79% (95% 74-
84%) and the AUROC was 0.85 (0.81-0.88). Since the authors had taken an inclusive 
approach to trials included, the heterogeneity was high (I
2
 96%). The authors report a 
positive PCT would give a post-test probability (PTP) of sepsis of 48%. On the other 
hand a negative PCT would give a PTP to exclude sepsis of 7%. The authors conclude 
that PCT is a helpful biomarker but cannot be used as a single biomarker of sepsis.  
Despite the differing methods and conclusion made by the authors of these three meta-
analyses, the diagnostic performance of PCT has been fairly consistent across the three 
meta-analyses. The PTP reported by Wacker et al(Wacker et al., 2013) serves as a 
useful summary of the limitations of PCT as a single biomarker of sepsis. Despite this it 
has been used in a number of RCTs to influence patient outcome. In the high profile 
PRORATA trial, patients with suspected bacterial infection either on admission or 
during their ICU stay were randomised to either a PCT-guided antibiotic initiation and 
discontinuation algorithm or to standard care(Bouadma et al., 2010). The primary 
outcomes were death from any cause 28 and 60 days and number of days without 
antibiotics at 28 days. 630 patients were randomised and of the 311 patients in the PCT 
group, antibiotic recommendations were not followed in 219 episodes, including 
episodes when antibiotics were started despite low PCT or not discontinued in light of 
low PCT. Despite this non-adherence, there were significantly fewer antibiotics used in 
the PCT group with an absolute difference of 2.7 days (95% CI 1.4-4.1). There was a 
non-inferior mortality difference between the two groups (0.8%, 90% CI -4.6-6.2). 
Another trial used PCT to reduce antibiotic exposure in patients with suspected 
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VAP(Stolz et al., 2009). Patients with suspected VAP were randomised to daily PCT 
with recommendations to discontinue antibiotics with low levels of PCT, or to standard 
care. The primary outcome measure was the number of AFD alive at 28 days. One 
hundred and one patients were randomised and those in the PCT group had significantly 
more AFD than the control group with a median of 13 (IQR 2-21) in the PCT group and 
9.5 (IQR 1.5-17) in the control group. The protocol of using PCT to rule out VAP is 
questionable since serum PCT has not been shown to have any diagnostic utility in 
VAP(Luyt et al., 2005, 2008; Zielińska-Borkowska et al., 2012). 
In contrast to these trials, another group of investigators used PCT to escalate care when 
raised rather than to use it as a tool for de-escalation(Jensen et al., 2011). Patients 
randomised to the PCT group had daily measurement of serum PCT and if ≥1 ng/ml the 
clinician received an alert triggering further investigation of potential infection and 
broadening of antibiotic spectrum. 1200 patients were randomised and as might be 
expected there were more broad-spectrum antibiotics used in the PCT group. The 
median duration of antibiotics was 6 days (IQR 3-11) in comparison to 4 days (IQR 3-
10) in the control group. There was no significant difference in death at 28 days but the 
length of ICU stay was extended by 1 day in the PCT group and the relative risk of days 
with estimated glomerular filtration rate of <60mL/min/1.73m
2
 was 1.21 (95% CI 1.15-
1.27). 
1.11.3 Biomarkers for VAP 
The most widely investigated biomarkers in the context of VAP have been PCT and 
soluble triggering receptor expressed on myeloid cells (sTREM-1). Although PCT has 
had some acceptance for bacterial infections in general, in the specific context of VAP 
its value is much more questionable. All the studies assessing PCT utility for diagnosing 
VAP used semi-quantitative or quantitative culture to base the VAP definition on, 
although the sampling methods varied. In a study of 96 patients with suspected VAP in 
which BAL was performed using a blind method, there was no significant difference in 
alveolar PCT between VAP and non-VAP patients(Duflo et al., 2002). However this 
study did find a diagnostic utility from serum PCT, with an AUROC of 0.79 and (at a 
cut-off of 3.9ng/ml) a sensitivity of 41% and a specificity of 100%, giving this a very 
strong ‘rule-in’ value. In a rigorous study in which BAL was performed to a clear 
standard operating procedure and samples excluded based on pre-defined quality 
definitions, no significant differences were found in serum or BAL fluid PCT or C-
reactive protein (CRP) between VAP patients (n=50) and non-VAP patients 
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(n=66)(Linssen et al., 2008). In two further studies no difference in serum or BAL PCT 
could be found between those who had VAP confirmed and those who did not(Luyt et 
al., 2008; Jung et al., 2010). PCT has also been evaluated for prognostic applications 
and falling levels over the course of the disease has been prognostic for survival from 
VAP(Luyt et al., 2005; Seligman et al., 2006), although in the context of biomarkers to 
improve antibiotic stewardship this has limited relevance. 
The evidence for sTREM-1 has been limited by methodological inadequacies and 
inconsistencies. In a study of 148 mechanically ventilated patients in whom pulmonary 
infection was suspected, blind BAL was performed and pneumonia diagnosed based on 
semi-quantitative culture(Gibot et al., 2004). 38 patients were diagnosed with 
community-acquired pneumonia, 46 patients with VAP and 64 as having no pneumonia. 
BAL fluid sTREM-1, TNF-α and IL-1β were raised in both pneumonias in comparison 
to those without pneumonia. On constructing ROC curves, the AUROC for sTREM-1 
was 0.93 (95% CI 0.92-0.95) and a cut-off of 5 pg/ml had a sensitivity of 98% and a 
specificity of 90%. The AUROC for IL-1β and TNF-α were 0.69 (95% 0.67-0.72) and 
0.64 (95% CI 0.62-0.69) respectively.  
Significant diagnostic performance for sTREM-1 was derived from a small study of 28 
patients, only 9 of whom had confirmed VAP(Determann et al., 2005). Similarly in this 
study, a blind BAL technique was used and performed on alternate days while patients 
were mechanically ventilated. BAL sTREM-1 increased on the day of clinical suspicion 
of VAP and the AUROC to discriminate VAP from non-VAP was 0.83 (95% CI 0.65-
1.00). A level of 200 pg/ml had a sensitivity of 75% and a specificity of 84%. The 
AUROC for TNF-α was 0.64 (95% CI 0.40-0.87), for IL-1β 0.66 (95% CI 0.42-0.89) 
and for IL-6 0.74 (95% CI 0.54-0.95). IL-1β, at cut-off of 1000 pg/ml had a sensitivity 
of 67% and a specificity of 69%. Furthermore, in a group of patients with bilateral 
infiltrates (rather than suspected VAP), sTREM-1 had sensitivity and specificity of 86% 
and 90% respectively for the presence of bacterial infection(Huh et al., 2008) 
In contrast, two studies in which BAL fluid was more rigorously obtained via 
bronchoscopy, no useful diagnostic value was found for sTREM-1. In one study there 
was no significant difference in sTREM-1 between the VAP and non-VAP 
groups(Horonenko et al., 2007) and in the other, although there was a significant 
difference between the groups, when a ROC was constructed the AUROC was poor 
(0.58, 95% CI 0.50-0.65)(Oudhuis et al., 2009). 
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In terms of prognostic value of sTREM-1, in a small study of 35 patients with suspected 
VAP, BAL was performed at enrolment and a further 2 BAL performed in the course of 
the illness(Wu et al., 2011). In this study the rate of confirmed VAP was unusually high 
at 70%. sTREM-1 was significantly raised in culture positive patients in contrast to non-
VAP patients at baseline and day 4-5. ROC curves were constructed for sTREM-1 at 
baseline, day 4-5 and day 7-9 to identify survivors versus non-survivors. At baseline the 
AUROC was 0.54 (NS), at day 4-5 the AUROC was 0.77 (95% CI 0.57-0.97) and at 7-9 
days the AUROC was 0.89 (95% CI 0.72-1.07). A fall in sTREM-1 of 10 pg/ml at day 
7-9 predicted survival with a sensitivity of 90% (non-survivors) and specificity of 
87.5% (survivors). 
Other biomarkers that have been investigated for VAP include elastin fibres (ETA)(el-
Ebiary et al., 1995), copeptin (serum)(Seligman et al., 2008a), nitrated proteins 
(BAL)(Mathy-Hartert et al., 2000), beta-d-glucan (serum)(Heyland et al., 2011), 
pancreatic stone protein (serum)(Boeck et al., 2011), midregional pro-atrial naturetic 
peptide (serum)(Seligman et al., 2008b), pentraxin 3 (serum)(Lin et al., 2013), Clara 
cell protein (BAL)(Vanspauwen et al., 2011), leukocyte RNA profiles (blood)(Cobb et 
al., 2009), leptin (serum)(Parmentier-Decrucq et al., 2014) and gene expression 
(blood)(Textoris et al., 2011). These studies have either found no diagnostic value or 
have demonstrated some prognostic value. They have all fallen short of a biomarker that 
can provide the crucial clinical need, a rapid rule-in or rule-out test for VAP. 
1.11.4 Importance of innate immune response biomarkers in BAL 
In a single-centre study Conway Morris et al measured a range of biomarkers of the 
innate immune response in the lung in BAL fluid(Conway Morris et al., 2010). 
Seventy-two patients with suspected VAP were included in the analysis. Patients were 
included if VAP was suspected, and excluded based on criteria that predicted poor 
tolerance of BAL (eg. severe hypoxia, haemodynamic instability and unstable intra-
cranial hypertension). VAP was confirmed by quantitative culture of BAL fluid with a 
pathogen growth of >10
4
 cfu/ml. The biomarkers measured in BAL fluid were TNF-α, 
IL-1β, IL-6, IL-8, IL-10, granulocyte colony-stimulating factor (G-CSF), MIP-1α, 
sTREM-1 and monocyte chemo-attractant peptide (MCP)-1. Urea was measured in 
BAL and serum and used as a correction factor for dilution of ELF by BAL(Rennard et 
al., 1986). 17 patients had confirmed VAP and 55 patients had culture growth below the 
threshold or had sterile culture and formed the non-VAP group. It is notable that no 
VAP was caused by P. aeruginosa. Significant differences were found between VAP 
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and non-VAP patients in BAL fluid IL-1β, IL-8, G-CSF and MIP-1α. ROC curves were 
constructed for these and IL-1β and IL-8 had AUROC with 0.81 (95% CI 0.71-0.91) 
and 0.83 (95% CI 0.74-0.95) respectively. The AUROC for G-CSF and MIP-1α were 
lower with 0.73 (95% CI 0.58-0.86) and 0.77 (95% CI 0.66-0.90) respectively. For IL-
1β an optimal cut-point determined by the Youden index at 10 pg/ml had a sensitivity of 
94% and a specificity of 64%. This corresponds to a negative predictive value of 97% to 
rule-out VAP. 
In a further report from the same cohort of patients, BAL fluid was tested for a range of 
markers of neutrophil activity and neutrophil protease inhibitors(Wilkinson et al., 
2012). The neutrophil proteases measured were HNE, MMP-8 and MMP-9. 
Endogenous inhibitors of these proteases were also quantified, including alpha-1 
protease inhibitors (α1-PI), secretory leucocyte protease inhibitor (SLPI) and elafin (all 
of which inhibit HNE) and tissue inhibitors of metalloproteinases (TIMPs, which inhibit 
MMP-8 and MMP-9). In addition the fibinolytic enzymes tissue-type plasminogen 
activator (t-PA) and urinary-type plasminogen activator (u-PA) were measured. All 
markers were quantified by ELISA with the exception of plasminogen activators, which 
were measured by semi-quantitative zymography. There were significant differences 
between the VAP and non-VAP groups in concentrations of HNE, MMP-8 and MMP-9. 
ROC curves were constructed and optimal cut-points calculated. For HNE the AUROC 
was 0.87 (95% CI 0.78-0.96) and at 670 ng/ml, the sensitivity was 93% and specificity 
was 79%. For MMP-8 the AUROC was 0.81 (95% CI 0.69-0.93) and at a cut-point of 
13 ng/ml the sensitivity was 91% and the specificity 63%. MMP-9 had an AUROC of 
0.79 (95% CI 0.66-0.92) and a cut-point of 22 ng/ml had a sensitivity of 82% and 
specificity of 63%.  
The diagnostic performance for the 5 biomarkers with the greatest promise are outlined 
in Table 7. 
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1.12 Aim and Hypothesis 
The aim of this work is to take forward the findings in the derivation cohort described in 
section 1.10.4.. There are two elements to this work, the first of which is to establish 
whether the diagnostic utility of IL-1β, IL-8, MMP-8, MMP-9 and HNE could be 
validated in a multi-centre observational study. The hypothesis is that these will be 
successfully validated and that an optimum combination of biomarkers will be 
determined with sufficient value as a test of exclusion for VAP to be used in a 
clinical trial. 
The second element, dependent on the successful validation of the biomarkers, is to 
determine the clinical utility of these biomarkers in reducing antibiotic exposure in 
 AUROC Cut-point Sensitivity Specificity 
IL-1 0.81 (0.71-
0.91) 
10pg/ml 94% 64% 
IL-8 0.83 (0.73-
0.95) 
2000pg/ml 81% 83% 
HNE 0.87 (0.78-
0.96) 
670ng/ml 93% 79% 
MMP-8 0.81 (0.69-
0.93) 
13ng/ml 91% 63% 
MMP-9 0.79 (0.66-
0.92) 
22ng/ml 82% 63% 
Table 7: Cut-points and diagnostic performance of 5 top biomarkers from derivation cohort. 
AUROC, area under ROC curve (95% CI). 
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patients with suspected VAP by prompting early discontinuation of antibiotics in cases 
of biomarker-excluded VAP. This will be measured by number of antibiotic-free days 
(AFD) in the days following BAL. The hypothesis is that biomarker-guided 
decisions regarding antibiotic prescribing will reduce antibiotic use and thereby 
improve antibiotic stewardship. 
This work represents a significant part of the translational research process, bridging 
initial derivation to determining clinical utility. The two elements of this thesis are 
conducted in a highly complex and sensitive clinical setting and so the lessons learnt 
through this process are highly valuable. The potential clinical value is significant. I 
have highlighted the scale of impact that VAP, the scale of antibiotic use and need to 
reduce antibiotic use as part of a multi-faceted approach to tackling AMR. If this 
intervention demonstrates a reduction in antibiotic use, this would be a significant step 
in tackling this problem. 
1.13 Thesis overview 
Chapter 2 outlines the methods used in this work. Chapters 3 and 4 present the findings 
of a multi-centre validation study and a multi-centre RCT respectively. Final 
conclusions are presented in chapter 5. At the time of writing this thesis, the RCT was 
still in progress. To allow completion of this thesis, data from a subset of recruited 
patients were analysed to demonstrate the principles of the analysis. This subgroup 
analysis was performed at a time that it could not influence trial course and the chief 
investigator was unaware of the results until the close of the trial. The trial statistician 
provided assistance using blinded data, such that only I was aware of the unblinded 
results. This strategy was approved by the data monitoring and ethics committee 
(DMEC) and trial Sponsor.  
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Chapter 2. Methods 
2.1 Introduction to chapter 
This chapter will outline the methods used in the two studies reported in this thesis, a 
multi-centre validation study and a multi-centre RCT. I shall outline the design of these 
studies, the clinical elements, laboratory protocols and statistical considerations. 
2.2 Design of studies 
2.2.1 Design of validation study 
The validation study was a prospective, multi-centre observational study conducted in 
the general ICUs of 9 NHS Trusts (12 ICUs in total). The participating sites were: 
Royal Victoria Infirmary (ward 18 and 32), Newcastle upon Tyne; Freeman Hospital, 
Newcastle upon Tyne; Sunderland Royal Hospital, Sunderland; Edinburgh Royal 
Infirmary, Edinburgh; Western General Hospital, Edinburgh; Heartlands Hospital, 
Birmingham; Preston Royal Hospital, Preston; Salford Royal Hospital, Manchester; 
Countess of Chester Hospital, Chester; Royal Victoria Hospital, Belfast; and Chelsea 
and Westminster Hospital, London. A flow diagram of patient recruitment is shown in 
Figure 1.  
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Figure 1: Flow diagram of validation study recruitment
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2.2.2 Design of RCT 
The RCT was a multi-centre, prospective, RCT in which patients with suspected VAP 
were randomised 1:1 to either a biomarker-based rule-out of VAP in addition to 
standard care (microbiological culture) or to standard care only. This trial adheres to the 
Consolidated Standards of Reporting Trials statement(Schulz, Altman and Moher, 
2010) (Figure 2). 
The RCT was conducted in 23 ICUs from 17 NHS trusts. In addition to the sites 
involved in the validation study, the RCT also included the following ICUs: North 
Tyneside General Hospital, North Shields; Wansbeck General Hospital, Ashington; 
University Hospital, Coventry; Queen Elizabeth Hospital, Gateshead; James Cook 
University Hospital, Middlesbrough; Royal Infirmary, Manchester; Sandwell Hospital, 
Birmingham; City Hospital, Birmingham; The Royal Liverpool University Hospital, 
Liverpool; City Hospital, Belfast; and Russell Hall Hospital, Dudley.  
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Figure 2: CONSORT diagram for RCT 
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2.3 Participants: inclusion and exclusion criteria 
2.3.1 Validation study participants 
Patients with suspected VAP were identified by the following inclusion criteria: 
Mechanically ventilated for ≥48 hours, ≥18 years of age (16 for Scotland) and new or 
worsening chest radiograph alveolar changes and at least 2 of the following criteria: 
 temperature <35OC or >38OC,  
 blood white cell count (WCC) <4x109/L or >11x109/L  
 purulent tracheal secretions 
Patients were excluded on the basis of criteria that predict poor tolerance of 
bronchoscopy and BAL(Meduri and Chastre, 1992). These criteria were: 
 PaO2<8kPa on FiO2>0·7,  
 Positive end-expiratory pressure >15cmH2O, 
 Peak airway pressure >35 cmH20  
 Heart rate > 140 beats per minute 
 Mean arterial pressure <65mmHg  
 Myocardial infarction in the last month 
 Bleeding diathesis (including platelet count <20x109 per litre of blood or 
international normalised ratio (INR) >3) 
 Poorly controlled intracranial pressure (> 20mmHg) 
 ICU consultant assesses procedure not to be safe 
Other exclusion criteria included a previous BAL as part of this study and if consent 
was declined. The exclusion of myocardial infarction in the past month was later 
removed in an amendment 6 months into the study. 
2.3.2 RCT participants 
The inclusion criteria used in the validation study were also used in the RCT with a 
number of alterations. Firstly, all patients were 18 years of age or over, including 
Scottish patients. Secondly radiological changes could include worsening CT scan 
changes. Thirdly there was the addition of the criterion that patients had to be 
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considered potentially suitable for early discontinuation of antibiotics. Considering that 
the primary outcome measure was AFD in the 7 days following BAL (see section 
2.11.2) it was felt necessary to exclude patients who were receiving antibiotics for 
alternative (ie extra-pulmonary) sources of infection in whom the biomarker test could 
not influence the number of AFD. Patients who could not have antibiotics stopped due 
to a confirmed alternative source were excluded. Patients were not to be excluded based 
on clinician willingness to stop antibiotics due to the clinician’s pre-test probability of 
VAP, judgement of severity of illness or perceived risk of stopping antibiotics. This 
criterion required on-going education of trial sites to ensure correct interpretation. 
Patients were otherwise excluded on the same criteria as for the validation study. Co-
enrolment was allowed with other RCTs after consideration of biological and statistical 
interactions and consideration of burden to patients and to patients’ families. Once there 
was agreement between investigators to allow co-enrolment, an agreement was drawn 
up in keeping with the recommendations of the Intensive Care Society(Krige et al., 
2013). Co-enrolment was allowed with observational studies without prior agreement. 
2.4 Screening and consent/assent process 
All patients within the participating ICUs were screened on weekdays for eligibility. 
While weekday only screening was not mandated during the validation study, few ICUs 
had research support on weekends and only 1 patient was enrolled on a weekend. 
Weekday screening was only possible during the RCT as laboratories supporting the 
biomarker assay only provided weekday support. Potentially eligible patients were 
discussed with the ICU consultant to determine any safety concerns of performing a 
bronchoscopy and, for the RCT, to determine the appropriateness of potential early 
discontinuation of antibiotics. 
Consent and assent procedures were in keeping with the legal framework of either 
England, Northern Ireland (Mental Capacity Act, 2005) or Scotland (Adults with 
Incapacity (Scotland) Act, 2000) for consent/assent of adults without capacity. In 
England and Northern Ireland assent is obtained, where possible, following discussion 
with the patient’s next of kin (personal consultee). A nominated consultee provided 
assent for patients without a personal consultee. This was usually the ICU physician in 
charge of that patient, providing the individual was not also a member of the research 
team.  
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In Scotland the patient’s relative or welfare attorney provides consent for incapacitated 
patients. If the patient’s relative or welfare attorney were unavailable, consent was 
provided in a telephone conversation providing a second member of staff witnessed the 
discussion. 
Patients recovering capacity were approached to provide retrospective consent. The 
decision as to whether the patient had regained capacity resided with the treating team.  
2.5 Bronchoscopy (validation study, RCT) 
A standard operating procedure was used based on previously published 
recommendations on a standardised approach to BAL in critically ill patients(Meduri 
and Chastre, 1992). All bronchoscopy was performed under the supervision of an ICU 
doctor (registrar or consultant) who managed the patient’s anaesthesia and monitoring. 
Patients were ventilated with 100% oxygen prior to bronchoscopy. Frequently patients 
were also given a neuromuscular blocking agent in addition to sedation, although this 
was not mandated. Bronchoscopy for both studies was considered to be a clinical 
procedure (in addition to research purposes) and therefore was carried out by either the 
research team or the clinical team. The bronchoscope was passed through the ETT or 
tracheostomy tube to the lobe that corresponded to the area of new CXR change. If 
multiple areas were involved on CXR then the lobes were inspected at bronchoscopy 
and the area with the most prominent purulent secretions was lavaged. If the CXR 
demonstrated a ‘white out’ or no particular lobe had purulent secretions, the posterior 
segment of the right lower lobe was lavaged. Autopsy data have demonstrated that VAP 
has a predominance for the posterior segments of the lower lobes(Rouby et al., 1992). 
BAL was performed by wedging the bronchoscope in the relevant subsegment and 
instilling 20mls of sterile 0.9% saline, which was aspirated and discarded as the 
‘bronchial sample’. A further 120mls of sterile 0.9% saline was then instilled in 40ml 
aliquots with aspiration and collection of BAL fluid between each 40ml aliquot into 
collection traps. The BAL fluid aspirated from each aliquot was pooled. 
2.6 Biomarker assay 
2.6.1 Reagents and equipment 
All reagents and equipment for the project were supplied by BD Biosciences (with the 
exception of Spherotech Ultra rainbow beads (Spherotech, Lake Forest, Illinois). CBA 
assay diluent, CBA detection reagent diluent, CBA capture bead diluent, CBA wash 
buffer, human IL-8, IL-1, IL-6, IL-12p70 and TNF- flex set are commercially 
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available reagents (BD Biosciences, New Jersey, USA). Enhanced sensitivity IL-1 and 
IL-8 flex sets, and enhanced sensitivity master buffer kits, were also supplied by BD. 
MMP-8 CBA beads (6x10
6
 beads/ml), MMP-8 phycoerythrin (PE) CBA detection 
reagent (0.1mg/ml), MMP-9 CBA beads (6x10
6
 beads/ml), MMP-9 PE CBA detection 
reagent (0.1mg/ml), HNE CBA beads (6x10
6
 beads/ml) and HNE PE CBA detection 
reagent (0.1mg/ml) were custom made by BD Biosciences, San Diego. 
Human recombinant MMP-8 (100ug/ml) and human recombinant MMP-9 (100ug/ml) 
were purchased from R&D systems (Minneapolis, USA). Recombinant HNE was 
purchased from Merck Millipore (Massachusetts, USA). 50ug was reconstituted in 
500μl HNE buffer (sodium acetate 50mM-200mM NaCl pH5.5) to give a 100g/ml 
stock solution. 
Urea was measured using a QuantiChrom urea assay kit (Bioassays Systems, Hayward, 
USA). 
CBA assays were performed on Accuri C6 flow cytometers. These were supplied to 
Newcastle University by BD for the validation study and then one to each of the 6 
testing hubs for the RCT (Freeman Hospital, Newcastle; Royal Infirmary of Edinburgh, 
Edinburgh; Salford Royal Hospital, Salford; Heartlands Hospital, Birmingham; Royal 
Victoria Infirmary, Belfast; and Chelsea and Westminster Hospital, London). Accuri 
quality control (QC) procedures were carried out using BD cytometer setup and tracking 
beads (BD Biosciences, New Jersey, USA) and with Spherotech ultra rainbow beads 
(Spherotech, Lake Forest, Illinois) in keeping with Newcastle University’s Flow 
Cytometry Core Facility standard operating procedures (SOP). QC data were monitored 
by the flow cytometry core facility during the study. 
2.6.2 Processing BAL and blood (validation study and RCT) 
During both the validation study and the RCT, BAL aliquots collected from the three 
instillations of 40mls of saline were pooled. A 2ml sample was sent to the hospital 
microbiology laboratory for semi-quantitative culture. In the validation study the 
remaining BAL was centrifuged at 700g for 10mins at room temperature. The 
supernatant was aspirated and stored at -80
o
C where possible and otherwise stored at -
20
o
C. Samples were stored at the study sites and transported to Newcastle University at 
the end of the study period.  
During the RCT, fresh BAL samples were transported from recruiting sites to testing 
hubs at 4
o
C for processing. Samples were centrifuged as above but prior to freezing, a 
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500µl aliquot was taken for immediate biomarker analysis in patients randomised to the 
intervention arm. 
Serum tubes were centrifuged at 1500g for 30mins at 4
O
C. Serum was aspirated and 
stored as per the same SOP for BAL fluid. 
2.6.3 Measurement of BAL biomarkers (validation study) 
Concentrations of IL-1, IL-8, MMP-8, MMP-9 and HNE were measured in BAL by 
CBA in a 5-bead multi-plex assay. All buffers were brought to room temperature and 
samples were thawed at room temperature before being stored on ice. 
Preparation of CBA bead master mix 
Beads were supplied at 6x10
6
 beads/ml and used at 6000 beads per test, corresponding 
to 1l of each bead solution used per test. Bead stocks were vortexed for 30 seconds and 
a sufficient aliquot of each bead stock was pipetted into a 15ml falcon tube. 0.5ml of 
wash buffer was added to the bead mixture and then the beads were centrifuged for 5 
minutes at 200g at room temperature. The supernatant was aspirated and the beads re-
suspended in a volume of capture bead diluent (for serum) to give 50l capture bead 
solution per test. 50l of bead mixture was added to each labelled tube and incubated in 
the dark, at room temperature for 15 minutes to equilibrate. 
Reconstitution of lyophilised standard spheres (IL-1 and IL-8) 
Standards for BD flex sets are supplied as lyophilised spheres. These were reconstituted 
in 500l of assay diluent (20 ng/ml) and allowed to equilibrate for 15 minutes at room 
temperature. 
Preparation of dilution series of standard master mix 
Recombinant MMP-8, MMP-9 and HNE standards were pre-diluted 1:10 (10g/ml) in 
assay diluent. To make the master mix of standards, 62.5l of reconstituted lyophilized 
spheres, 20l of pre-dilution of MMP-8 and MMP-9 and 4l of HNE, was made up to 
500l with assay diluent. The final concentration of IL-1 and IL-8 was 2500pg/ml, 
MMP-8 and MMP-9 was 400ng/ml and HNE was 80ng/ml. 1:2 serial dilutions were 
performed to give 10 standard concentrations with the lowest concentration for IL-1 
and IL-8 being 5pg/ml, MMP-8 and MMP-9 being 0.78ng/ml and HNE being 
0.16ng/ml. 
Preparation of sample dilutions 
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Samples were centrifuged for 2 minutes at 10,000g at room temperature to spin down 
any aggregates prior to performing dilutions. Samples were prepared in dilutions of 1:5, 
1:50 and 1:500 in a 96 well plate using assay diluent. In repeat assays, any sample in 
which the IL-1 in the 1:5 dilution fell below the standard range, was repeated as a neat 
sample. 
Addition of standard or samples to beads 
50l of either standard or sample was added to the 50l of bead mixture in each tube. 
Each sample was mixed thoroughly by pipetting. Samples were incubated at room 
temperature in the dark for 1 hour. 
Preparation of PE detection reagent master mix 
A master mix of PE detection reagent was made as per the bead master mix. 1l per test 
of each detector was added to a 15ml falcon tube, with the exception of HNE PE, which 
was used at 2l per test. The mix was made up to a volume of 50l per test with 
detection reagent diluent. 
Addition of PE detection reagent to tests 
Once the beads had incubated with samples for 1 hour, 50l of PE detector reagent was 
added to test tubes. The tests were incubated for a further 2 hours in the dark at room 
temperature. 
Washing samples 
1ml of wash buffer was added to each tube and then centrifuged at 200g for 5 minutes at 
room temperature. The supernatant was decanted and 200l of wash buffer added. 
Analysis 
Samples were immediately analysed on an Accuri C6 flow cytometer. The cytometer 
laser configuration was FL1 530/30, FL2 585/40, FL3 780/60 and FL4 675/25 (2 blue, 2 
red). Results were analysed using FCAP array V3.0 software (Soft Flow, Pecs, 
Hungary). 
2.6.4 Measurement of urea and concentration correction (validation 
study) 
Urea was measured using the QuantiChrom urea assay kit (BioAssay Systems, 
Hayward, USA). This method uses a chromogenic reagent that binds to urea to form a 
coloured complex. The colour intensity is directly proportional to the urea 
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concentration. The assay has a linear detection range of 0.08mg/dL to 100mg/dL and is 
performed in a clear bottom 96-well plate.  
All reagents were brought to room temperature before use. Urea standard was supplied 
at 50mg/dL. Serum samples were assayed neat. 5µl of water (blank) and 5µl of standard 
(50mg/dL), in duplicate, were pipetted to wells as the assay control. 5µl of sample, in 
duplicate, were placed into the remaining wells on a 96 well plate. Working solution 
was added at 200µl and allowed to incubate for 20 minutes before reading the optical 
density (OD) at 520nm.  
For the low urea concentrations of BAL the assay was modified as per the 
manufacturer’s instructions by transferring 50µl of water, 50µl of standard (5µl of stock 
diluted into 50µl of water to give 5mg/dL) and 50µl of sample in duplicate. These were 
incubated for 50 minutes before reading OD at 430nm. 
Urea concentration (mg/dL) was calculated by the following formula: 
[Urea] = {(ODSAMPLE - ODBLANK) / (ODSTANDARD - ODBLANK)} x n x [STD] 
Where ODSAMPLE, ODBLANK and ODSTANDARD are the OD values for sample, water and 
standard respectively. n is the dilution factor (1 for serum, 50 for BAL) and [STD] is the 
urea standard concentration (50mg/dL for serum assays and 5mg/dL for BAL assays). 
ELF biomarker concentration was determined by correcting the BAL biomarker 
concentration by the following equation: 
VolumeELF = ([UreaBAL] x VolumeBAL) / [UreaPLASMA](Rennard et al., 1986) 
Dilution factor = VolumeBAL / VolumeELF 
Dilution factor = [UreaSERUM] / [UreaBAL] 
[BiomarkerELF] = [BiomarkerBAL] x ([UreaSERUM] / [UreaBAL]) 
2.6.5 Measurement of serum biomarkers (validation study) 
Biomarkers in serum that have diagnostic utility in patients with suspected VAP would 
be of great value, as it would avoid the need to perform a BAL. Serum biomarkers were 
measured in the original derivation cohort and no difference was found between the 
VAP and the non-VAP groups(Conway Morris et al., 2010). Considering the potential 
value of a serum biomarker, this was attempted in this study also. A pilot study of IL-
1, IL-8, IL-6, TNF-, IL-12p70, HNE, MMP-8 and MMP-9 was conducted in 20 
validation study serum samples to determine which of these 8 biomarkers should be 
tested on the full validation cohort and which dilutions should be used in the main 
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cohort. Samples were diluted using assay diluent in concentrations of 1:4, 1:20, 1:100 
and 1:500. 
From this, a multiplex of IL-8, MMP-8, MMP-9, HNE and IL-6 were tested on the full 
cohort of validation study samples in dilutions of 1:4, 1:20 and 1:100. The CBA 
procedure was the same as the assay outlined in the above section. The standard for IL-6 
was handled in the same way as IL-8 and the top standard was also 2500pg/ml. 
2.6.6 Enhanced sensitivity assay (validation study) 
IL-1 and IL-8 were also tested using an enhanced sensitivity assay. The standard range 
for the enhanced sensitivity flex set is 274-200,000 fg/ml and so has improved detection 
of low concentration biomarkers. 
All reagents were brought to room temperature and samples thawed at room 
temperature before being stored on ice prior to testing. The enhanced sensitivity assay is 
identical to the CBA for stages preparing the CBA bead master mix, preparation and 
dilution of standards. The samples were similarly centrifuged at 10,000g prior to 
diluting 1:3, 1:30 and 1:500. Beads were incubated with sample or standard for 2 hours 
in the dark at room temperature (as compared with 1 hour in the standard assay).  
During this time the detection reagents part A and part B were prepared. Reagent part A 
was prepared as per standard PE detector reagent with 1µl of each reagent (IL-1 and 
IL-8) per test being added to a volume of detector reagent diluent to give a final volume 
of 20µl per test. Reagent part B is provided as a lyophilised cake that is reconstituted in 
0.55ml of detection reagent. This is incubated in darkness at room temperature for 15 
minutes. 530µl of the reconstituted part B reagent was added to 4770µl of detection 
reagent diluent and mixed by vortexing. After the initital 2-hour incubation period, 20µl 
of detection reagent part A was added to the samples and further incubated for 2 hours. 
After this incubation period, the samples were washed by adding 1ml of wash buffer 
and centrifugation at 200g at room temperature. The supernatant was decanted off 
before 100µl of detection reagent part B was added and gently mixed. The samples were 
incubated for a further 1-hour period in the dark at room temperature. A final wash was 
performed (as previously described) before 200µl of wash buffer was added and then 
samples analysed on the Accuri C6. 
2.6.7 Biomarker assay protocol for RCT 
Collaborators at BD made a number of modifications to standard flex set CBA assay for 
the RCT in comparison to the validation study protocol. The intra-assay variation is 
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greatest at the extremes of the standard curve and so the 5pg/ml point was removed and 
9 points on the standard curve, with the lowest point being 10pg/ml, were used for IL-
1 and IL-8. 
There were two controls built into the assay to ensure robustness of the results. Since 
some patients will have low IL-1 levels or even no detectable IL-1, there are 
concerns about the robustness of detecting very low levels of an analyte. IL-8 acts as a 
control in this regard since IL-8 was present in all but 2 samples from the validation 
cohort.  The 2 samples with undetectable IL-8 had globally low or undetectable 
biomarkers, suggesting low quality BAL. Therefore the IL-8 acts as a control to ensure 
that there is measureable protein in the sample. In addition to the IL-8 control, an IL-1 
and IL-8 positive control was incorporated into the assay and this had to fall within 
predetermined limits for the result to be reliable. This controlled for assay quality 
including correct solubilising of lyophilised standard, correct reagent temperature and 
timing of incubation periods. Internal control limits were initially determined from 17 
independent experiments for IL-8 and 8 independent experiments for IL-1 (performed 
by myself and BD scientist). These were later expanded based on CBA assays from the 
RCT to include a total of 26 experiments for IL-1 and 35 experiments for IL-8. 
Samples were tested neat, 1:5, 1:50 and 1:500 dilutions. The positive control was 
diluted 1:40. As previously described, samples were measured on the Accuri C6 and 
results analysed using FCAP software. An analysis template (Excel file) was created to 
guide the technicians through the steps of checking the IL-8 and positive control quality 
control steps and then determining which sample dilutions should be included to 
calculate average IL-1 and IL-8 values. The template incorporated a locked cell that 
contained the logistic regression equation to calculate the final result and a logical 
formula to state if it was ‘VAP’ or ‘non-VAP’. This was to reduce the chance of error at 
this interpretation point.  
2.7 Microbiology (validation study and RCT) 
Culture of BAL fluid followed the same SOP in both the validation study and the RCT. 
VAP was defined as growth of a potentially pathogenic organism at >10
4
 cfu/ml during 
the validation study, in keeping with widely accepted thresholds(Chastre et al., 1995). 
For practical purposes the threshold was changed to ≥104cfu/ml for the RCT. This 
change was made as it was felt, given the semi-quantitative nature of quantification, 
   
  88 
laboratory reporting and clinical interpretation would not distinguish between >10
4
 and 
≥104 cfu/ml in a practical sense. 
All microbiology samples were handled in a NHS or Health Protection England (HPE) 
(previously Public Health England) microbiology laboratory. BAL was handled 
following a SOP in accordance with the UK Standards for Microbiology 
Investigation(Health Protection Agency, 2012). BAL fluid samples did not undergo 
Gram staining unless specifically requested by the clinical team or if this was routine 
for the laboratory. Each specimen was mixed well by vortexing and then using a sterile 
10µl loop the following plates were inoculated with fluid (Table 8): 
Media Atmosphere Temp Duration Target organism 
Chocolate blood 
agar + Bacitracin 
5-10% CO2 35-37C 40-48 hrs H. influenza 
M. catarrhalis 
S. aureus 
S. pneumoniae 
BA+ Optochin disc 5-10% CO2 35-37C 40-48 hrs S. pneumoniae 
Fastidious anaerobic 
agar  
AnO2 35-37C 40-48 hrs Anaerobes 
CLED or 
MacConkey 
Air 35-37C 40-48 hrs Enterobacteriaceae 
Pseudomonads 
Sabouraud’s agar 
(x2) 
Air 30 & 35-
37C 
40-48 hrs Fungi 
Table 8: Culture conditions for semi-quantitative cultures. CLED, cysteine lactose electrolyte deficient. 
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The number of colonies were counted on the plate and interpreted as cfu/ml. Less than 
10 colonies was interpreted as <10
3
 cfu/ml, 10-100 colonies was interpreted as 10
3
-10
4 
cfu/ml and >100 colonies was interpreted as >10
4 
cfu/ml. 
During the validation study, all bacteria isolated at >10
4
 cfu/ml were identified to 
species level. This proved a barrier in the labs when moving to the RCT and so only 
potentially pathogenic organisms isolated at >10
4 
cfu/ml were identified to species level. 
All yeasts were identified to species level and filamentous fungi were sent to an 
appropriate mycology lab for speciation. Antimicrobial susceptibility testing was 
performed according to local practice. 
An important consideration for culture results is the previous administration of 
antibiotics. The derivation study excluded patients who had had a change in prescribed 
antibiotics in the previous 3 days(Conway Morris et al., 2010). Previous studies have 
shown that the development of suspected VAP while receiving antibiotics for another 
infection, does not influence the diagnosis of VAP since the emerging infection will be 
resistant to the current antibiotic treatment(Montravers et al., 1993; Timsit et al., 1995). 
The recent initiation of antibiotics for suspected VAP can, however, have a significant 
impact on the subsequent culture results and lead to false negative results(Fabregas et 
al., 1996; Souweine et al., 1998). In both the validation study and the RCT, the decision 
was made to allow recruitment of patients who had antibiotics started within 48 hours. 
Although this was not ideal, a pragmatic decision was made to ensure sufficient patient 
accrual. 
2.8 Hub set up and training methods/materials (RCT) 
The biomarker assay was carried out in 6 laboratories that acted as ‘hubs’ for the 
recruiting ICUs. All sites were within an approximate travel time of 1 ½ hour from the 
hub to avoid samples having excessive transit times. 
The set up of the hub was dependent on local arrangements and generally the biomarker 
test was hosted in microbiology labs, since these labs were already engaged in the 
project. Salford, Belfast and Heartlands incorporated the biomarker assay within a NHS 
microbiology lab. Newcastle (Freeman Hospital) and Edinburgh utilised the academic 
microbiology labs. Chelsea and Westminster performed the test in an academic 
immunology lab. All labs were within NHS hospitals. 
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With the exception of Chelsea & Westminster, which used scientists with flow 
cytometry experience, all other sites used scientists with a microbiology background 
and limited flow cytometry experience. Essential training in the Accuri C6 and CBA 
assay was provided. Training material was designed for a user with limited flow 
cytometry experience. The Accuri C6 is a flow cytometer that is designed for its ease of 
use. The fluorescence detectors are pre-optimised and so adjustment of detector voltage 
is not necessary. It has minimum set up time and when using software templates, it is 
close to a ‘plug-and-play’ flow cytometer. It also has a small bench footprint and is easy 
to move if necessary which proved valuable in laboratories with limited bench space.  
Training was provided to the technicians in two, 2-day sessions in London (Chelsea & 
Westminster) or Newcastle. Training material was developed in collaboration with BD 
Biosciences scientists and a manual was given to technicians. Training for the Accuri 
included an overview of the Accuri C6; templates; set-up and shut-down; maintenance; 
QC; and lasers and filters. Other topics related to the trial itself and included an 
overview of the trial; sample transport and handling; randomisation process; biomarker 
assay protocol; processing samples on Accuri C6; analysing Accuri data on FCAP 
software; final data sorting and interpretation; and reporting results to the clinical team. 
On site training was provided for Salford and Belfast in the same format as the 
centralised training.  
2.9 Randomisation and blinding (RCT) 
Randomisation was performed using a web-based randomisation service hosted by 
Newcastle Clinical Trials Unit (NCTU). Patients were randomised in a 1:1 ratio by 
variable size permuted blocks and stratified by site. Since randomisation determined by 
which means the BAL fluid was analysed and up to that point all patients undergo the 
same study procedures of bronchoscopy and BAL, the technicians performed the 
randomisation. To perform the randomisation the technician contacted NCTU and the 
patient’s details were entered into the online randomisation service. The automated 
message instructed that the patient was randomised to ‘biomarker-guided 
recommendation on antibiotics, analyse sample on arrival’ or to ‘routine use of 
antibiotics, do not analyse sample on arrival’. This instruction was emailed to the 
technician. 
The clinical team were blinded to allocation for the first 6 hours of trial involvement 
until the results were called back. The technicians reported the results to the clinical 
team according to standard scripts. To ensure consistent unblinding, the clinical team 
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were informed if the patient was randomised to standard care after a similar interval 
(approximately 6 hours). The instructions were: 
If the biomarker result was below threshold: 
“Biomarker result below cut-off. The negative predictive value is 1 and a diagnosis of 
VAP is very unlikely. Consider discontinuation of antibiotics.” 
If the biomarker result was above the threshold: 
“Biomarker result above the cut-off. VAP cannot be excluded, consider continuing 
antibiotics.” 
If the assay did not meet quality control standards the clinical team were advised to 
default to standard care. If the assay did not meet the internal control check-point the 
clinical team were advised: 
“Biomarker assay has not met internal control standard. Unable to return biomarker 
result. Await microbiology result and default to standard care”. 
If the assay did not meet the IL-8 check-point, the clinical team were advised: 
“IL-8 undetectable in BAL. The quality of BAL is uncertain. Unable to return 
biomarker result. Default to standard care.” 
2.10 Trial intervention (RCT) 
Since all included patients had suspected VAP, they all underwent the sample study 
procedures of bronchoscopy and BAL. It was anticipated that all patients would have 
antibiotics started at the point of suspicion, around the time of BAL, although this 
would not always be the case depending on the clinical index of suspicion. Those who 
underwent biomarker testing would have a result in approximately 6 hours and those 
who had VAP ruled out would be able to have antibiotics discontinued. In comparison, 
those in the ‘routine use of antibiotics group’ would ordinarily be first considered for 
discontinuation of antibiotics when microbiology results return, typically 48-72 hours 
after BAL. 
2.11 Outcome measures 
2.11.1 Validation study outcome measures 
The primary outcome measure of the validation study was the presence of confirmed 
VAP based on a potential pathogen at >10
4
 cfu/ml. This provided the standard against 
which the BAL fluid biomarkers were measured.  
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Secondary outcome measures were biological measures (ie. biomarkers), safety and 
clinical measures. Biological measures included IL-1, IL-8, MMP-8, MMP-9, HNE 
and urea in BAL fluid. In serum, the markers were IL-1, IL-8, IL-6, TNF-, IL-12p70, 
HNE, MMP-8, MMP-9 and urea. Safety measures included SaO2, heart rate, BP, 
PaO2:FiO2 ratio, before and after the procedure. Clinical measures included 
demographics, all-cause ICU mortality and hospital mortality. 
2.11.2 RCT outcome measures  
The primary outcome measure for the RCT was the frequency distribution of AFD in 
the 7 days following BAL. This time-course was felt most appropriate since this is the 
typical duration of a course of antibiotics for VAP in the UK(Browne et al., 2014). 
Days of antibiotic treatment were counted in whole numbers of days. Durations of 
antibiotic prescribing was counted from the date of the BAL procedure to date of 
treatment termination (or censoring from death or discharge), with the proviso that any 
courses started and stopped on the same day will be classed as one day of antibiotic use. 
Antibiotics that were not administered for active clearance of infection (e.g. those given 
as “prophylaxis” against infection or those used for an alternative indication such as a 
pro-motility function in the gastrointestinal tract) were not counted in the analysis.  
Secondary outcome measures included antibiotic days and AFD, expressed as 
continuous variables, at day 7, 14 and 28; ventilator-free days at 28 days; 28-day all-
cause mortality and critical care mortality; sequential organ failure assessment (SOFA) 
at days 3, 7 and 14 with modification for non-neurological assessment(Vincent et al., 
1996); duration of critical care, level 2-, level 3- and hospital-stay; the presence of 
Clostridium difficile and MRSA infections up to hospital discharge, death or 56 days; 
and number of antibiotic-resistant pathogens cultured up to hospital discharge, death or 
56 days 
VFD is defined as the number of days from enrolment up to 28 days that the patient 
breathes unassisted. A common situation in the ICU is that the patient will have a trial 
without assisted breathing and if the patient fails this trial, mechanical ventilation is 
restarted. For this reason the period of unassisted breathing begins when assisted 
breathing is discontinued for a period that is >48hrs. If the patient receives a further 
period of mechanical ventilation once unassisted breathing has been achieved, this is 
subtracted from the VFD. Death within the 28-day period will be assigned zero VFD. 
Mechanical ventilation for surgical procedures is not counted. Unassisted breathing is 
defined as:  
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 Extubated breathing on supplemental oxygen or room air. 
 Open T-tube breathing. 
 Tracheostomy mask breathing. 
 Continuous Positive Airway Pressure (CPAP) <5 cmH2O without pressure 
support. 
2.12 Clinical data collection (validation study and RCT) 
In the validation study clinical data were collected on age, sex, admission category 
(medical or surgical), Acute Physiology and Chronic Health Evaluation (APACHE) 2 
score, use of organ support (renal replacement, vasopressors), corticosteroid use, 
presence of ARDS, temperature on day of BAL, white cell count on day of BAL, 
PaO2/PaCO2/pH on day of BAL, ICU length of stay, hospital length of stay, ICU 
mortality, hospital mortality, antibiotic use on the day of BAL and in the 3 days 
preceding the BAL, and antibiotic use in the 7 days following BAL. Safety measures 
were collected in relation to the BAL including oxygen saturations, heart rate, blood 
pressure, and PaO2:FiO2 ratio. 
Clinical data collection for the RCT was similar to the validation study. Baseline data 
were collected on the day of enrolment (day 0). In addition to the above clinical data, 
reasons for ICU admission were collected, along with functional co-morbidities index 
score(Groll et al., 2005), neutrophil count, platelet count, CRP, positive end-expiratory 
pressure, peak airway pressure, tracheal secretion character, CXR findings, pulse, mean 
arterial pressure, intracranial pressure, and indications for antibiotic use at the time of 
BAL and in the preceding 3 days. Patients were followed up on days 3, 7, 14 and 28, 
and the final follow-up was at death, discharge from hospital or at 56 days. Clinical data 
to assess primary outcome and secondary outcomes were collected. 
2.13 Statistical methods 
2.13.1 Validation study statistical considerations 
The sample size for the validation study was based on validating the negative post-test 
probability (PTP) of VAP (ie. exclusion of VAP) using the IL-1 threshold determined 
in the derivation study(Conway Morris et al., 2010). The derivation study stated that 
BAL IL-1 below 10pg/ml excluded VAP with a PTP of 2.8% (95% CI 0.1-15.9). A 
95% confidence interval of 0-8% around a PTP of 3% was felt to be tight enough for 
clinical use. Estimating the prevalence of VAP to be 24% based on the derivation 
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cohort, 140 patients were required to achieve this and accounting for an approximately 
15% dropout rate, we planned to recruit 160 patients. 
Statistical analysis was performed using SPSS version 19 (Chicago, Illinois, USA), 
Prism 6 (La Jolla, California, USA) and R 3.0.0(Team, 2013). Comparisons of non-
parametric continuous data were performed using Mann-Whitney U test and parametric 
data using the Student’s T-test. Proportions were analysed by Chi-squared test. To 
determine diagnostic utility of the biomarkers the population was dichotomised into a 
VAP and non-VAP group based on the BAL culture thresholds (>10
4
 cfu/ml = VAP). 
ROC curves were constructed for individual biomarkers. Biomarkers were tested in 
combination by log10 transformation of biomarkers with the addition of a constant of 
one before being entered into a logistic regression model. ROC curves were constructed 
from the output of the logistic regression. The AUROC was calculated and optimum 
cut-points determined. The pre-specified method for this was to use the Youden 
index(Youden, 1950). This statistic takes the optimal balance of sensitivity and 
specificity from the ROC curve. In a post-hoc analysis, cut-points were determined by 
fixing a minimum NPV of 95% to ensure a high rule-out performance. The diagnostic 
rules, performance measures and 95% confidence intervals were derived using the 
OptimumCutpoints library in R3.0.0(Lopez-Ranton and Rodriguez-Alvarez, 2013). 
Post-hoc sub-groups analyses were performed to investigate the effect of antibiotic use 
on the biomarker performance, to investigate differences in medical versus surgical 
patients and to investigate differences in VAP, sub-VAP and sterile culture. 
2.13.2 RCT statistical considerations 
As stated earlier, at the time of writing this thesis the RCT was still on going. A sub 
analysis was performed of a group of recruited patients who had a considerable amount 
of follow up data collected. This was not a formal interim analysis, as it was not used to 
inform RCT direction. In fact the results of this analysis was not made available to the 
chief investigator until the trial had closed. This strategy was approved by the trial 
sponsor and by the DMEC. 
In relation to the RCT, the primary outcome measure of measuring a change in the 
frequency distribution of AFD in the 7 days following BAL was reached after a series 
of considerations. Firstly, although AFD is a continuous variable, it is bounded at its 
lower and upper values, 0 and 7 AFDs, and a non-trivial proportion of patients will have 
AFD values at the boundaries. This has implications for power calculations and for 
analysis based on location-shift models (ie. a change in mean, median or mode) since 
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these data are not normally distributed(Lesaffre et al., 1993). For this reason, this 
outcome cannot be handled as a simple continuous variable.  
The initial solution was to use a proportions model. Two groups were created, 0-2 AFD 
and 3-7 AFD and sample size estimated based on the number of patients required to 
detect an increase of 50% in those with 3-7 AFD. Initial estimations were based on 
derivation study data(Conway Morris et al., 2010). Baseline proportions based on those 
data were that 59% of patients had 0-2 AFD and 41% of patients had 3-7 AFDs. To 
detect a 50% increase in the proportion of patients with 3-7 AFD with 80% power and 
an alpha of 0.05, 93 patients were required per trial arm. Allowing for a 15% drop out 
rate, 214 patients were initially estimated. This estimation was, however, based on data 
from a single centre. The completion of the validation study mandated a review of the 
power calculation based on the validation cohort AFD data. In the validation cohort 
78.1% of patients had 0-2 AFD and 21.9% had 3-7 AFD. The difference between the 
AFD proportions had significant consequences for the sample size. A 50% increase 
from 22% to 33% would require 276 per arm of the trial. That would have been too 
large in terms of project budget and expected recruitment period.  
One approach to reducing sample size was to power to a larger effect size. An increase 
in the proportion in the 3-7 AFD group from 22% to 44% (a 100% increase) required a 
sample size of 80 patients per group. Although this was an attractive sample size in 
terms of patient accrual, it is a large effect size. The biomarker sensitivity and 
specificity profile also made this impractical. A specificity of 44% means that 44% of 
non-VAPs will have a biomarker result below the threshold, but that is 29% of the 
whole population of suspected VAP. It then becomes apparent that a small percentage 
of the patients must have a sufficient effect from the intervention to detect the change in 
the whole trial arm. In fact an increase in the proportion of 3-7 AFD from 22% to 44% 
would have required 100% compliance in antibiotic guidance, which was considered an 
unrealistic expectation. 
Using a binary outcome such as proportions in one of two groups misses much of the 
information around change in the primary outcome and large sample sizes are required. 
An alternative approach was to use a change in the frequency distribution of AFD. AFD 
were handled as ordinal values with patients being in 1 of 8 categories, 0-7 AFD. Using 
ordinal outcomes over dichotomous outcomes gives more statistical power, allowing a 
smaller sample size, and captures more of the information around the changes in the 
outcome measure(McHugh et al., 2010). The baseline distribution, established from the 
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validation study, was skewed to the left with the majority of patients having 0-2 AFD (0 
AFD = 57.6%, 1 AFD = 8.6%, 2 AFD = 11.9%). Models were created to demonstrate a 
shift in distribution towards the right representing a move towards more patients having 
more AFD. These models are demonstrated in Table 9. The effect sizes are the sum of 
the squared differences between the proportions for each AFD category. 
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Proportion of AFD (%)  
N per 
arm 
 
Effect 
Size 
0 1 2 3 4 5 6 7 
Standard Care (from validation 
study) 
55 10 10 5 5 5 5 5   
Model 1 40 20 15 5 5 5 5 5 215 0.033 
Model 2 35 20 15 10 5 5 5 5 138 0.052 
Model 3 30 20 15 10 10 5 5 5 96 0.075 
Model 4 25 20 20 10 10 5 5 5 68 0.106 
Table 9: Models of different frequency distributions of AFD. Standard care distribution is based on data 
obtained from validation cohort. The different models demonstrate increasing shifts in the frequency 
distribution towards more AFD in the sample. These distributions are illustrative and different 
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The changes in distribution in the models represent clinically significant changes in 
antibiotic use since any shift towards patients having more AFD is relevant in a clinical 
environment where antibiotic use is so high and antibiotic resistance is such a concern. 
A sample size of 90 patients per arm would have 80% power to be able to detect an 
effect size of 0.0797 (slightly higher than model 3). With approximately 15% predicted 
drop out rate, 210 patients were required. By way of illustration the change in 
distribution from baseline to model 4 is illustrated in Figure 3. 
 
 
Figure 3: Shift in distribution of AFD from baseline to model 4. 
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The analysis plan for the RCT aimed to present baseline clinical characteristics using 
summary statistics without formal tests of equality. The primary outcome, handled as an 
ordinal variable, was analysed by chi-squared test in a 2x8 contingency table. AFD were 
censored to death or hospital discharge. 
. 
Secondary outcomes measures were compared between the trial arms by Chi-squared, 
Mann-Whitney U or T-test depending on the nature of variable and its distribution. 
Data analysis was performed on an intention-to-treat basis. Exploratory per-protocol 
analyses were planned a priori , in particular accounting for patients randomised to the 
intervention arm but in whom the biomarker assay was not reported for technical 
reasons and so defaulted to standard care. 
2.14 Statement of significant contributions by others 
The acknowledgements section outlines the contributions of many individuals who 
assisted in the delivery of two complex studies. This section aims to layout with more 
detail elements of the work that was carried out either entirely by others or with a 
significant contribution by others. This is largely with respect to the statistical elements 
of the research. 
The power calculations for the validation study and the RCT were entirely performed by 
the trial statistician (Niall Anderson). For the validation study analysis, I carried out the 
analysis of demographics and constructed ROC curves for individual biomarkers. The 
statistician calculated optimum cut-points using R and performed the logistic regression 
analysis for the combination of biomarkers (including generation of graphs). I ensured 
that I was able to replicate this process with SPSS, to generate my own logistic 
regression output and graphs.  
The urea testing of serum and BAL fluid as well as the CBA testing of serum (not 
including the pilot testing), was entirely performed by Jonathan Scott, laboratory 
technician. 
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Chapter 3. Results: Validation study 
3.1 Introduction to chapter 
This chapter reports the results of a multi-centre validation study. The purpose of the 
validation study was to determine whether BAL fluid biomarkers could effectively 
exclude VAP when tested in a multi-centre setting. The validation study was a 
preparatory study for the RCT and so the results reported here and considerations 
discussed are framed in the context of their implications for the RCT. 
3.2 Screening and recruitment 
Patients were recruited from 12 ICUs from 9 NHS Trusts between February 2012 and 
February 2013. This was slower than the expected timeline of 6 months (Figure 4).  
 
 
 
Patients were recruited from a large number of general ICUs. Although admission 
diagnosis was not recorded, it would be expected that this is representative of the 
general UK ICU population. Although screening logs were kept on each site, these were 
not monitored through the NCTU since this was an observational study rather than a 
trial. Some sites recorded number of patients screened whereas other sites recorded 
0
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Figure 4: Validation study accrual. Actual versus predicted accrual rate. 
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screening episodes. Therefore the total number of patients screened is an approximation. 
It is estimated that 1385 patients were screened and of these 415 patients met the 
inclusion criteria. Of these patients 248 were excluded and reasons were recorded for 
220 patients. 87 (21%) patients were excluded due to exclusion criteria or due to safety 
concerns. These included 14 patients with high oxygen requirements, 18 patients with 
high intracranial pressure, 20 with recent MI (this was removed as an exclusion criterion 
during the validation study), 5 with abnormal coagulation and 2 with high airway 
pressure. In addition 28 patients were excluded based on consultant assessment that the 
patient was too unstable for BAL. Patients were also excluded when, despite meeting 
the inclusion criteria, the clinical team did not suspected VAP (ie. either hospital- or 
community-acquired pneumonia) (10 patients), lack of availability of BAL (6), 
suspension of recruitment (5), previous BAL outwith study recruitment (5), patient 
improving and weaning (10), consent declined (15), planned withdrawal of care (21), 
planned extubation (19), lack of availability of research staff (4), administration of new 
antibiotics for VAP episode for >72hrs (5), co-enrolment issues (3) and other 
miscellaneous reasons (8). A further 21 patients were excluded based on a consultant 
decision distinct from the group where patients were classed as ‘too unstable’. The 
screening logs were not detailed enough to establish the reason but included factors 
such as safety, diagnostic issues, clinical indication for BAL and acceptability of BAL. 
One hundred and sixty seven patients were consented and of these 17 patients dropped 
out. Five patients were withdrawn by clinicians or relatives prior to performing BAL, 4 
patients deteriorated following consent making BAL unsafe, 7 samples were 
mishandled in the laboratory (either semi-quantitative culture not performed or sample 
incorrectly stored) and 1 patient improved between consent being obtained and BAL 
being performed. 
One hundred and fifty patients with paired semi-quantitative microbiology results and 
biomarker results were entered into the analysis. VAP was confirmed in 53 patients 
(35%) with cultures >10
4
 cfu/ml. The remaining 97 (65%) with sterile culture (54) or 
culture growth 104 cfu/ml (43) were classed as non-VAP. 
The Standards for Reporting of Diagnostic Accuracy (STARD) diagram is presented in 
Figure 10 (Section 3.8 Biomarker combinations) after rationale for biomarker selection. 
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3.3 Demographics and clinical data 
Demographics were similar between the VAP and non-VAP groups (Table 10). There 
was a predominance of surgical patients in the VAP group. There was no mortality 
difference between the VAP and non-VAP groups and the crude mortality rates were 
consistent with that expected for a sample of patients with suspected VAP(Chastre and 
Fagon, 2002; Bekaert et al., 2011). 
Characteristic VAP (N=53) 
Non-VAP 
(N=97) 
p value 
Age (years) – mean  SD 56.3  17.7 55.1  17.3 0.48 
Male – n (%) 42 (79.2) 69 (71.1) 0.28 
Time from ICU admission to 
consent (days) – median (IQR) 
5 (4-8) 7 (4-11) 0.43 
APACHE II score on admission
* 
- 
mean  SD 
17.3  6.0 19.1  7.8 0.15 
Surgical admission – n (%) 31 (58.5) 41 (42.3) 0.06 
Medical admission – n (%) 22 (41.5) 56 (57.7) 0.06 
Hospital mortality – n (%)† 19 (38.8) 31 (33) 0.49 
ICU mortality – n (%)‡ 13 (24.5) 23 (23.7) 0.68 
Hospital LOS (days) – median 
(IQR)‡ 
39 (25-65) 36 (20-51) 0.26 
ICU LOS (days) – median (IQR)§ 17 (14-34) 17 (11-31) 0.21 
Renal replacement therapy – n (%)¶ 5 (9.4) 12 (12.5) 0.57 
Vasopressors – n (%)§ 12 (23.1) 35 (36.5) 0.10 
ARDS criteria – n (%)// 8 (16) 19 (21.3) 0.44 
Receipt of corticosteroids – n (%)* 7 (13.2) 21 (22.8) 0.16 
Table 10: Demographics of VAP and non-VAP groups. IQR – Interquartile range; APACHE - Acute 
Physiology and Chronic Health Evaluation; ICU - Intensive Care Unit; LOS - length of stay; ARDS - Acute 
Respiratory Distress Syndrome. Data missing for: * 5 patients; † 7 patients; ‡ 21 patients; § 2 patients; ¶ 
1 patient; // 11 patients. 
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Table 11 outlines the clinical/laboratory data for the VAP and non-VAP groups. There 
was a significant difference in WCC between the two groups but with higher WCC in 
the non-VAP group. 
 
 
 
 
3.4 BAL and safety data 
The recruitment schedule identified patients during a morning screening round and 
patients generally underwent BAL in the afternoon. The most common time that BAL 
was sent to the laboratory was 15:30, with the earliest time 10:05 and latest 19:45. The 
frequency of pulmonary anatomical areas in which lavage was performed was: the right 
Parameter VAP (N=53) 
Non-VAP 
(N=97) 
p value 
Temperature – mean  SD (oC) 38.0  0.8 37.7  1.1 0.16 
White cell count – mean  SD 
(x10
9
/L) 
13.1  6.3 16.4  7.9 
0.01 
PaO2:FiO2 – median (IQR) 27.6 (20.6-33.9) 28.6 (22.3-39.0) 0.275 
Partial pressure CO2 – mean  SD 5.4  1.0 5.4  1.3 0.81 
pH – mean  SD 
7.44  0.06 
(n=42) 
7.32  0.82 
(n=83) 
0.33 
H
+
 - median (IQR) 
38.1 (33.6-45.4) 
(n=10) 
32.6 (30.6-37.4) 
(n=12) 
0.12 
Table 11: Laboratory data for VAP and non-VAP groups. Missing data: Temp = 0, WCC = 4, PaO2 = 2, 
PaCO2 = 2 
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lower lobe in 70 (47%) patients, the left lower lobe in 40 (27%) patients, the right 
middle lobe in 12 (8%) patients, the left upper lobe in 11 (7%) patients and right upper 
lobe in 6 (4%) patients. In addition 4 patients had bilateral BAL performed, 5 patients 
were recorded as having BAL performed on ‘right’ and 2 patients were recorded as 
having BAL performed on ‘left’. The volume of saline most commonly instilled was 
120mls, in keeping with the BAL SOP. The minimum volume used was 40mls and the 
maximum volume was 320mls. The mean volume retrieved from BAL was 32.0mls (SD 
21.5). 
18 patients had a drop in oxygen saturations of greater than 5% of the starting 
saturations during bronchoscopy and BAL. Amongst these 18 patients the mean that the 
saturations dropped to was 88% (range 79-94%). This fall in oxygen saturations, within 
5% of starting saturations, persisted for 3.7 minutes on average once the bronchoscope 
was removed (range 1-15 minutes). For 9 patients the saturations fell below 90% during 
the BAL, which persisted for 1-3 minutes. Two hours after bronchoscopy patients were 
followed up with regard to oxygen saturations and oxygen requirements. The mean 
oxygen saturation was 97% (range 90-100%) with the lowest recorded at 90%. The 
mean FiO2 was 0.52 (range 0.21-1.0). Comparisons were made of pre-BAL oxygen 
saturations and FiO2 and 2 hours post- BAL saturations and FiO2. Sixty-one patients 
had an increase in FiO2 of greater than 0.1. However not all of these patients had a fall 
in oxygen saturations (ie. some patients had an increase in saturations and therefore 
could have had FiO2 reduced). Nineteen patients had a FiO2 increase of greater than 0.1 
associated with any fall in percentage oxygen saturations and of these the drop in 
saturations was greater than 3% in 7 patients. In addition a total of 15 patients had a fall 
in oxygen saturations of greater than 3% but only 7 of these patients had their FiO2 
increased, suggesting a fall within an acceptable clinical range that did not necessarily 
prompt an increase in FiO2. 
3.5 Microbiology  
The microbiology results took on average 3.27 (SD 2.8) days to be reported to the 
clinical team. The most common time which results were reported was midday. The 
organisms that were cultured at >10
4
 cfu/ml are shown in Table 12. Gram negative 
bacteria accounted for 60% of identified organisms, Gram positive organisms 30%, and 
fungi 10%. The majority of VAP was caused by a single pathogen (39 patients (73%)). 
Polymicrobial VAP occurred in 14 (26%) patients with 12 patients having two micro-
organisms and two patients had three micro-organisms cultured at >10
4 
cfu/ml.
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Organism N 
Methicillin-sensitive Staphylococcus aureus 14 
Escherichia coli 8 
Pseudomonas aeruginosa 7 
Klebsiella pneumoniae 5 
Haemophilus spp 6 
Candida spp 5 
Enterobacter aerogenes 2 
Enterobacter cloacae 1 
Acinetobacter spp 2 
Coliform 2 
Moraxella catarrhalis 2 
Upper respiratory flora* 2 
Streptococcus pneumoniae 2 
Proteus mirabilis 2 
Serratia marcescens 1 
Citrobacter koseri 1 
Stenotrophomonas maltophilia 1 
Streptococcus pyogenes 1 
Methicillin-resistant Staphylococcus aureus 1 
Peptostreptococcus spp. 1 
Yeasts 2 
Streptococcus group C 1 
Table 12: Organisms cultured at >10
4 
cfu/ml.  
*in both cases normal flora growth was in addition to another organism at >10
4
 cfu/ml. N = the 
number of patients in whom the micro-organism in question was isolated from bronchoalveolar 
lavage fluid at >10
4
 cfu/ml. 
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3.6 Antibiotics and AFD 
Data were collected on antibiotics received in the 72 hours before BAL and antibiotics 
received in the 7 days following BAL. One hundred and ten patients were receiving 
antibiotics at the time of BAL with significantly more in the non-VAP than VAP groups 
(82.5% vs 56.6%, p=0.001). The proportion of patients with new antibiotics started in 
the 72 hours before BAL was not significantly different between the two groups (VAP 
15.1%, non-VAP 27.8%, p=0.08). 
The antibiotic days in the 7 days post-BAL was similar in the VAP and non-VAP 
groups with a median (inter-quartile range (IQR)) of 7 (5-7) for the VAP group and 6.5 
(5-7) for the non-VAP group. The median AFD for the VAP group was 0 (0-2) and for 
the non-VAP group was 0 (0-3). The distribution of AFD is illustrated in Figure 5. 
 
 
 
  
Figure 5: AFD expressed as integer value, n=145. Data missing for 5 patients 
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3.7 Biomarker results (standard flex sets) 
3.7.1 Uncorrected biomarker data 
IL-1, IL-8, MMP-8, MMP-8 and HNE were measured in BAL fluid of 150 patients. 
There were significant differences between the VAP and non-VAP groups across all 5 
biomarkers (p<0.001) (Table 13)
Biomarker VAP Non-VAP p value 
IL-1 pg/ml 712 (112-1999) 29 (3-184) <0·001 
IL-8 pg/ml 7546 (1987-23050) 1401 (369-4422) <0·001 
MMP-8 ng/ml 734 (113-2792) 66 (11-325) <0·001 
MMP-9 ng/ml 6840 (1721-22221) 491 (106-3146) <0·001 
HNE ng/ml 3882 (710-11183) 349 (96-1473) <0·001 
Table 13: Uncorrected BAL fluid biomarker concentrations for VAP and non-VAP groups. Data are 
expressed as median and IQR. 
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Since biomarker concentrations were significantly higher in the VAP group than the 
non-VAP group, diagnostic utility was determined by constructing ROC curves. The 
area under the curve reflects the overall ability of the test to discriminate between 
patients with the disease and those without. The ROC curves and AUROC is shown in 
Figure 6. 
 
 
Figure 6: ROC curves and AUC with 95% CI for uncorrected biomarker results. 
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A number of strategies were used to determine the optimum cut-point on the ROC for 
the diagnostic performance. The Youden index is the point that has the optimum 
balance of sensitivity and specificity. This diagnostic performance using the Youden 
index to derive a cut off value is shown in Table 14. 
Biomarker  
Sensitivity 
(95%CI), 
% 
Specificity 
(95% CI), 
%  
PPV 
(95% 
CI) 
NPV 
(95% 
CI) 
+LR 
(95% 
CI) 
-LR 
(95% 
CI) 
PTP 
(95% 
CI), % 
IL-1 
110 pg/ml 
77.4 
(65.0-87.2) 
71.1 
(61.6-79.5) 
0.59 
(0.48-
0.71) 
0.85 
(0.76-
0.92) 
2.68 
(1.90-
3.78) 
0.32 
(0.19-
0.53) 
14.8 
(7.1-22.6) 
IL-8 
6800 pg/ml 
54.7 
(41.3-67.7) 
82.5 
(74.1-89.1) 
0.63 
(0.49-
0.77) 
0.77 
(0.68-
0.84) 
3.12 
(1.90-
5.13) 
0.55 
(0.40-
0.75) 
23.1 
(15.0-
31.2) 
MMP-8 
619 ng/ml 
54.7 
(41.3-67.7) 
87.6 
(80.1-93.2) 
0.71 
(0.56-
0.83) 
0.78 
(0.70-
0.85) 
4.42 
(2.47-
7.93) 
0.52 
(0.38-
0.71) 
22.0 
(14.2-
29.8) 
MMP-9 
1675 ng/ml 
77.4 
(65.0-87.2) 
68.0 
(58.4-76.8) 
0.57 
(0.45-
0.68) 
0.85 
(0.76-
0.91) 
2.42 
(1.75-
3.35) 
0.33 
(0.20-
0.56) 
15.4 
(7.4-23.4) 
HNE 
2078 ng/ml 
64.2 
(50.8-76.2) 
81.4 
(72.9-88.3) 
0.65 
(0.52-
0.77) 
0.81 
(0.72-
0.88) 
3.46 
(2.18-
5.49) 
0.44 
(0.30-
0.64) 
19.4 
(11.6-
27.2) 
Table 14: Diagnostic performance at Youden index for uncorrected BAL fluid biomarkers. PPV, 
positive predictive value; NPV, negative predictive value; +LR, positive likelihood ratio; -LR, negative 
likelihood ratio; PTP, post-test probability. 
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The ideal diagnostic test would be able to effectively rule-in and rule-out a disease. 
Although the sensitivites and specificities are generally high, they are insufficient for 
any useful diagnostic purpose. Furthermore, since the purpose was to validate a rule-out 
test, the negative post-test probabilities (PTP) at the Youden index are not informative 
for this purpose. An alternative strategy was to set a minimum negative predictive value 
(NPV) at 95%. The cut-points at this level and the corresponding diagnostic 
performance are shown in Table 15. 
 
 
 
Biomarker Sensitivity 
(95% CI), 
% 
Specificity 
(95% CI), 
% 
PPV 
(95% 
CI) 
NPV 
(95% 
CI) 
+LR 
(95% 
CI) 
-LR 
(95% 
CI) 
PTP  
(95% 
CI), % 
IL-1 
17 pg/ml 96.2 
(87.2-99.0) 
43.3 
(33.9-53.2) 
0.48 
(0.39-
0.58) 
0.96 
(0.85-
0.99) 
1.70 
(1.41-
2.04) 
0.09 
(0.02-
0.35) 
4.5 
(3.1-5.1) 
IL-8 
382 pg/ml 98.1 
(90.1-99.7) 
24.7 
(17.2-34.2) 
0.42 
(0.33-
0.50) 
0.96 
(0.80-
0.99) 
1.30 
(1.16-
1.47) 
0.08 
(0.01-
0.55) 
4.0 
(0.7-
19.5) 
MMP-8 
160 pg/ml 100 
(93.3-100) 
5.2 
(1.7-11.6) 
0.37 
(0.29-
0.45) 
1.0 
(0.57-
1.0) 
1.05 
(1.01-
1.10) 
0.0 
(NE) 
0.0 
(0.0-
0.43) 
MMP-9 
296 ng/ml 96.2 
(87.0-99.5) 
43.4 
(33.3-53.7) 
0.48 
0.38-
0.58) 
0.96 
(0.85-
0.98) 
1.70 
(1.41-
2.04) 
0.09 
(0.02-
0.35) 
4.5 
(3.9-
15.3) 
HNE 
161 ng/ml 98.1 
(89.9-99.9) 
34.0 
(24.7-44.3) 
0.45 
(0.36-
0.54) 
0.97 
(0.85-
0.98) 
1.49 
(1.28-
1.72) 
0.06 
(0.01-
0.39) 
2.9 
(1.9-
15.0) 
Table 15: Diagnostic performance at cut-point with minimum NPV of 95% for uncorrected BAL fluid 
biomarkers. NE, Not evaluable. 
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Setting the minimum NPV at 95%, IL-1 and MMP-9 have the best profile of 
sensitivity and specificity. To further illustrate the rule-out performance of this cut-point 
for IL-1, Figure 7 plots VAP and non-VAP values on a logarithmic scale with the cut-
point marked. This plot highlights the proportion of the population of suspected VAP 
who could be correctly identified as not having VAP, these are the non-VAP patients 
who fall below the cut-point line (bottom right, ‘True negatives’). Patients with VAP 
who fall below the line are ‘false negatives’ (bottom left) and setting a minimum NPV 
of 95% aims to minimise this number. 
 
Figure 7: Scatterplot of IL-1 on a logarithmic scale in the VAP and the non-VAP groups. The horizontal 
dotted line represents 17pg/ml. 43.3% of non-VAP patients and 3.8% of VAP patients fall below this 
level. 
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3.7.2 Urea values and urea-corrected biomarkers 
Urea was measured in BAL and serum and used to calculate a dilution factor for 
correction of biomarker levels. The mean serum urea was 40.9mg/dL (SD 21.9) and the 
mean BAL urea was 4.1mg/dL (SD 4.8). The mean dilution factor was 39.0 (SD 81.5), 
but with a minimum value of 0.9 and a maximum value of 709.4 the range was very 
high. Five patients could not have a dilution factor calculated because the BAL urea was 
unrecordable, therefore this section analyses 145 patients (94 non-VAP and 51 VAP). 
A significant difference between the VAP and non-VAP groups remained after urea-
correction but levels are considerably higher than uncorrected values (Table 16). ROC 
curves were constructed (Figure 8) and cut-points determined using the same strategy 
as with the uncorrected values using the Youden index (Table 17) and using a 
minimum NPV threshold of 95% (Table 18).  
Biomarker urea-
corrected 
VAP Non-VAP p value 
IL-1 pg/ml 8100 (3056-21255) 521 (55-3731) <0·001 
IL-8 ng/ml 100.5 (56.4-222.1) 30.7 (7.9-8.5) <0·001 
MMP-8 ng/ml 8633(4119-31234) 1550 (286-7738) <0·001 
MMP-9 mg/ml 81.3 (34.2-261.7) 13.7 (2.6-65.1) <0·001 
HNE mg/ml 47.8 (21.0-116.5) 8.0 (2.0-28.0) <0·001 
 
 
 
Table 16: BAL fluid urea-corrected biomarker concentrations for VAP and non-VAP groups. Data 
are expressed as median and IQR. Note change in units from uncorrected biomarker 
concentrations. n=145. 
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Figure 8: ROC curves and AUC with 95% CI for urea-corrected biomarker results. 
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Biomarker 
(urea-
corrected)  
Sensitivity 
(95% CI), 
%  
Specificity 
(95% CI), 
% 
PPV 
(95% 
CI) 
NPV 
(95% 
CI) 
+LR 
(95% 
CI) 
-LR 
(95% 
CI) 
PTP  
(95% 
CI),% 
IL-1 
2566 pg/ml 
82.3 
(72.9-
93.1) 
71.3 
(62.1-
80.2) 
0.61 
(0.50-
0.72) 
0.88 
(0.81-
0.95) 
2.87 
(2.06-
4.02) 
0.25 
(0.13-
0.44) 
11.8 
(4.5-
18.6) 
IL-8 
67806 pg/ml 
72.5 
(59.6-
83.8) 
72.3 
(63.3-
81.1) 
0.59 
(0.46-
0.70) 
0.83 
(0.74-
0.90) 
2.62 
(1.79-
3.70) 
0.38 
(0.25-
0.61) 
17.1 
(9.5-
25.7) 
MMP-8 
2519 ng/ml 
86.3 
(77.7-
95.9) 
58.5 
(49.0-
68.6) 
0.53 
(0.43-
0.64) 
0.89 
(0.81-
0.97) 
2.08 
(1.62-
2.73) 
0.24 
(0.11-
0.46) 
11.3 
(3.3-
18.6) 
MMP-9 
25619 ng/ml 
84.3 
(75.3-
94.5) 
59.6 
(50.0-
69.6) 
0.53 
(0.43-
0.64) 
0.88 
(0.80-
0.96) 
2.09 
(1.62-
2.76) 
0.26 
(0.13-
0.49) 
12.5 
(4.8-
20.0) 
HNE 
16886 ng/ml 
84.3 
(75.2-
94.5) 
66.0 
(56.6-
75.4) 
0.57 
(0.47-
0.69) 
0.89 
(0.82-
0.96) 
2.48 
(1.85-
3.37) 
0.24 
(0.12-
0.44) 
11.4 
(3.9-
18.4) 
Table 17: Diagnostic performance at Youden index for urea-corrected biomarkers 
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The AUROC of urea-corrected values remains close to the uncorrected values. 
Furthermore the diagnostic performance at the cut-point of the Youden index is similar, 
if not better, than for the uncorrected values. However when setting a minimum NPV of 
95%, the specificities of the urea-corrected cut-points become unacceptably low.  
3.8 Biomarker combinations 
Biomarkers were tested in combination using uncorrected biomarker values. Urea-
corrected biomarker values did not offer greater discriminatory value and were 
associated with significant logistical challenges (see 3.12 Discussion). Therefore urea-
corrected values were not tested further in the biomarker combinations. Combinations 
of biomarkers were modelled after log10 transformation with the addition of a constant 
of 1 (to remove zeros). All biomarkers were highly correlated and IL-1β had the greatest 
prognostic value, as reflected by the p-value of the IL-1β covariant in the equations 
below. Therefore combinations of biomarkers were all tested in combination with IL-
1β.  
Biomarker (urea-
corrected)  
Sensitivity 
(95% 
CI), %  
Specificity 
(95% 
CI), %  
PPV 
(95% 
CI) 
NPV 
(95% 
CI) 
+LR 
(95% 
CI) 
-LR 
(95% 
CI) 
PTP 
(95% 
CI), % 
IL-1 
41 pg/ml 
100 
(100-100) 
24.5 
(16.1-
33.3) 
0.42 
(0.33-
0.51) 
1.0 
(1.0-
1.0) 
1.32 
(1.19-
1.49) 
0.0 
(NE) 
0 
(0-0) 
IL-8 
1161 pg/ml 
100 
(100-100) 
7.4 
(2.1-12.4) 
0.37 
(0.29-
0.45) 
1.0 
(1.0-
1.0) 
1.08 
(1.02-
1.14) 
0.0 
(NE) 
0 
(0-0) 
MMP-8 
400 pg/ml 
100 
(100-100) 
3.2 
(0-6.5) 
0.36 
(0.28-
0.44) 
1.0 
(1.0-
1.0) 
1.03 
(1.0-
1.07) 
0.0 
(NE) 
0 
(0.0-
0.0) 
MMP-9 
3376 ng/ml 
98.0 
(94.5-100) 
28.7 
(19.9-
37.9) 
0.43 
(0.34-
0.52) 
0.96 
(0.90-
1.0) 
1.38 
(1.21-
1.57) 
0.07 
(0.01-
0.47) 
3.6 
(0.0-
10.1) 
HNE 
581 ng/ml 
100 
(100-100) 
11.7 
(5.0-17.7) 
0.38 
(0.30-
0.46) 
1.0 
(1.0-
1.0) 
1.12 
(1.05-
1.21) 
0.0 
(NE) 
0 
(0-0) 
Table 18: Diagnostic performance of urea-corrected biomarkers setting minimum NPV at 95%. NE, 
Not evaluable 
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The equations for the logistic regressions tested are shown below (Table 19-22): 
 
IL-1β and IL-8: 
-2.738 + 1.463 x Log10(1+IL1β) – 0.272 x Log10(1+IL8) 
IL-1β/IL-8 B SE Wald p-value 
Log10 (1+IL-1β) 1.463 0.352 17.287 0.000 
Log10 (1+IL-8) -0.272 0.371 0.538 0.463 
Constant -2.738 0.915 8.953 0.003 
 
IL1β, IL-8 and MMP-9: 
-2.806 + 1.397 x Log10 (1+IL1β) – 0.314 x Log10 (1+IL8) + 0.109 x Log10 
(1+MMP9) 
IL-1β/IL-8/MMP-9 B SE Wald p-value 
Log10 (1+IL-1β) 1.397 0.457 9.352 0.002 
Log10 (1+IL-8) -0.314 0.417 0.569 0.451 
Log10 (1+MMP-9) 0.109 0.476 0.053 0.819 
Constant -2.806 0.972 8.327 0.004 
Table 19: Variables in logistic regression. IL-1β/IL-8. B = coefficient, SE = standard error, Wald = Wald 
chi-squared. 
Table 20: Variables in logistic regression. IL-1β/IL-8/MMP-9. B = coefficient, SE = standard error, Wald = 
Wald chi-squared. 
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IL-1β, IL-8, MMP-9 and MMP-8: 
-2.999 + 1.445 x Log10(1+IL1β) – 0.266 x Log10(1+IL8) + 0.274 x Log10(1+MMP9) 
– 0.266 x Log10(1+MMP8) 
IL-1β/IL-8/MMP-
9/MMP-8 
B SE Wald p-value 
Log10 (1+IL-1β) 1.445 0.478 9.147 0.002 
Log10 (1+IL-8) -0.266 0.435 0.375 0.540 
Log10 (1+MMP-9) 0.274 0.608 0.203 0.652 
Log10 (1+MMP-8) -0.266 0.615 0.187 0.666 
Constant -2.999 1.093 7.529 0.006 
Table 21: Variables in logistic regression. IL-1β/IL-8/MMP-9/MMP-8. B = coefficient, SE = standard 
error, Wald = Wald chi-squared. 
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IL-1β, IL-8, MMP-9, MMP-8 and HNE: 
-3.151 + 1.417 x Log10(1+IL1β) – 0.286 x Log10(1+IL8) + 0.206 x Log10(1+MMP9) 
– 0.392 x Log10(1+MMP8) + 0.263 x Log10(1+HNE) 
IL-1β/IL-8/MMP-
9/MMP-8/HNE 
B SE Wald p-value 
Log10 (1+IL-1β) 1.417 0.484 8.584 0.003 
Log10 (1+IL-8) -0.286 0.442 0.420 0.517 
Log10 (1+MMP-9) 0.206 0.643 0.103 0.748 
Log10 (1+MMP-8) -0.392 0.739 0.281 0.596 
Log10 (1+HNE) 0.263 0.710 0.137 0.711 
Constant 
-3.151 1.191 6.993 0.008 
 
From these predictive models ROC curves were constructed as with the single 
biomarkers and once again coordinates were selected to give a minimum NPV of 95%. 
The cut-points and the corresponding diagnostic parameters are shown in Table 23 
below. 
  
Table 22: Variables in logistic regression. IL-1β/IL-8/MMP-9/MMP-8/HNE. B = coefficient, SE = 
standard error, Wald = Wald chi-squared. 
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As can be seen from the combinations of markers, there is little improvement in 
diagnostic performance beyond IL-1β as this is the predominant component of all 
regression equations. 
The cut-points used in the single biomarkers correspond to a specific concentration. 
This is less clear in the combinations as the cut-point is derived from the linear 
predictive scale. The cut-point for IL-1 as a single biomarker is 17pg/ml, which is 
above the second point on the standard curve against which it is measured. It was 
necessary to determine the IL-1 level at the cut-point in the combinations to ensure it 
fell within the standard curve. 
To determine the IL-1 level at the cut-point, plots were constructed of the linear 
predictor against Log10 (1+IL1β) with the cut-point marked. The plot below for the 
combination of IL-1β and IL-8 shows that the cut-point corresponds to an IL-1β level 
that is approximately 15pg/ml (Figure 9). Cut-points of other combinations correspond 
with a similar level of IL-1β ranging between 16-19pg/ml. (A plot equivalent to Figure 
Biomarker 
combination  
Sensitivity 
(95% CI), 
%  
Specificity 
(95% CI),  
%  
PPV 
(95% 
CI) 
NPV 
(95% 
CI) 
+LR 
(95% 
CI) 
-LR 
(95% 
CI) 
PTP 
(95% 
CI),  
% 
IL-1/IL-8 
-1.7616 
100 
(93.2-100) 
44.3 
(34.2-
54.8) 
0.50 
(0.39-
0.59) 
1.0 
(0.92-
1.0) 
1.80 
(1.50-
2.15) 
0.0 
(NE) 
0.0 
(0.0-
9.2) 
IL-1/IL-8/ 
MMP-9 
-1.7172 
98.1 
(89.9-100) 
44.3 
(34.2-
54.8) 
0.49 
(0.39-
0.60) 
0.98 
(0.88-
0.98) 
1.76 
(1.47-
2.11) 
0.04 
(0.01-
0.30) 
2.3 
(1.5-
11.9) 
IL-1/IL-8/ 
MMP-8/MMP-
9 
-1.7015 
100 
(93.3-100) 
46.4 
(36.2-
56.8) 
0.51 
(0.41-
0.60) 
1.0 
(0.92-
1.0) 
1.87 
(1.55-
2.24) 
0.0 
(NE) 
0.0 
(0.0-
7.8) 
IL-1/ IL-8/ 
MMP-8/MMP-
9/ HNE 
-1.6464 
98.1 
(90.0-100) 
46.4 
(36.2-
56.8) 
0.50 
(0.40-
0.60) 
0.98 
(0.89-
0.99) 
1.83 
(1.52-
2.21) 
0.04 
(0.01-
0.29) 
2.2 
(1.4-
11.5) 
Table 23: Diagnostic performance for biomarker combinations at cut-points from predictive model. NE, Not 
evaluable 
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9 could also be constructed to display the contribution of IL-8 to the overall prediction; 
however, the range of IL-8 values observed was far above the limit of detection, 
therefore the same concern around prediction from values below the standard curve did 
not exist for this biomarker and this plot is not shown.) 
 
 
 
 
  
Figure 9: Plot of linear predictor of IL-1 and IL-8 against Log10(1+IL-1). Horizontal dotted line 
represents the cut-point and vertical line marks the point that this intersects with the diagonal line 
and therefore the IL-1 level at the cut-point. 
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The ‘best’ biomarker combination had to be identified to take forward into the RCT 
phase. All of these combinations of biomarkers make minor changes to diagnostic 
performance in comparison to IL-1 as a single biomarker. Although the four biomarker 
combination of IL-1β, IL-8, MMP-8 and MMP-9 has the highest specificity and 
sensitivity, limitations in terms of assay consistency and cost did not favour this 
combination (see 3.12 Discussion). Therefore the IL-1β and IL-8 combination was 
taken forward to the RCT and its diagnostic performance is demonstrated in the 
following STARD diagram (Figure 10) and 95% CI are provided below (Table 24). 
 
 
Table 24: Diagnostic performance for combination of IL-1b and IL-8 with 95% CI. NE, Not evaluable 
Biomarker 
combination  
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
+LR 
(95% CI) 
-LR 
(95% CI) 
PTP (%) 
(95% CI) 
IL-1/IL-8 
-1.7616 
100% 
(93.2-
100.0) 
44.3% 
(34.2-54.8) 
0.50 
(0.39-
0.59) 
1.0 
(0.92-
1.0) 
1.80 
(1.50-
2.15) 
0.0 
(NE) 
0.0 
(0.0-9.2) 
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Figure 10: STARD diagram for combination of IL-1 and IL-8 
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By way of additional ‘validation’ of this diagnostic rule, the regression equation was 
applied to the cohort of patients from the original derivation study(Conway Morris et 
al., 2010). Applying the same threshold -1.76 the sensitivity was 94% (95% CI 71-99%) 
and specificity was 58% (95% CI 44-71%). These results are reassuringly close to the 
main analysis. 
 
3.9 Biomarker results (enhanced sensitivity) 
The lowest point on the standard curve for IL-1 is 5pg/ml and since the cut-point for 
IL-1 was 17pg/ml, this falls between the second and third standard curve point. The 
area of the standard curve that has the lowest intra-assay variability is the linear segment 
of the curve. Therefore IL-1 and IL-8 were also measured using enhanced sensitivity 
CBA flex sets. The standard range for the enhanced sensitivity flex set is 274-200,000 
fg/ml. The cut-point of 17pg/ml would fall within the linear segment of this standard 
curve. 
A total of 143 samples (50 VAP, 93 non-VAP) were available to be tested by the ES 
assay. Biomarker concentrations using ES assay closely replicated the standard CBA 
(Table 25). 
Biomarker (ES assay) VAP Non-VAP 
IL-1 pg/ml 527.3 (79.6 – 1981.9) 25.0 (5.7 – 164.7) 
IL-8 pg/ml 6957 (1688-21551) 1347 (277 – 5858) 
 
 
ROC curves were constructed for ES IL-1 and ES IL-8 and these closely reflected the 
standard CBA kit results (Figure 11). For ES IL-1 a cut-point of 22.5 pg/ml had a 
sensitivity of 96.0% and a specificity of 47.3%. For ES IL-8 a cut-point of 313.2 pg/ml 
Table 25: Concentrations of IL-1 and IL-8 when measured with ES CBA assay for VAP and non-VAP 
group. Concentrations expressed as median and IQR. 
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had a sensitivity of 98.0% and a specificity of 26.9%. Again these results closely 
reflected the results of the standard CBA assay. 
 
 
 
 
A combination of ES IL-1β and ES IL-8 were modelled by logistic regression. The 
predictive model was given by the equation: 
-5.480 + 1.606 x Log10 (1+ES IL1β) – 0.507 x Log10 (1 + ES IL8) 
The AUROC curve was 0.81 (95% CI 0.74 - 0.88). Taking a cut-point that corresponds 
to the performance of the standard, uncorrected biomarkers, a cut-point of -1.7045 had a 
sensitivity of 100% and a specificity of 41.9%.  
The biomarker diagnostic profile from the ES assay, as single biomarkers and in 
combination, closely reflected the standard CBA assay but did not provide greater 
diagnostic performance. This offered reassurance of the initial results, in that they were 
so closely replicated in a different assay.  
  
Figure 11: ROC and AUROC for ES IL-1b and ES IL-8 
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3.10 Serum biomarkers 
A pilot group of 20 serum samples (RVI 1-22, RVI 2 and 10 not included in analysis) 
were analysed with the primary purpose of determining which biomarkers were 
detectable in serum. No comparisons were made at this stage between VAP and non-
VAP (Table 26). 
Biomarker (n=20) Median (IQR) 
IL-8 pg/ml 51.1 (34.5-137.6) 
IL-1β pg/ml 0.0 (0.0-0.0) 
MMP-8 ng/ml 71.0 (12.2-108.4) 
MMP-9 ng/ml 1616.4 (594.5-4384.2) 
HNE ng/ml 680.4 (329.2-907.5) 
IL-6 pg/ml 82.6 (57.1-200.7) 
TNFα pg/ml 12.1 (2.8-18.0) 
IL-12p70 pg/ml 0.0 (0.0-0.0) 
Table 26: Levels of 8 biomarkers measured in serum of a pilot of 20 patients 
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This pilot data suggested that IL-1β, IL-12p70 and TNFα would not be detectable in any 
meaningful concentrations in serum of patients with suspected VAP. Therefore IL-6, 
IL-8, MMP-8, MMP-9 and HNE were tested in the cohort of validation study patients 
(n=150).  
There were no significant differences between the VAP and non-VAP patients (Table 
27), and consequently the AUROC curves did not demonstrate any diagnostic utility.  
 
Biomarker VAP (n=52) Non-VAP (n=97) p value AUROC 
IL-6 pg/ml 103.4 (62.95-238.6) 101.5 (29.11-237.3) 0.299 0.552 
IL-8 pg/ml 75.32 (36.33-166.3) 71.12 (36.26-195.6) 0.669 0.479 
MMP-8 ng/ml 70.00 (29.18-129.2) 73.07 (23.29-120.6) 0.802 0.512 
MMP-9 ng/ml 1380 (720.6-2042) 1033 (485.6-1770) 0.069 0.591 
HNE ng/ml 797.3 (449.0-1146) 783.1 (353.8-1751) 0.892 0.507 
 
 
3.11 Sub-group analysis 
Post hoc sub-analyses were performed to determine the effect of antibiotic use on the 
BAL biomarker analysis, to explore differences between medical and surgical patients 
and the effect of sterile culture or sub-threshold pathogen growth in comparison to 
confirmed VAP. 
3.11.1 Effect of antibiotic on diagnostic performance 
There was high use of antibiotics at the time of BAL with a greater proportion of non-
VAP than VAP patients being on antibiotics at the time of BAL (82.5% vs 56.6%, 
p=0.001). The concern was that patients might be inappropriately assigned as ‘non-
Table 27: Serum biomarker concentrations in VAP and non-VAP patients.  
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VAP’ due to falsely negative culture due to the antibiotics. It was reassuring that the 
proportion of patients having new antibiotics started in the 72 hours prior to BAL was 
similar in both groups (VAP 15.1%, non-VAP 27.8%, p=0.08)  
It is conceivable that patients with VAP and therefore local pulmonary inflammation 
but who are falsely classed as non-VAP, could still have a local inflammatory profile 
that reflects VAP (ie. high biomarkers). If this was the case, the effect of antibiotics 
would be to reduce the diagnostic performance of the biomarkers. The biomarker 
analysis was performed with respect to IL-1β, initially including patients that were not 
in receipt of any antibiotics and then in those that did not have any new antibiotics 
started in the 72 hours before BAL. 
Patients who were not in receipt of any antibiotics were few and this therefore limits 
this analysis. 23 patients with VAP and 17 patients with non-VAP were included and 
significant differences were demonstrated in IL-1β concentration, with a median of 
796pg/ml in the VAP group and 40pg/ml in the non-VAP group (p=0.0012). A ROC 
curve was constructed and the AUROC was 0.80 (95% CI 0.65-0.94). The specific 
diagnostic performance is of limited value given the small numbers but at the threshold 
close to the main analysis of 17.9pg/ml, the sensitivity is 91% (95% CI 72-99%) and 
specificity is 29% (95% CI 10-56%). The wide CI highlights the limitations of these 
small numbers. 
The sub-group of patients who had no new antibiotics started in the 72 hours prior to 
BAL was larger with 46 VAP patients and 69 non-VAP patients included. Again there 
were significant differences in the concentration of IL-1β with a median in the VAP 
group of 590pg/ml and a median of 30pg/ml in the non-VAP group (p <0.0001). The 
AUROC was 0.78 (95% CI 0.70 – 0.87). At a cut-point of 17pg/ml the sensitivity was 
93% (95% CI 82-98%) and the specificity was 39% (95% CI 27-52%). 
The overall trend of this sub-group analysis was reassuring in that it closely reflected 
the results of the main analysis and in fact the diagnostic performance was actually 
worse in this sub-group analysis. Although it does not entirely determine whether 
antibiotics could have influenced individual patients’ biomarkers, it does suggest that 
there was not a significant effect in the overall analysis. 
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3.11.2  Sub-group analysis of medical and surgical patients 
It is of interest to determine whether the diagnostic rule has the same diagnostic 
performance in different patient groups and a sub-group analysis was performed on 
medical and surgical patients.  
72 surgical and 68 medical patients were analysed separately. Considering individual 
biomarkers, the AUROC were greater for surgical patients (Table 28). 
 
 
Biomarker AUROC Surgical AUROC Medical 
IL-8 0.80 (0.70-0.90) 0.66 (0.52-0.79) 
IL-1β 0.84 (0.75-0.93) 0.76 (0.65-0.87) 
MMP-8 0.80 (0.69-0.90) 0.71 (0.58-0.84) 
MMP-9 0.82 (0.72-0.92) 0.74 (0.62-0.87) 
HNE 0.84 (0.74-0.93) 0.71 (0.58-0.84) 
 
Applying the IL-1β and IL-8 predictive model and applying the cut-point of -1.7616, the 
sensitivity in surgical patients was 100% and specificity was 22%. Amongst medical 
patients the sensitivity was 100% and specificity was 41%. Importantly the sensitivity 
of the cut-point is high in both groups, which maintains its value to rule-out VAP but 
the specificities vary, which may result in different rates of false positives in different 
patient groups. 
3.11.3 Sub-group analysis of VAP, sub-VAP and sterile culture 
The threshold used to define VAP at >10
4
 cfu/ml, while derived from autopsy 
studies(Chastre et al., 1995) and although widely accepted, is contentious. Measurement 
of biomarkers of the local inflammatory response could add clarity in determining 
whether, in terms of the inflammatory response, this threshold is discriminatory. Since 
the cultures taken were semi-quantitative rather than fully quantitative cultures, it is not 
Table 28: AUROC for the 5 biomarkers for medical and surgical categories 
   
  129 
possible to plot inflammatory response against culture growth, which potentially could 
allow for a biomarker-based threshold to be determined. 
Biomarkers were compared between those who had confirmed VAP, those who had 
sub-threshold culture, and those who had a sterile culture (Table 29). 
Comparisons across all groups were significant by Kruskal-Wallis test (Figure 12). 
Dunn’s multiple comparison post hoc tests were performed between all groups. There 
were significant differences between VAP and both the sterile and the sub-VAP groups 
across all 5 biomarkers. There were no significant differences between the sterile and 
sub-VAP groups for any biomarker. 
 
 
Biomarker Sterile (n=54) Sub-VAP (n=44) VAP (n=52) 
IL-1β pg/ml 12.4 (1.1-136.2) 62.0 (12.8-452.1) 685.9 (110.8-2065) 
IL-8 pg/ml 1061 (246.7-4283) 2241 (916.3-5710) 7634 (1956-23505) 
MMP-8 ng/ml 42.9 (5.29-209.7) 152.2 (28.3-477.4) 684.7 (113.4-2910) 
MMP-9 ng/ml 247.5 (82.5-1848) 1151 (243.7-4847) 6442 (1698-21011) 
HNE ng/ml 214.4 (64.5-1305) 596.4 (176.7-2006) 3836 (680.3-11210) 
Table 29: Biomarker levels between VAP, sub-VAP and sterile culture. Data reported as median and IQR. 
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Figure 12: Comparison of biomarker levels between VAP, sub-VAP and sterile culture. Significant 
differences across all 5 biomarkers by Kruskal-Wallis test (p<0.0001). Significant differences 
between VAP, sub-VAP and sterile groups across all biomarkers by Dunn’s multiple comparison 
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The significant difference between the VAP and the sub-VAP group does suggest that 
the diagnostic threshold of >10
4
 cfu/ml is associated with a difference in immunological 
signal that can be detected. This suggests that this culture threshold does represent 
different inflammatory states. 
3.12 Discussion  
This validation study has successfully demonstrated that BAL fluid biomarkers, in 
particular IL-1, can effectively rule-out VAP, when tested in a multi-centre setting. As 
one might expect in a validation study, the diagnostic performance using the same 
statistical method as the derivation study, the Youden index, did not deliver as high 
sensitivity and specificity. Using the Youden index, the cut-point of 110pg/ml for IL-1β 
had a sensitivity of 77% and a specificity of 71%. These values are nonetheless high 
and of themselves they do successfully validate the previous diagnostic utility of IL-1β. 
These values are however not sufficiently discriminatory to be used as a diagnostic rule 
for clinical application. Therefore a minimum NPV of 95% was set to ensure sufficient 
‘rule-out’ performance. The Youden index represents a point on the ROC curve with the 
optimum balance of sensitivity and specificity, taking alternative points on the ROC 
curve will change the balance of sensitivity and specificity. Opting to achieve a 
minimum NPV of 95% to achieve a rule-out profile, the increase in sensitivity comes 
with a compromise in the specificity.  
It is noticeable that the cut-points determined in the validation study are considerably 
higher than the derivation study, particularly considering that the derivation study 
reported urea-corrected biomarkers. One explanation could be that the volumes of saline 
instilled for the BAL was different with 120mls in this study and 200mls in the 
derivation study. 
The selection of biomarker combination to take forward from the validation study to the 
RCT involved a number of important considerations. The primary consideration was the 
statistical performance of the biomarker test and the balance of sensitivity and 
specificity. Of the combinations tested the combinations of IL-1/IL-8 (sensitivity 
100%, specificity 44.3%) and IL-1/IL-8/MMP-8/MMP-9 (sensitivity 100%, specificity 
46.4%), had the best profile. In fact with the high NPV of 1 both of these combinations 
represent the near perfect rule-out test profile 
A further consideration was that the biomarker assay used in the RCT would have to be 
robust enough to be consistent in a pragmatic trial. IL-1 and IL-8 were supplied as 
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commercial kits whereas MMP-8, MMP-9 and HNE were custom made for the 
validation study. In practical terms handling the IL-1 and IL-8 reagents is logistically 
easier. For example kits are supplied with a lyophilised standard. In contrast the custom 
made beads were supplied with aliquots of standard that were reconstituted and stored at 
-80
o
C. The commercial kits performed in a more consistent manner during the 
validation sample testing. There was concern regarding the complexity of reagent 
handling, storage and consistency for the custom made kits. In addition there were cost 
implication to increasing numbers of biomarkers when considering the difference 
between the IL-1/IL-8 combination and the IL-1/IL-8/MMP-8/MMP-9 combination 
had only marginal statistical differences. Based on these considerations, the 
combination that was taken forward to the RCT phase was IL-1/IL-8.  
Beyond the combination of biomarkers to be used in the RCT, these data also informed 
the RCT planning in terms of the biomarker assay to be used. Again, important 
considerations were the practicalities of utilising the assay in a large multi-centre RCT, 
aiming to minimise logistical barriers and ensure robustness of the assay in that setting. 
The first was regarding urea-correction of biomarker levels. The urea-corrected values 
did not deliver a biomarker performance of sufficient discriminatory value to be used in 
a RCT. In addition to this, some BAL had unrecordable urea, which made urea-
correction impossible in these patients. Since urea-correction is of doubtful value in this 
regard(Ward et al., 1992, 2000), it was felt to be a level of complexity that could be 
abandoned. 
The enhanced sensitivity assay was also considered. This was an attractive alternative 
since the IL-1 cut-point would fall on the linear section of the standard curve with 
expected lower intra-assay variability. Despite this potential benefit, there were practical 
barriers to using the enhanced sensitivity kit in the RCT. Bronchoscopy and BAL were 
often not performed until mid or late afternoon and since biomarkers were measured in 
real-time in the RCT, the assay would not commence until late afternoon. The standard 
flex set assay takes approximately 5 hours to complete and the enhanced sensitivity 
assay approximately 7 hours. This difference was important in relation to buy-in from 
the laboratories and willingness of technicians to work after hours. This also has 
implications for delivery of the trial intervention and future implementation into clinical 
service. Further to this, the enhanced sensitivity assay had not undergone the same 
derivation and validation process that the standard flex sets had undergone and so taking 
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it straight to RCT would have been questionable. Therefore the standard CBA assay 
was used in the RCT. 
The BAL method used reflects both a strength of this study and a weakness. To my 
knowledge, this is the first study to successfully validate BAL-based diagnostics for 
VAP in a multi-centre study. Previous studies have used a wide range of diagnostic 
methods including BAL (with different procedures), blind-BAL and ETA(el-Ebiary et 
al., 1995; Mathy-Hartert et al., 2000; Duflo et al., 2002; Gibot et al., 2004; Determann 
et al., 2005; Horonenko et al., 2007; Huh et al., 2008; Linssen et al., 2008; Luyt et al., 
2008; Oudhuis et al., 2009; Jung et al., 2010; Vanspauwen et al., 2011; Wu et al., 
2011). It has already been highlighted that the differences in BAL methods between the 
derivation study and the validation study could account for quite considerable 
differences in biomarker concentrations. However the differences in BAL and blind-
BAL or ETA, could be expected to be more considerable as these could reflect entirely 
different anatomical regions (lung parenchyma vs bronchial area). Notwithstanding the 
differences in BAL instillation volume used, both the derivation study and the 
validation study used a similar BAL SOP and this consistency could well contribute to 
the successful validation of these biomarkers. The limitation of this is that these 
findings are bounded by the methods used. The approach to VAP diagnosis in the UK is 
highly variable(Browne et al., 2014) and BAL is not used consistently in ICUs across 
the UK. For ICUs that are not routinely performing BAL for management of VAP, the 
use of these biomarkers would require a change in routine practice, although arguably 
for the better. 
Considering the invasive nature of BAL testing, identifying biomarkers in serum would 
be highly desirable. Interestingly some markers of inflammation (IL-1β, IL-12p70 and 
TNFα) were not identifiable in the pilot study of 20 samples. Furthermore no significant 
differences were found between VAP and non-VAP patients in any of the biomarkers 
tested in serum. It is also noteworthy that the concentrations measured in serum were 
considerably lower than in BAL. This is in keeping with the previously suggested 
paradigm of lung infection as a compartmentalised inflammatory response(Boutten et 
al., 1996; Millo et al., 2004). 
Of patients screened, 40% who met the inclusion criteria were included in the study. 
The level of detail obtained in the screening logs was insufficient to have a clear 
understanding as to why such as large proportion of patients were not eligible for the 
study. This limitation of data collection in the screening log is due to the fact that this 
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was an observational study and this was not mandated as it would be for a RCT. This 
raises concerns about the external validity of these results but some practical 
considerations mitigate against this risk. Understandably ICU clinicians had to give 
final approval for a patient to be enrolled in the study and therefore undergo BAL. The 
inclusion criteria were quite broad and anecdotally, a significant number of patients met 
these initial inclusion criteria based on temperature, white cell counts and purulent 
secretions (not necessarily CXR changes). Often if clinicians did not suspect VAP based 
on the wider clinical picture, no CXR was pursued but these patients may have been 
recorded as meeting inclusion criteria when they strictly did not without having a CXR. 
Furthermore clinicians could exclude patients if they felt that patients would not tolerate 
BAL outside of the exclusion criteria. This study has been performed in a large number 
of ICUs in which ICU clinicians have probably had a significant influence on including 
patients in whom they feel that this was a relevant clinical query for the patient (ie they 
suspected VAP) and therefore reflects a pragmatic strength of the study. 
Another potential limitation is the high level of antibiotics at the time of BAL and in 
particular the imbalance between the VAP and non-VAP groups. Our definition of VAP 
was based on microbiological strategy with a culture >10
4
 cfu/ml. The use of antibiotics 
could potentially result in a falsely low cfu/ml count in a patient with VAP that is 
partially treated and incorrectly classes as ‘non-VAP’. This could lead to two 
possibilities. The first is that the lung still has on going inflammation and so the 
biomarkers are high. This would undermine the analysis, as the microbiology and 
biomarker levels would be discordant. The second possibility is that the inflammation is 
also resolving with antibiotic treatment and so the culture growth and biomarker levels 
are lower due to partial treatment with antibiotics. 
In an effort to address this, sub-group analyses were performed for patients who had 
either no antibiotics and for patients who had no new antibiotics started in the 72 hours 
prior to BAL being performed. Reassuringly the AUROC curves were close to those 
generated by the main analysis, and in fact at the cut-point the specificity was lower 
than in the main analysis, where one might expect this to be higher if there were 
significant numbers of falsely negative non-VAP patients. Although this does not give 
confirmation on the effect that antibiotics have on culture growth or more importantly, 
on biomarker levels, it does suggest that antibiotic use has not had a large effect on 
determining the diagnostic utility of these biomarkers. 
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Another potential limitation is to class Candida spp. as VAP. Guidelines recommend 
that Candida should not be treated as a VAP(American Thoracic Society, 2005). The 
view was taken in this study that significant levels of Candida spp. may well be treated 
by physicians with anti-fungals and therefore should be classed as VAP. This is 
supported by a previous autopsy study that has demonstrated VAP caused by invasive 
Candida spp.(Corley et al., 1997). Furthermore, in addition to the reported sub-
analyses, biomarker levels were examined based on causative pathogens. This analysis 
is limited due to small numbers (5 patients with Candida spp.) and hypothesis testing is 
of limited value. Notwithstanding this limitation, it is interesting that there was a signal 
of higher biomarker levels in Candida spp. in particular for IL-8, MMP-9 and HNE in 
comparison to the non-VAP group (data not shown). 
Data on antibiotic use in the 7 days following BAL demonstrated a high level of 
antibiotic use across both patients with confirmed VAP and those in the non-VAP 
group, with 57.6% of patients having zero AFD. These data were collected in order to 
inform the power calculation for the RCT primary outcome. Therefore data were 
collected on number of AFD only and not the indication for antibiotic use. It is 
unknown if patients, particularly in the non-VAP group, were receiving antibiotics for 
suspected VAP or a non-pulmonary infection. It does however, go some way to 
highlight the burden of the potential overuse of antibiotics in patients with suspected 
VAP. The overuse of antibiotics has been framed in the context of the growing issue of 
AMR(Davies, 2011). However there is evidence to suggest a potential detrimental 
impact to the individual patient. Strategies to improve compliance with multi-antibiotic 
empiric treatment or PCT-triggered escalation of antibiotics, which resulted in increased 
antibiotic use, have been associated with an increase in mortality, increased length of 
ICU stay and organ-related harm(Jensen et al., 2011; Kett et al., 2011). In contrast to 
this a more conservative approach to antibiotics has resulted in a lower antibiotic 
burden, a lower all-cause mortality and reduced length of ICU stay(Hranjec et al., 
2012). A biomarker approach to antibiotic de-escalation of antibiotics, using PCT, has 
resulted in more AFD both in patients with suspected bacterial infections and in patients 
with suspected VAP(Stolz et al., 2009; Bouadma et al., 2010).  
The successful validation of these biomarkers in a large, multi-centre study represents a 
significant step forward in diagnostics for VAP. In terms of the potential impact that 
this test could have on antibiotic prescribing, consider that in this population with 
suspected VAP, VAP was confirmed in approximately 1/3 of patients with 2/3 of 
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patients making up the non-VAP group. With a NPV of 1, all VAP patients will be 
correctly identified as being above the threshold. With a PPV of 0.5, half of the non-
VAP group will fall below the threshold. Therefore in a population of suspected VAP, 
this biomarker test could allow for 1/3 of the population to have antibiotics discontinued 
on the day of suspicion of infection. This is in comparison with conventional 
microbiological antibiotic de-escalation, where antibiotics could be stopped after 3 days, 
once the culture results are finalised. However this assumes that antibiotics are de-
escalated in the face of negative cultures. Previous trials have reported or even insisted 
that antibiotics are not stopped if cultures are negative(Ruiz et al., 2000; Canadian 
Critical Care Trials Group et, 2006). A negative biomarker result on the day of 
suspicion of VAP could be a strong impetus to discontinue antibiotics early rather than 
mid-way through an antibiotic course. 
The high antibiotic use in this study does also set the scene for the scale of the antibiotic 
burden that the biomarker-test is aiming to alter. Since the reason for the antibiotic use 
is unknown from these data, we do not know whether these are antibiotics for suspected 
VAP, amongst which we could have an impact on or antibiotics for another reason that 
we cannot alter. 
In conclusion this study has demonstrated that BAL fluid IL-1 can effectively exclude 
VAP when tested in patients with suspected VAP, in a multi-centre study. In 
combination with IL-8, a test with confident rule-out performance has been identified. 
The next stage is to determine the clinical effectiveness of a biomarker-based diagnostic 
strategy to reduce antibiotic use in a clinical trial conducted in a highly complex and 
high antibiotic-use clinical environment. The interim results of this trial will be 
presented in Chapter 4. 
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Chapter 4. Results: Randomised controlled trial 
4.1 Introduction to chapter 
The RCT extends from the validation study and aims to determine whether the 
biomarker-based exclusion of VAP has clinical effectiveness to reduce antibiotic use 
amongst patients with suspected VAP. At the time of writing this thesis the RCT was in 
the later stages of patient recruitment. Therefore for the purposes of this thesis, a 
subgroup analysis was performed on 140 patients for whom there was close to complete 
data collection around the time of my submission deadline. This analysis presents 
preliminary results to demonstrate the principles of analysis and give insights into what 
the completed trial may demonstrate. 
4.2 Screening and recruitment 
The projected recruitment period for the trial underwent a number of revisions. The 
initial projected recruitment duration was to recruit 210 patients (see Chapter 2, 2.13.2) 
between July 2013 and the end of January 2015. The trial did not commence until 
November 2013 and the first patient was recruited on the 18
th
 December 2013. Revising 
the end date to the actual start date resulted in a target of May 2015. Due to logistical or 
regulatory reasons, not all study sites commenced screening and recruitment at the 
opening of the trial. The trial started with only two sites (Freeman Hospital and Royal 
Victoria Infirmary) in November and December 2013. A further 6 sites joined in 
January 2014 (Chelsea and Westminster, Salford Royal, Sunderland, Belfast, 
Heartlands, North Tyneside General). Coventry joined in Feb 2014, Chester and Preston 
in March 2014 and Wansbeck General, Edinburgh Royal Infirmary and Western 
General Hospital, Edinburgh in May 2014.  
At a research steering group (RSG) review of progress in July 2014, 60 patients had 
been randomised with recruitment considerably behind schedule. The two main reasons 
were the staggered start for the recruiting sites and the slower than expected rate of 
recruitment. At this stage, the combined sites were recruiting an average of 8.65 patients 
per month. It was estimated that at this recruitment rate, the trial would complete in 
January 2016 and this was set as the revised target. Additional sites were added at this 
stage including the Queen Elizabeth, Gateshead; James Cook, Middlesbrough; Sandwell 
and City Hospitals, Birmingham; Royal Liverpool Hospitals, Liverpool; Manchester 
Royal Infirmary, Manchester; City Hospital, Belfast; and Russells Hall Hospital, 
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Dudley (for summary of sites see Methods, 2.2). These sites were brought on between 
October 2014 and January 2015. 
A further RSG was held in December 2015, just prior to the planned completion date of 
the trial. At this stage, 175 patients had been randomised and the milestone was further 
extended to the end of September 2016. 
This analysis reports on the first 140 patients randomised between November 2013 and 
the end of July 2015. Recruitment up to July 2015 is shown on Figure 13 against the 
three different projected trial end dates. 
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Screening logs were maintained although precise details of all exclusions were not 
recorded. Between November 2013 and July 2015, 511 patients were screened. Of 
these, 296 patients met the inclusion criteria for suspected VAP (see Methods, 2.3). One 
hundred and twenty nine patients were not eligible including 90 patients who were not 
suitable for early discontinuation of antibiotics (inclusion criterion) and 39 patients who 
met exclusion criteria (Figure 14). A further 26 patients were eligible based on 
inclusion and exclusion criteria but not consented without a reason recorded. Of those 
eligible patients, 141 were consented and of these 140 were randomised (1 patient was 
consented but not randomised as there was no laboratory cover to process the sample). 
Of these, 4 patients were not included in this analysis for the following reasons: 
SUN001 was randomised but deteriorated and did not undergo BAL; MAN012 was 
randomised in error and did not undergo BAL; RLH003 was randomised but the sample 
was not processed as the lab had insufficient reagents; and CHS006 was randomised but 
the sample arrived too late in the lab to be processed and so was rejected. These patients 
were excluded because they had too many missing data points. For the purposes of this 
thesis, I set the threshold for intention to treat (ITT) analysis as having had a sample that 
had undergone its laboratory handling. 
Of the 136 patients included in the analysis 68 were randomised into each trial arm and 
included in the ITT analysis. Eleven patients in the biomarker-guided arm had a failure 
of the biomarker test and therefore for these patients, the clinical teams were given the 
instruction to default to ‘standard care’. These 11 patients were excluded in the per-
protocol analysis. The recruitment and follow up of patients is outlined a CONSORT 
diagram (Figure 14). The number of patients followed up reflects the patient having 
follow-up data recorded for that visit but does not reflect completeness of those data. 
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Screened: 511 
Consented: 141 
Randomised:140 
Biomarker: 68 Standard care: 68 
Day 7: 68 Day 7: 68 
Day 28: 66 Day 28: 67 
Final: 66 Final: 67 
Drop out: 4 
Entered into analysis:136 
Assay failure: 
11 
(Default to 
standard care) 
 
Inclusion criteria for 
suspected VAP: 296 
Eligible based on 
criteria but not included 
(reason not recorded): 
26 
Not eligible: 129 
 
Not suitable for early 
discontinuation of antibiotics: 
90 
PaO2<8kPa on FiO2>0·7: 6  
PEEP >15cmH2O: 1 
HR > 140 bpm: 1 
Bleeding diathesis: 3 
ICP > 20mmHg: 9 
Day 14: 67 Day 14: 66 
Figure 14: CONSORT diagram of patients enrolled by end of July 2015. 
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4.3 Process of trial conduct 
The trial intervention was complex and so examining the detailed delivery of the trial is 
relevant. The majority of patients were consented, randomised and had BAL performed 
on the same day. Consent was obtained on the day before BAL in 8 patients. For these 
patients, the BAL was performed in the morning in 6 patients. Overall the median time 
that BAL was performed was at 13:30 with the earliest time of 8:35 and latest time of 
17:00. The median time that BAL fluid was sent to the lab was 14:00, with the earliest 
time of 9:00 and latest of 17:06. The median time at which randomisation was 
performed was 13:25 (earliest 8:25 and latest 16:50).  
The median time that the samples arrived in the laboratory was 15:00 (earliest 10:10 
and latest 17:50). The technicians contacted the clinical teams once the biomarker 
results were available or, if the patient was in the standard care group, after 
approximately 6 hours to ensure approximate equality of the period in which clinicians 
were blinded to the test result. Overall the clinical teams were contact at a median time 
of 19:08, with the earliest at 6:24am and latest 1:30am. Whether results were 
communicated to the clinical team on the next working day, is not recorded. If the result 
was called back at 1:30am then that would be the next calendar day but a call at 6:24am 
was assumed to be the next working day too. A further 3 results were communicated to 
clinical teams before midday but these were in the standard care arm, and in this setting 
it appears that there was no period of blinding given to the clinical team (ie the result 
was presumably communicated as soon as the patient was randomised to standard care, 
without a 6 hour delay). Comparing the two groups, the teams were contacted at a 
similar median time, 20:44 for the biomarker group and 20:00 for the control group. As 
might be expected the latest times for communication of results were in the biomarker 
group with 9 results being called back after 23:00. In the standard care group the latest 
the teams were contacted was at 22:30. 
The validation study demonstrated that patients generally underwent BAL in the 
afternoon. This was a cause for concern for the RCT because the biomarker assay takes 
approximately 6 hours to complete, and this would make the logistics of delivering a 
result to clinical services on the same working day a challenge. This proved to be the 
case with clinical teams being contacted in the evening and in the case of some 
biomarker results, the night. 
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4.4 Demographics 
The demographics of the two trial arms are presented as summary statistics (Table 30). 
The two trial arms were overall similar in terms of age, sex, and severity of disease on 
admission (APACHE 2 and SOFA at baseline). The case mix of admission categories 
and degree of comorbidities as measured by the functional comorbidities index was also 
similar between the two groups. In terms of organ support, more than twice as many 
patients were receiving RRT in the biomarker group than in the standard care group. 
The rate of ARDS was slightly higher in the control group. The rate of VAP was also 
slightly greater in the biomarker group. A significant number of microbiology samples 
(17 patients) were handled incorrectly with the laboratory not reporting semi-
quantitative results. This occurred disproportionally more frequently in the biomarker 
group (12 of the 17 patients), which could be the cause of this imbalance. The 
proportion of patients receiving antibiotics at baseline was similarly high in both 
groups. 
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Characteristic 
Biomarker-guided 
recommendation  on 
antibiotics N=68 
Routine use of 
antibiotics N=68 
Age in years, median (IQR) 61.5 (50.0-70.5) 57.5 (43.5-68.5) 
Female, n (%) 24 (35.3) 26 (38.3) 
APACHE 2, median (IQR) 18.0 (12.5-24.0) 17.0 (12.0-22.0) 
SOFA Day 0, mean (SD)
1 
5.2 (2.5) 6.0 (2.8) 
Medical admission (n=81), n (%)
2 
39 (59.1) 42 (64.6) 
Surgical admission (n=50), n (%)
2 
27 (40.9) 23 (35.4) 
Admission category, n (%)
3 
Respiratory 
Gastrointestinal/Liver 
Cardiovascular 
Trauma 
Sepsis 
Obstetric/Gynaecology 
Neurology 
Other 
 
10 (15.2)
 
7 (10.6) 
7 (10.6) 
13 (19.7) 
2 (3.0) 
0 
16 (24.2) 
11 (16.7) 
 
16 (23.5) 
7 (10.3) 
6 (8.8) 
17 (25.0) 
0 
1 (1.5) 
11 (16.2) 
10 (14.7) 
Function comorbidities index 
score, median (IQR)
4 1.0 (0-2.0) 1.0 (0-2.0) 
Renal replacement therapy, n 
(%)
3 7 (10.6) 3 (4.4) 
Vasopressors, n (%)
3 
25 (37.3) 22 (32.8) 
ARDS, n (%) 10 (14.7) 16 (23.5) 
ALI, n (%) 8 (11.8) 3 (4.4) 
Corticosteriod use, n (%) 11 (16.2) 12 (17.6) 
Antibiotics at randomisation, n 
(%) 
53 (77.9) 57 (83.8) 
Days from ICU admission to 
BAL, median (IQR) 
7 (5-9.5) 8 (4-13) 
Confirmed VAP, n (%)
5 23 (41.1) 18 (28.6) 
Clinician pre-test suspicion of 
VAP, n (%)
6 
Low 
Medium 
High 
 
 
7 (10.4) 
19 (28.4) 
41 (61.2) 
 
 
4 (6.0) 
34 (50.7) 
29 (43.3) 
   
Table 30: Baseline demographics of trial population.  
Missing values, total (biomarker arm): 
1 
9(6), 
2 
5(2), 
3 
2(2), 
4 
3(2), 
5
17(12), 
6
2(1) 
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The clinical and laboratory characteristics of the two groups are presented in Table 31.  
Clinical/laboratory 
parameters 
Biomarker-guided 
recommendation on 
antibiotics N=68 
Routine use of 
antibiotics  N=68 
Temperature 
O
C, median (IQR) 37.4 (36.6-38.1) 37.7 (37.0-38.3) 
WCC x10
9
/L, median (IQR) 13.8 (10.7-16.4) 14.3 (11.8-16.7) 
Neutrophils x10
9
/L, median 
(IQR) 
10.8 (8.1-14.1) 11.0 (9.2-13.8) 
Platelets x10
9
/L, mean (SD) 251 (146) 282 (195) 
CRP mg/L, mean (SD)
1 
170 (87) 165 (112) 
PEEP cmH2O, median (IQR)
2 
8 (5-10) 7.5 (5-10) 
PAP cmH2O, median (IQR) 21 (13-23) 18 (12.5-25) 
Heart rate bpm, mean (SD)
3 
89 (22) 92 (21) 
MAP mmHg, median (IQR)
4 
75 (68-85) 78 (69-88) 
ICP mmHg, median (IQR) 
(monitored patients only, n=14, 
biomarker-guided=7)  
13 (9-15) 10 (0-11) 
pH, median (IQR)
5 
7.43 (7.40-7.46) 7.44 (7.39-7.47) 
PaCO2 kPa, median (IQR)
6 
5.48 (4.90-6.33) 5.60 (4.50-6.30) 
PaO2:FiO2 kPa, mean (SD)
6
  30.9 (12.2) 26.6 (12.7) 
Tracheal secretion, n (%)
7 
None 
Non-purulent 
Purulent  
 
1 (1.5) 
9 (13.2) 
58 (85.3) 
 
3 (4.5) 
9 (13.4) 
55 (82.1) 
CXR, n (%)
8 
Diffuse 
Localised 
Bilateral  
 
7 (10.8) 
37 (56.9) 
21 (32.3) 
 
9 (13.2) 
35 (51.5) 
24 (35.3) 
   
Table 31: Clinical and laboratory characteristics for trial population. Missing values, total 
(biomarker-guided arm): 
1
53(28), 
2
5(3), 
3
4(2), 
4
10(4), 
5
7(3), 
6
5(2), 
7
1(0), 
8
3(3) 
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4.5 BAL and safety data 
The majority of sampling occurred in the lower lobes with 64 (47%) being performed in 
the right lower lobe and 48 (36%) in the left lower lobe. Numbers performed in the right 
upper lobe, right middle lobe and left upper lobe were 10 (7%), 11 (8%) and 2 (2%), 
respectively. In keeping with the BAL SOP the median volume instilled was 120mls 
(IQR 120-120), and a minimum and maximum volume of 60mls and 160mls 
respectively. 
Prior to BAL the median oxygen saturation was 97% (IQR 96-99) with a median FiO2 
0.41 (IQR 0.35-0.50). Prior to BAL, on a FiO2 of 1.0, the lowest oxygen saturation was 
94%. During BAL oxygen saturation fell below 5% of starting saturations in 32 
patients. In these patients the saturation fell to a median of 88% (IQR 85-88) for a 
median time of 2 minutes (IQR 2-4). Amongst these, 23 patients had saturations that fell 
below 90% and this lasted for a median time of 2 minutes (IQR 0-3). One patient had 
saturations that fell to 59% for 60 seconds during BAL and saturations remained below 
90% for 45 minutes but at the two hour follow up point, this patient was saturating at 
pre-BAL level with only an increase in FiO2 of 0.05. Five patients met our predefined 
criteria to report an adverse event during BAL (drop of 5% or below 90% for greater 
than 5 minutes), although 4 were recorded as adverse events in the CRF (these did not 
require separate reporting to NCTU). 
Two hours after BAL the median saturation was 97% (IQR 96-99) and the median FiO2 
was 0.50 (IQR 0.40-0.60). Fifty-three patients had an increase in FiO2 of ≥0.1. Of these 
patients, 6 had ≥3% lower oxygen saturations than at baseline despite this increase in 
FiO2 (range -3 - -5%). A further 9 patients had a reduction in saturations of between -
1% and -2%. The remaining patients had either no change in baseline saturations (5 
patients) or an increase in oxygen saturations with the increase in FiO2. Nine further 
patients had falls in oxygen saturations at 2 hours post BAL of 3-9% without any 
increase in FiO2. A total of 43 adverse events were recorded in the CRF with our 
predefined criteria for adverse events during BAL (these did not require separate 
reporting to NCTU). 
Five serious adverse events (SAE) were recorded and all were judged to be in relation to 
the patient’s critical illness rather than trial involvement. Three SAE were in relation to 
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one patient who was admitted with gastrointestinal bleeding and had two further 
episodes of GI bleeding. This patient died and the death was recorded as SAE. In the 
other two patients, one suffered a tension pneumothorax and the other a ventricular 
fibrillation cardiac arrest. Both of these incidents happened around the time of the BAL 
but in both cases the PI judged that there was no causal relationship. In both cases the 
Sponsor reviewed the incident and was in agreement with the PIs. In the case of the 
cardiac arrest, the DMEC also reviewed the case and felt there was no causal link. 
4.6 Microbiology 
The median time taken from BAL to return of microbiology results was 2 days (IQR 2-
4). As described above, a total of 17 samples were not reported as a semi-quantitative 
result, and so these could not be defined as VAP or non-VAP. Therefore, based on our 
criteria for defining VAP as a culture growth of ≥104 cfu/ml, VAP was confirmed in 41 
of 119 patients (34.5%). Of those below the threshold and classed as non-VAP, 32 
(26.9%) had a culture growth below the threshold and 46 (38.7%) had a sterile culture. 
Considering all organisms grown (VAP and sub-VAP), 18% were yeasts, 30% were 
Gram-positive and 52% were Gram-negative. Of organisms cultured above the 
threshold of ≥104 cfu/ml, 5% were yeasts, 39% Gram-positive and 56% Gram-negative. 
Polymicrobial growth occurred in 37% of patients with VAP. The organisms cultured at 
≥104 cfu/ml are presented in Table 32. 
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Organism Frequency Percent 
MSSA 16 27.6 
Haemophilus spp. 10 17.2 
Pseudomonas aeruginosa 5 8.6 
Proteus mirabilis 4 6.9 
Escherichia coli 3 5.2 
Klebsiella pneumoniae 3 5.2 
Candida spp. 2 3.4 
Serratia marcescens 2 3.4 
Staphylococcus spp. 2 3.4 
Stenotrophomonas maltophilia 2 3.4 
Acinetobacter baumannii 1 1.7 
Corynebacterium spp. 1 1.7 
Enterobacter spp. 1 1.7 
Moraxella catarrhalis 1 1.7 
Prevotella bivia 1 1.7 
Beta haemolytic Streptococcus 1 1.7 
Streptococcus pneumoniae 1 1.7 
Normal upper respiratory tract flora 1 1.7 
Yeasts 1 1.7 
Total 58 100.0 
Table 32: Organisms cultured above the threshold to define VAP. More than one pathogen could be 
cultured per BAL sample. 
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The proportion of patients already in receipt of antibiotics at the time of enrolment was 
high in both trial arms (Table 26). This was observed in the validation study too and in 
the validation study there was a greater proportion of non-VAP in patients who had 
received antibiotics (raising the theoretical possibility of false negative culture). Taking 
the trial population as a whole, there were more non-VAP patients who had received 
antibiotics (87.2%) in comparison to VAP patients (68.3%) (Chi-squared p=0.013).  
At the time of recruitment, before BAL was performed, clinicians were asked to give 
their pre-test level of suspicion of VAP (low, medium or high). There was no 
relationship between clinician pre-test and VAP diagnosis (Table 33). Interestingly, for 
the majority of patients, the clinician’s suspicion of VAP was rated as ‘medium’ (40%) 
or ‘high’ (51%), with only 9.1% of non-VAP and 7.5% of VAP rated as ‘low’. 
Considering that VAP was confirmed in 34.5% of this RCT cohort and in 35% of the 
validation study cohort, clinician expectation of confirming VAP is incongruous with 
the observed VAP rate. 
 
N (%) 
Pre BAL 
LOW 
Pre BAL 
MEDIUM 
Pre BAL 
HIGH 
Non-VAP 7 (9.1) 32 (41.6) 38 (49.4) 
VAP 3 (7.5) 15 (37.5) 22 (55.0) 
Table 33: Clinician pre-test suspicion of VAP compared to VAP status. Chi-squared: p=0.84. n=117, 
clinician pre-BAL suspicion of VAP not available for 2 patients. 
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4.7 Biomarker performance 
One area of concern in the design of this trial was whether the biomarker assay would 
demonstrate similar diagnostic parameters as it did in the validation study. In other 
words, would the assay accurately identify patients with non-VAP in whom early 
discontinuation of antibiotics would be most appropriate?  
Of the 68 patients who underwent the biomarker testing, there were 11 assay failures 
and 12 patients who did not have semi-quantitative culture (2 patients fell into both 
categories). A further 5 patients had missing data for biomarker results and so 42 
patients were included in this analysis. Overall there were 15 patients in whom the 
biomarker assay fell below the threshold. Amongst the 42 patients in this analysis, there 
were 11 assays that fell below the threshold to exclude VAP (26%). There was one false 
negative (SUN005), which was below the threshold on the biomarker test but had a 
positive culture (Enterococcus spp. ≥104 cfu/ml). Of the 23 patients classed as ‘non-
VAP’, the biomarker correctly identified 10 as ‘non-VAP’ (43.5%) 
As a further ‘validation’ of the biomarker assay, ROC curves were constructed for IL-
1, IL-8 and the linear predictor of the IL-1/IL-8 combination. The median 
concentrations of IL-1 and IL-8 and the AUROC curves are presented in Table 34. 
 
 
 VAP n=19 Non-VAP n=23 p value AUROC 
IL-1 pg/ml 246 (191-1994) 36 (3-325) 0.0021 0.77 
IL-8 pg/ml 6382 (3175-18219) 1024 (350-6361) 0.0066 0.74 
Table 34: Biomarker concentrations between VAP and non-VAP groups. Concentrations presented as 
median (IQR). p value reported from Mann Whitney U test.  
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The smaller numbers in this analysis limits drawing comparisons to the validation study. 
The concentrations of IL-1 and IL-8 in the non-VAP groups are similar to the 
validation study, as is the level of IL-8 in the VAP group (see Results: Validation study, 
3.7). The IL-1 concentration in the VAP group is lower than in the validation study. 
However the IQR for these values closely reflect the validation study.   
The AUROC for IL-8 closely replicates the validation study value but the AUROC for 
IL-1 is lower. When the coordinates of the ROC are examined to determine cut-points 
that are close to the validation cut-points for single biomarkers (17pg/ml for IL-1 and 
382pg/ml for IL-8), a cut-point of 17.5pg/ml for IL-1 had a sensitivity of 95% and a 
specificity of 39% and a cut-point of 379pg/ml for IL-8 had a sensitivity of 100% and a 
specificity of 26%. The sensitivity and specificity at these cut-points are close to the 
validation study values (IL-1 sensitivity 96% and specificity 43%, IL-8 sensitivity 
98% and specificity 25%). 
The logistic regression output from the combination of IL-1 and IL-8 was also plotted 
on a ROC curve. The AUROC for the linear predictor was 0.76. At a coordinate close to 
the validation study cut-point (-1.7616) of -1.713, the sensitivity was 95% and the 
specificity was 43.5%. Again this is close to the validation study biomarker 
performance (IL-1/IL-8 sensitivity 100% and specificity 44%). 
This close replication of the validation study sensitivity and specificity is reflected by 
43.5% of the non-VAP patients being correctly identified as non-VAP by the biomarker 
test at this stage in the trial. 
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4.8 Primary outcome analysis in the ITT population 
The AFD in the 7 days following BAL was presented as an integer value ranging from 
0-7 AFD. The frequency distribution was compared in a 2x8 contingency table (Table 
35). 
 AFD 
0 1 2 3 4 5 6 7 
Biomarker 
arm 
33 9 6 5 4 0 2 6 
Control 28 10 6 10 6 0 4 3 
Table 35: Frequency of AFD in the 7 days following BAL. Figures represent the number of patients in 
each AFD category. Chi-squared p=0.65. Missing values, total (biomarker): 4(3). 
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There was no difference between to the two arms of the trial when compared by Chi-
squared test, p=0.65. The frequency distribution of AFD is illustrated in Figure 15. 
 
 
 
The distribution of AFD was similar to the observed distribution in the validation study 
with a skew to the left, reflecting the majority of patients having few AFD. The 
proportion of patients with 0 AFD was 50.8% in the biomarker arm and 41.8% in the 
control arm. The remaining categories have between 3.1% and 14.9% of patients. The 
distribution between the two groups is similar. 
One limitation of this analysis is that it does not account for deaths within the first 7 
days, ie a patient that dies on day 4 on antibiotics has the same number of AFD as the 
patient who has 7 days of antibiotics and does not die. To determine whether deaths 
Figure 15: Frequency distribution of AFD in ITT population. 
   
  154 
within the first 7 days had a significant impact on the primary outcome, the number of 
days of antibiotics, number of days alive without antibiotics and the number of days 
dead in the first 7 days were calculated (Table 36).  
There is no imbalance between the two groups at day 7 with regards to number of 
antibiotic days, number of days alive without antibiotics and number of days dead, 
which suggests that deaths within the first 7 days has not had  a significant influence on 
the primary outcome. 
 
Outcome 
Biomarker-guided 
recommendation on 
antibiotics N=68 
Routine use of 
antibiotics N=68 
Day 7 antibiotic days (mean, 95% CI) 5.17 (4.57-5.77) 4.93 (4.38-5.47) 
Number of days alive without antibiotics 
at day 7 (mean, 95% CI) 
1.65 (1.08-2.21) 1.81 (1.29-2.32) 
Number of days dead at day 7 (mean, 95% 
CI) 
0.18 (0-0.38) 0.28 (0.04-0.52) 
4.9 Secondary outcome analysis in the ITT population 
Secondary outcome measures were compared between the two groups with no 
significant difference between the two groups in any of these (Table 37). The antibiotic 
use at days 7, 14 and 28 was high in both groups. The median AFD at day 7 was 0 (IQR 
0-3) in the biomarker arm and 1 (IQR 0-3) in the control arm. The AFD at day 14 and 
day 28 in the biomarker arm was 5.0 (SD 3.9) and 11.6 (SD 7.6) respectively and in the 
control arm was 5.2 (SD 3.8) and 12.5 (SD 8.2) respectively.  
There were no significant differences between the biomarker arm and the control arm in 
terms of ICU-mortality (19.1% and 23.5%, respectively; p=0.627); 28-day mortality 
(25% and 23.5%, respectively; p=0.844); VFD at 28 days (13.0 [IQR 0-21.0] and 12.0 
[IQR 0-19.0], respectively; p=0.723); duration of invasive ventilation (16.0 days [IQR 
11.5-26.5] and 19.0 days [IQR 12.5-29.0], respectively; p=0.433); length of hospital 
stay (33 days [IQR 25-57] and 43 days [25.5-77.0], respectively; p=0.242); and length 
Table 36: Days alive without antibiotics 
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of critical care stay (21.0 days [16.0-31.0] and 24.5 days [17.0-36.0], respectively; 
p=0.394). 
The presence of antibiotic-resistant pathogens or C. difficile could be influenced by 
antibiotic use and so the occurrence of these were monitored up to final follow up at 
hospital discharge, death or 56 days. There were a total of 8 MRSA positive cultures 
with no difference between the biomarker and control arms. There were 2 C. difficile 
infections and these occurred equally in both trial arms. Multi-resistant organisms 
(defined as resistance to 2 or more antibiotics) were detected in 29.4% of the patients in 
the biomarker arm and 20.6% of the patients in the control arm (p= 0.235). The median 
number of multi-resistant cultures was 2 (IQR 1-3) in both the biomarker and control 
arms. 
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Outcome 
Biomarker-guided 
recommendation on 
antibiotics N=68 
Routine use of 
antibiotics N=68 
p value 
28-day mortality n (%, 95%CI)†1 16 (25, 14.5-35.8) 16 (23.5, 14.3-33.3) 0.844 
ICU mortality n (%, 95% CI)†2 13 (19.1, 10.6-29.3) 14 (22.6, 11.4-33.3) 0.627 
Day 3 SOFA score*
3 
3.0 (2.0-5.5) 4.0 (2.0-6.0) 0.419 
Day 7 SOFA score*
4 
3.5 (2.0-4.5) 3.5 (2.0-5.0) 0.546 
Day 14 SOFA score*
5 
3.0 (0.5-4.0) 3.0 (2.0-4.0) 0.711 
Day 7 antibiotic days, IQR (95% CI)*
6 
6,4-7 (6-7) 6, 4-7 (4-7) 0.360 
Day 7 AFD, IQR (95% CI)*
6 
0, 0-3 (0-1) 1, 0-3 (0-2) 0.380 
Day 14 antibiotic days, SD (95% CI)**
7 
7.8, 4.0(6.8-8.8) 7.3, 3.9 (6.3-8.2) 0.464 
Day 14 AFD, SD (95% CI)**
7 
5.0, 3.9 (4.0-6.0) 5.3, 3.8 (4.4-6.2) 0.625 
Day 28 antibiotic days, SD (95% CI)**
8 
9.7, 6.0 (8.2-11.3) 9.3, 6.4 (7.7-10.9) 0.724 
Day 28 AFD, SD (95% CI)**
8 
11.6, 7.6(9.6-13.6) 
12.5, 8.2 (10.5-
14.5) 
0.552 
VFD at 28 days, IQR (95% CI)*
9 
13, 0.0-21(3.5-18.0) 12, 0-19 (2-16) 0.723 
Duration invasive ventilation, days, IQR 
(95% CI)*
10 
16.0, 11.5-26.5 (14-
21.5) 
19.0, 12.5-29.0 
(16.5-21) 
0.433 
Length of hospital stay, days, IQR (95% 
CI)*
11 
33.0, 25.0-57.0 (27.5-
41) 
43.0, 25.5-77.0 (32-
54) 
0.242 
Length of critical care stay, days, IQR 
(95% CI)*
12 21.0, 16.0-31.0 (18-26) 
24.5, 17.0-36.0 (20-
27) 
0.394 
Length of Level 3 stay, days*
13 
16.0 (12.0-26.0) 20.0 (13.0-26.0) 0.282 
Length of Level 2 stay, days*
14 
2.0 (0.0-6.0) 3.0 (0.0-6.0) 0.690 
MRSA n (%)***
15 
3 (4.5) 5 (7.6) 0.718 
Clostridium difficile n (%)***
15 
1 (1.5) 1 (1.5) 1.000 
Presence of multi-resistant organisms (56 
days) n (%)† 
20 (29.4) 14 (20.6) 0.235 
Number of multi-resistant cultures (56 
days)* 
2 (1-3) 2 (1-3) 1.000 
    
Table 37: Secondary outcome measures in the ITT population. †Chi-squared, **parametric mean (SD) 
& T-test, *non-parametric median (IQR) & Mann-Whitney U, ***Fisher’s exact. Missing values, total 
(biomarker-guided arm): 
1
4(4), 
2
6(0), 
3
12(5), 
4
42(20), 
5
83(40),
6
4(3),
7
6(5), 
8
11(9), 
9
11(7), 
10
 17(9), 
11
14 
(9), 
12
8(6), 
13
18(11), 
14
19(11), 
15
4(2). 
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4.10 Primary outcome analysis in the per-protocol population 
When BAL fluid from patients who were randomised to the biomarker arm resulted in a 
failed biomarker-assay, the clinical teams were advised to default to ‘standard care’. In 
the 11 instances where this occurred, all resulted from a failure of the assay to meet the 
internal control thresholds. This indicated that there was a problem in performing the 
assay. The other quality control used was the presence of IL-8. Given the usual 
abundance of IL-8 in BAL fluid, if no IL-8 was detectable in the sample, this called into 
question the quality of the BAL. No samples failed on this criterion. The 11 patients in 
whom the assay failed were excluded from the per-protocol analysis. All of the standard 
care group were included. 
There were no differences in the frequency distribution of AFD in the 7 days following 
BAL between the biomarker and control arms (p=0.42) (Table 38 and Figure 16). 
 AFD 
0 1 2 3 4 5 6 7 
Biomarker 29 5 6 5 3 0 1 6 
Control 28 10 6 10 6 0 4 3 
Table 38: Frequency of AFD in the 7 days following BAL in the per-protocol population. Number of 
patients in each AFD category. Chi-squared p=0.42. n=55, 1 patient with missing AFD data at 7 days 
amongst the 11 patients excluded in the per-protocol analysis. Missing values, total (biomarker): 3(2). 
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4.11 Secondary outcome analysis in the per-protocol population 
There were minimal differences observed in the biomarker arm with the removal of the 
11 patients in whom there was an assay failure. There remained no differences between 
the biomarker and control arms of the trial (Table 39).  
Figure 16: Frequency distribution of AFD in the 7 days following BAL for the per-protocol population. 
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Outcome 
Biomarker-guided 
recommendation on 
antibiotics N=57 
Routine use of 
antibiotics N=68 
p value 
28 day mortality (%, 95% CI)†1 12 (22.6, 11.5-35.2) 16 (23.5, 13.8-33.3) 0.909 
ICU mortality (%, 95% CI)†2 10 (17.5, 7.8-28.8) 14 (22.6, 12.3-33.9) 0.494 
Day 3 SOFA score*
3 
4.0 (2.5-6.0) 4.0 (2.0-6.0) 0.641 
Day 7 SOFA score*
4 
3.0 (2.0-4.0) 3.5 (2.0-5.0) 0.295 
Day 14 SOFA score*
5 
3.0 (0.5-4.0) 3.0 (2.0-4.0) 0.570 
Day 7 antibiotic days, IQR (95% 
CI)*
6 6.0, 4.0-7.0 (5-7) 6.0, 4.0-7.0 (4-7) 0.433 
Day 7 AFD, IQR (95% CI)*
6 
0.0, 0.0-3.0 (0-2) 1.0, 0.0-3.0 (0-2) 0.400 
Day 14 antibiotic days, SD (95% 
CI)**
7 7.7, 4.2 (6.6-8.9) 7.3, 3.9 (6.3-8.2) 0.530 
Day 14 AFD, SD (95% CI)**
7 
5.2, 4.1 (4.0-6.3) 5.3, 3.8 (4.4-6.2) 0.804 
Day 28 antibiotic days, SD (95% 
CI)**
8 9.5, 5.8 (7.8-11.2) 9.3, 6.4 (7.7-10.9) 0.883 
Day 28 AFD, SD (95% CI)**
8 
11.9, 7.5 (9.7-14.0) 12.5, 8.2 (10.5-14.5) 0.699 
VFD at 28 days, IQR (95% CI)*
9 
17.0, 0.0-21.0 (7-19) 12.0, 0.0-19.0 (2-16) 0.331 
Duration invasive ventilation, days, 
IQR (95% CI)*
10 16.0, 11.0-26.0 (14-22) 
19.0, 12.5-29.0 (16-
21) 
0.358 
Length of hospital stay, days, IQR 
(95% CI)*
11 32.5, 25.0-55.0 (28-41) 
43.0, 25.5-77.0 (29-
52) 
0.228 
Length of Critical care stay, days, 
IQR (95% CI)*
12 20.5, 15.5-28.5 (18-26) 
24.5, 17.0-36.0 (19-
25) 
0.318 
Length of Level 3 stay, days*
13 
16.5 (12.0-26.5) 20.0 (13.0-26.0) 0.341 
Length of Level 2 stay, days*
14 
2.0 (0.0-6.0) 3.0 (0.0-6.0) 0.694 
MRSA n (%)***
15 
3 (5.5) 5 (7.6) 0.727 
Clostridium difficile n (%)***
15 
1 (1.8) 1 (1.5) 1.000 
Multi-resistant organisms (56 days) 
n (%)† 
16 (28.1) 14 (20.6) 0.329 
Number of multi-resistant cultures 
(56 days)* 
2.0 (1.0-3.5) 2.0 (1.0-3.0) 0.552 
    
Table 39: Secondary outcome measures for the per-protocol population. †Chi-squared, **parametric 
mean (SD) & T-test, *non-parametric median (IQR) & Mann-Whitney U, ***Fishers exact. Missing 
values, total (biomarker-guided arm): 
1
4(4), 
2
6(0), 
3
12(5), 
4
40(18), 
5
76(33),
6
3(2), 
7
5(4), 
8
10(8), 
9
11(7), 
10
15(7), 
11
12(7), 
12
7(5), 
13
16(9), 
14
17(9), 
15
4(2). 
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4.12 Antibiotic use overall 
Since there were no differences between the trial arms in terms of antibiotic use, a 
description of antibiotic prescribing practices in the trial population as a whole was 
undertaken.  
The median (IQR) antibiotic days at 7, 14 and 28 days are 6 (4-7), 7.5 (4-10) and 8 (6-
13), respectively. The median AFD (IQR) at 7, 14 and 28 days are 1 (0-3), 5 (2-8) and 
12 (5-19), respectively. The distribution of AFD at day 7, 14 and 28 are shown in 
Figure 17, 18 and 19. 
 
Figure 17: Distribution of AFD at 7 days n=132. 
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Figure 18: Distribution of AFD at 14 days n=130. 
Figure 19: Distribution of AFD at 28 days n=125 
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Indications for antibiotic prescriptions were recorded for all antibiotics. Patients could 
have more than one indication for antibiotics recorded. At baseline the proportion of 
patients not receiving antibiotics was 18%. At baseline all indications for antibiotics 
were recorded, including antibiotics used for prophylaxis. Antibiotics for prophylaxis 
were subsequently not recorded at day 7, 14 or 28 as these did not contribute to AFD. 
At baseline the proportion of patients with 1, 2, 3 or 4 indications for antibiotics were 
60%, 13%, 8% and 1% respectively. The proportion of patients with 1, 2, 3 or 4 
antibiotics concurrently prescribed was 46%, 21%, 8% and 7% respectively. The 
indication for antibiotics at baseline is illustrated in Figure 20. 
 
 
 
 
 
CAP 
8% 
HAP 
12% 
VAP 
36% 
Intra-abdomen 
7% 
Urinary 
1% 
Skin 
5% 
Prophylaxis 
7% 
Other 
24% 
Baseline antibiotic indications 
Figure 20: Indications for antibiotics at baseline. The figure presents the indication for antibiotics as a 
proportion of all recorded indications (rather than patients). More than one indication can be stated 
per patient.  
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At day 7, 58% of patients had 1 indication for antibiotics. A further 16% had 2 
indications, 5% had 3 indications and 21% were not on antibiotics. The proportions of 
patients receiving 0, 1, 2, 3, 4, 5 and 6 antibiotics were 21%, 32%, 22%, 21%, 3% and 
1%, respectively. Indications for antibiotics prescribed at day 7 are illustrated in Figure 
21. VAP was an indication for antibiotics in 67 (49%) patients receiving antibiotics. 
VAP was the sole indication for antibiotics in 46 (34%) patients. Considering 
prescriptions classified as ‘Other’ but that were for positive respiratory cultures (either 
sputum or BAL), then VAP was a reason in addition to another indication in 29 (21%) 
patients. 32 (24%) patients had antibiotics for a non-VAP source.  
Of those patients with confirmed VAP by semi-quantitative culture (41), 15 (37%) 
patients were on antibiotics solely for VAP, 13 (32%) were on antibiotics for VAP and 
another indication and 11 (27%) were on antibiotics for a reason other than VAP. Of 
those patients who did not have VAP confirmed (78), 24 (31%) were on antibiotics 
solely for VAP, 11 (14%) for VAP and another indication and 18 (23%) were on 
antibiotics for a non-VAP indication.  
Considering the antibiotic indications at day 7 for 15 patients who had a BAL fluid 
biomarker assay result below the cut off for VAP (without making the exclusions made 
in section 4.7), 4 patients had treatment for VAP solely, 2 had treatment for VAP and 
another indication, 4 had treatment for a non-VAP indication and 5 had no antibiotics. 
The indications for antibiotics at day 14 and day 28 show that a significant proportion of 
recorded indications where for pulmonary infection, either HAP or VAP (Figure 22 and 
23). In addition to this 3 patients at day 14 and 5 at day 28 were recorded as ‘Other’ but 
were treated for ‘chest’, ‘lower respiratory tract infection’ or ‘positive sputum culture’. 
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HAP 
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VAP 
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5% 
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5% 
Other 
19% 
Indication for antibiotics at day 7 
Figure 21: Indications for antibiotics at day 7. Indications presented as a proportion of all recorded 
indications. 
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2% Urinary 
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Indications for antibiotics at day 14 
HAP 
19% 
VAP 
19% 
Intra-abdominal 
5% 
Urinary 
12% 
Skin 
7% CNS 
2% 
Other 
36% 
Indications for antibiotics at day 28 
Figure 22: Indications for antibiotics at day 14. Indications presented as a proportion of all recorded 
indications. 
Figure 23: Indications for antibiotics at day 28. Indications presented as a proportion of all recorded 
indications. 
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4.13 Discussion 
In this chapter I have reported the findings of an analysis of the first 140 patients (136 
included in ITT) of an RCT that aims to recruit 210 patients. This strategy was pursed 
because the delays in trial set up and recruitment (Figure 13) meant that it was 
impractical to await the trial completion for inclusion in this thesis. This created a 
conflict between meeting the requirements of this thesis while not compromising the 
trial integrity. The trial was not blinded beyond the first 6 hours after randomisation and 
so the outcome measures were not blinded. Therefore accessing these outcomes before 
the close of the trial did not compromise the trial blinding. The time required to access 
the data, clean the dataset and analyse the data (approximately 7 months), was such that 
the analysis occurred after the last patient was randomised to the trial. The chief 
investigator was not aware of these results until after the trial had closed to recruitment 
and the trial statistician provided assistance with the analysis with only blinded data. 
Therefore this analysis could not bias the conduct and outcome of the trial as a whole. 
The trial sponsor and the DMEC approved this strategy. 
Although this analysis does not have the statistical power to make firm conclusions on 
the trial overall, it does provide some valuable insights into the intervention, the trial 
design and the clinical context in which the intervention was tested. 
This trial was designed to determine whether rapid, biomarker-based exclusion of VAP 
could improve antibiotic stewardship and reduce antibiotic use in patients with 
suspected VAP without compromising patient safety. VAP is a common reason for 
antibiotic prescriptions in ICU(Vincent et al., 2009) and since infection is confirmed in 
30-60% of patients with suspected VAP(Fagon et al., 2000; Canadian Critical Care 
Trials Group et, 2006), the assumption is that many patients receive unnecessary 
antibiotics. Since microbiology results typically take 2-3 days to become available, 
rapid diagnostics, and in the case of this intervention, a rule-out test, could allow for 
antibiotics to be discontinued early if VAP can be excluded with high probability.  
To determine whether this would be achieved, I conducted a multi-centre RCT in 23 
ICUs in the UK. I measured whether antibiotic exposure in the 7 days following BAL, 
as measured by AFD, would be different between patients randomised to an antibiotic 
management strategy based on a rapid biomarker-based rule out of VAP and patients 
randomised to an antibiotic strategy based solely on microbiology results. The 
biomarker result was returned generally on the same day as the BAL (as compared to 2 
days later for the microbiology results). There was no difference in the two trial arms in 
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the distribution of AFD in the 7 days following BAL. Furthermore there were no 
differences between the two groups in any secondary outcomes including antibiotic use 
at 14- or 28-days, duration of critical care stay, duration of hospital stay or mortality. 
These were general ICUs and the patients included in this study were admitted with a 
broad range of admission categories. The cohort of patients enrolled was similar in 
characteristics to the cohort of patients enrolled in the validation study as reflected by 
median age, APACHE 2 score, and length of critical care and hospital stay. This is a 
sicker group of patients with a longer length of ICU and hospital stay than the average 
UK critical care population (Intensive Care National Audit and Research Centre, 2015) 
but with similar characteristics to previous trials in patients with suspected VAP(Fagon 
et al., 2000; Canadian Critical Care Trials Group et, 2006). Overall VAP was confirmed 
in 34.5% of patients, consistent with the validation study. There was an imbalance in the 
VAP rate between the intervention and the control arm of the trial, although a greater 
proportion of microbiology specimens were not reported as semi-quantitative in the 
intervention arm, which could account for this difference. The median number of days 
between ICU admission and BAL was 7 (IQR 5-9.5) for the intervention group and 8 
(IQR 4-13) for the control group, suggesting this is predominantly a group of patients 
with late-onset VAP. In keeping with this, 56% of organisms cultured were Gram-
negative, although the single most common organism was methicillin-sensitive S. 
aureus, as it was in the validation study. Similar to the validation study there were more 
patients classed as non-VAP who had antibiotics at enrolment than VAP patients, 
raising the possibility of false negative cultures and misclassification as ‘non-VAP’. 
Previous studies have shown that antibiotics do reduce the chances of obtaining a 
positive result for microbiology samples(Fabregas et al., 1996), which is a limitation 
when using a microbiological definition for VAP. 
The trial aimed to influence antibiotic use and this trial demonstrated that this is an 
environment and patient group in whom the antibiotic exposure is high. At baseline 
77.9% of the intervention group and 83.8% of the control group were receiving 
antibiotics. Antibiotic use at 7 days was high in both arms of the trial, with a median of 
0 AFD (IQR 0-3) in the intervention arm and 1 AFD (IQR 0-3) in the standard care arm, 
with no difference in the frequency distribution of AFD between the two groups. Since 
there was no difference in antibiotic use between the two trial arms, antibiotic use was 
also described using the trial population as a whole. The median number of antibiotic 
days at day 7, 14 and 28 was 6 (IQR 4-7), 7.5 (IQR 4-10) and 8 (6-13), respectively. 
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This suggests that the bulk of antibiotic use was in the 7 days following BAL, at the 
moment of suspicion of VAP. The median number of AFD at 28-days of 12 (IQR 5-19) 
was similar to other clinical trials. In a trial comparing 8 versus 15 days of antibiotic 
treatment for VAP, the mean AFD at 28-days in the 8-day arm was 13.1 (SD 
7.4)(Chastre et al., 2003). Considering that a 7-day course of antibiotics is considered 
standard in UK practice(Browne et al., 2014), it seems reasonable that the number of 
AFD would match the 8-day arm of that trial. In an ICU population with suspected 
bacterial infections (in the context of a trial of PCT-guided antibiotic discontinuation), 
the 28-day AFD were 14.3 (SD 9.1) in the PCT group and 11.6 (8.2) in the control 
group(Bouadma et al., 2010). In contrast to this AFD at 30-days has been reported to be 
much lower in other studies. A trial of early versus late tracheostomy found that the 
median AFD at 30-days was only 5 days (IQR 1-10)(Young et al., 2013). 
Biomarker-based antibiotic stewardship interventions have mainly utilised PCT, with 
mixed results. A number of high quality trials have utilised serum PCT to guide 
antibiotic use in suspected infection in ICU (ie. not VAP specific) and have clearly 
shown that it can influence antibiotic use. The PRORATA trial showed a significant 
reduction in antibiotics at 28-days but a non-significant trend to increased mortality at 
60 days (30% vs 26%)(Bouadma et al., 2010). A recent pragmatic trial aimed to 
determine the utility of PCT to reduce antibiotics while also assessing mortality as a 
safety endpoint(de Jong et al., 2016). In this trial of 4507 patients, there was a reduction 
in antibiotic use in those randomised to PCT-guided antibiotic management, as 
measured by DDD, with a median of 7.5 DDD (IQR 4.0-12.7) in the PCT group and 9.3 
DDD (5.0-16.6) in the control group. In this trial there was in fact a reduction in 
mortality in the PCT group at 28-days (20% in PCT versus 25% in control group, 
p=0.0122). These two trials used a PCT threshold of 0.5ng/ml to rule out infection. In 
contrast to these trials, a trial using a lower threshold of 0.1ng/ml was unable to find a 
reduction in antibiotic use with PCT-guided antibiotic management compared to the 
control group(Shehabi et al., 2014). More specifically investigating the impact in 
respiratory infections, a trial conducted in the emergency department setting, using PCT 
to guide antibiotic use in community-acquired LRTI found that serum PCT use was 
both safe and reduced the median duration of antibiotic use (5.7 days versus 8.7 days for 
PCT and control groups respectively)(Schuetz et al., 2009). Furthermore in a trial of 
patients with VAP (using a clinical definition), the use of serum PCT resulted in more 
AFD at 28-days with 13 (IQR 2-21) and 9.5 (IQR 1.5-17) for the PCT and control 
groups respectively(Stolz et al., 2009). As a further demonstration of the ability to PCT 
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to influence antibiotic use, in a trial of a PCT intervention to increase early antibiotic 
use in suspected infections, an algorithm that encouraged antibiotic use, did in fact 
increase antibiotic use in the PCT group but there were also worse outcomes, with the 
length of ICU stay increasing by 1 day, an increased rate of mechanical ventilation and 
worsening renal function in the PCT group(Jensen et al., 2011). 
Studies of newer diagnostic technologies, such as PCR have generally included patients 
with confirmed blood culture and through rapid identification of the pathogen, have 
aimed to rapidly optimise treatment. In a non-randomised study of patients with S. 
aureus bacteraemia, the use of PCR allowed for more rapid de-escalation of empirical 
antibiotics (1.7 days earlier) and also resulted in a reduction in hospital costs(Bauer et 
al., 2010). In a randomised trial of patients with a positive blood culture the use of rapid 
multiplex PCR resulted in more rapid detection of microorganism (1.3 hours versus 
22.3 hours for PCR and control groups respectively) and less time on broad-spectrum 
antibiotics (44 hours versus 56 hours for PCR and control groups respectively)(Banerjee 
et al., 2015). There were no differences in mortality, length of stay or cost between the 
two groups. A recent randomised trial utilising PNA FISH diagnostics, including 
patients with confirmed blood culture, did not find a reduction in empirical antibiotic 
use in the absence of an antibiotic stewardship programme to drive the 
change(Cosgrove et al., 2016). These studies are valuable in terms of showing that these 
technologies can more rapidly refine antibiotic prescribing but fail to address the issue 
around avoiding antibiotic prescribing in the absence of infection. 
Considering the lack of difference between the two trial arms of this trial, it is worth 
considering the 15 patients in whom the biomarker was below the threshold and in 
whom the clinicians were advised to discontinue antibiotics. Considering the antibiotic 
use in these patients could give an indication into clinician compliance with the 
biomarker antibiotic-discontinuation recommendation. Conclusions drawn from this 
group of 15 patients must be considered with considerable caution. The median AFD at 
7 days amongst these 15 patients was 2.5 (IQR 0.0-6.0) in comparison to a median AFD 
in the control group of 1.0 (IQR 0.0-3.0). Four of these patients had antibiotics for VAP 
and so the recommendation on antibiotics was not followed. For another 6 patients there 
was an indication other than VAP for which antibiotics were given. Antibiotics were not 
given in 5 patients (33%). 
The suggestion from these 15 patients is that clinicians complied with the antibiotic-
discontinuation recommendation in some circumstances but not all. In fact in the 
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description of antibiotic prescribing in the whole trial population (at baseline and at 
days 7, 14 and 28), VAP was an indication for antibiotics in 19-48% of recorded 
indications. Therefore it is likely that alternative sources of infection were a barrier to 
biomarker-recommendation compliance.  
In the PRORATA trial, PCT thresholds were used for both starting and stopping 
antibiotics. Although there was significantly lower antibiotic use in the PCT group, 
clinician compliance with the recommendations was surprisingly low with the 
recommendation not followed in 72% of episodes(Bouadma et al., 2010). This included 
57% of episodes in which antibiotics were given despite recommendation to not give 
antibiotics and 14% of episodes in which antibiotics were stopped despite 
recommendations to give antibiotics. Overwhelmingly the trend was for clinicians to 
give antibiotics based on their own judgement of the likelihood of infection rather than 
based on the PCT level. Interpreting this is difficult because the diagnostic accuracy of 
PCT in meta-analyses has been far from perfect. The most recent meta-analysis of PCT 
for bacterial infections concluded a positive PCT had a PTP to rule in sepsis of 48% and 
a negative PTP to exclude sepsis of only 7%(Wacker et al., 2013)(see Introduction, 
1.10.2). Since PCT is not a gold standard for diagnosis of bacterial infections, not 
complying with the recommendation may be considered entirely reasonable.  
The BAL biomarker test used in this trial has a diagnostic threshold to achieve a clear 
diagnostic purpose, the exclusion of VAP. At the threshold, the validation study 
suggested that VAP could be excluded with a PTP of 0% and a 95% CI of 0.0-9.2%. 
The hope was that this very low PTP would give clinicians confidence that a rule-out 
biomarker would really mean a rule-out of VAP. Research teams were asked to 
complete a questionnaire providing information as to why antibiotic-discontinuation 
recommendations were not followed. Only two of these were completed by the time of 
my data collection and for both of those patients an alternative source of infection was 
being treated. Interestingly, if we consider the antibiotic prescribing for the non-VAP 
patients, 45% were receiving antibiotics for VAP, although 11% had an alternative 
indication. This suggests that the semi-quantitative culture was not used to guide 
antibiotic use either. 
The validation AFD data had demonstrated that this was a high antibiotic clinical 
environment and there was a concern that detection of a signal of reduced antibiotic use 
would be difficult. This was taken into consideration when designing the trial. In 
addition to the inclusion criteria used in the validation study, the criterion that the 
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patient must be considered suitable for early discontinuation of antibiotics was added. 
The exact description of this criterion was difficult to determine. Alternatives that were 
considered were to ‘exclude patients on any antibiotics’ or on ‘antibiotics for a non-
VAP source of infection’. These were considered inappropriate because they would 
have excluded so many patients that accrual would have been too difficult. The 
description of the criterion that was used was not as clearly defined as the alternatives, 
and depended on clinicians’ interpretation and judgement as to whether they thought the 
biomarker test would be appropriate for the patient and whether they would consider 
discontinuing antibiotics if VAP was ruled out. Changing the inclusion criteria risked 
recruiting a different trial population to the validation study. In fact the most common 
reason for a screen failure was the patient not being suitable for early antibiotic 
discontinuation. These were patients who may well have been suitable for inclusion in 
the validation study. If the population were different to that in the validation study, then 
a natural concern would be that the biomarker would not perform with the same profile 
of sensitivity and specificity. In fact the patient demographics and VAP rate were 
similar to those in the validation study. Furthermore, in analysing the limited number of 
biomarker results, the ROC coordinates at thresholds used in the validation study gave 
similar sensitivities and specificities. The specificity of the combination of IL-1/IL-8 at 
a threshold of -1.713 (close to the -1.7616 of the validation study), was 43.5% and this 
was reflected in the number of non-VAP patients correctly identified as ‘non-VAP'. We 
can therefore conclude that the biomarker performed as expected, and that any failure to 
detect a difference in the trial arms was not due to failure of the biomarker performance. 
Deciding on the primary outcome measure for a trial is of paramount importance. It 
must be clinically relevant and the intervention should be expected to produce a signal 
in this measure. Mortality is a commonly used outcome for many trials in the ICU (and 
other clinical environments) and is clearly an important patient-centred outcome, 
particularly in a clinical setting where mortality is high. Many ICU RCTs fail to show a 
significant difference in the primary outcome measure and this is particularly true of 
trials with mortality endpoints, with just 10% having a positive result(Harhay et al., 
2014).  
A mortality endpoint has a number of benefits in that preventing death in critically ill 
patients is an important clinical goal, it is a clear endpoint with no confusion over 
definition and if ICU- or hospital-mortality is used, completed follow up is easy to 
attain. Mortality endpoints are limited by the fact that arbitrary time intervals are 
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selected for measurement. Although ICU- and hospital-mortality are easy to measure, 
they are of limited use if patients die shortly after discharge from hospital. In fact there 
is an increased risk of death post-hospital discharge for ICU patients that is highest at 3 
months and continues for 3 years(Brinkman et al., 2013). Other arbitrary time points to 
measure mortality (eg. 14-, 28-, 60- or 90-day mortality) are similarly limited by 
making assumptions that the intervention will have its effect within this timescale.  
Amongst a patient group with high baseline mortality, the influence of a particular 
complication on overall mortality can be hard to define. This is highly relevant in VAP 
where the attributable mortality has been reported to range from 1.5-9%(Bekaert et al., 
2011; Melsen et al., 2011). With such low attributable mortality rates, detecting a 
mortality benefit in a VAP trial would require an impractically large sample size. 
Measurement of antibiotic therapy in terms of antibiotic-days or antibiotic-free days can 
be considered a ‘process outcome’ and measures healthcare delivery(McGregor & 
Furuno, 2014). Process outcomes are intermediate outcomes that should be associated 
with other favourable outcomes, eg clinical outcomes. This raises interesting questions 
when using antibiotic therapy as an outcome, as it has been in previous trials(Fagon et 
al., 2000; Chastre et al., 2003). The association between antibiotic use and antibiotic 
resistance is established and reducing antibiotic selective pressure reduces antibiotic 
resistance(Geissler et al., 2003; Goossens et al., 2005). This represents a benefit to 
society but whether there is a benefit to an individual patient is not established. There 
are data from quasi-experimental studies that challenge perceptions that antibiotics are a 
benign treatment and suggest firstly that over-treatment with antibiotics could be 
harmful and secondly that a more restrictive approach to antibiotics could result in 
better clinical outcomes(Kett et al., 2011; Hranjec et al., 2012). 
The primary outcome measure used was the change in the frequency distribution of 
AFD in the 7 days following BAL. There were a number of statistical considerations 
with respect to the analysis of AFD at 7 days (outlined in Methods, 2.13.2). Due to the 
high baseline use of antibiotics, detecting a change in antibiotic use in terms of location-
shift or change in proportions, may not have been sensitive enough to detect subtle 
reductions in antibiotic use. Analysing a change in frequency distribution of AFD at 7 
days was expected to be able to detect more subtle changes. Despite this, at this stage of 
the trial, no difference was detected.  
As outlined, both the primary outcome measure and inclusion criteria were influenced 
by the high baseline antibiotic use and this gave the trial elements of an efficacy trial 
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and an effectiveness trial(Singal, Higgins and Waljee, 2014). Selecting patients in 
whom antibiotic discontinuation was felt to be appropriate (a highly selected group of 
patients) is in keeping with an efficacy trial. This population does not represent all 
patients receiving antibiotics for suspected VAP, rather a subgroup thought likely to 
benefit from the biomarker assay. The complexity of the timing of the trial processes of 
enrolment, randomisation and BAL meant that the process of VAP investigation for 
these patients might not reflect real-world practice. In fact, the control arm was termed 
‘routine use of antibiotics’ because the term ‘standard care’ was felt inappropriate, since 
many ICUs do not use BAL and semi-quantitative culture as standard(Browne et al., 
2014). On the other hand, there were elements of the trial that were more representative 
of a ‘pragmatic’ or ‘effectiveness’ trial. The trial was conducted in a large number of 
general ICUs and the intervention had to be worked into the usual workflow of the ICU. 
Clinicians in the ICUs, rather than a centralised group of researchers, performed BALs. 
How the biomarker results were utilised in clinical practice was not dictated in the trial 
protocol. The decision to give antibiotics was entirely left to the clinical team. An 
element of blinding was included in the trial, a feature of an efficacy trial, but in fact 
beyond the first 6 hours, once the results were made known to the clinical team, the trial 
arm was unblinded. An argument could have been made not to perform the blinding 
element of the trial, and instead to take a more pragmatic approach of allowing 
clinicians the opportunity to know that the biomarker assay was going to be performed, 
so that it could be incorporated into their decision-making process. 
The trial intervention should be considered a ‘complex intervention’ for a number of 
reasons(Craig et al., 2008). There were a number of behavioural components to the 
intervention, including: identification of suspected VAP based on pre-determined 
criteria versus pure clinician judgement; decisions regarding suitability for early 
antibiotic discontinuation; clinician judgement to discontinue antibiotics on the basis of 
biomarker assay results in the context of other clinical information such as previous 
positive microbiology; clinician pre-test level of suspicion of VAP; acceptability of 
BAL; and confidence in the biomarker test. There were logistical complexities to the 
intervention including the time in which the biomarker result was returned to clinicians 
(which was often late in the evening or even in the night). It is possible that the clinical 
teams may not have got these results until the next day, or that they were received at a 
time when they were unlikely to be incorporated into main decision points of the 
working day (ie. the ward rounds). The intervention involved a large number of 
individuals including research, clinical and laboratory teams, and of course the patients 
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and their representatives. This required communication between all of these individuals, 
often in different sites, to ensure delivery of the intervention. The complexity and 
difficulty of delivering the intervention could have been a barrier to patient accrual. To 
help explain the results of trials of complex interventions, it is advised that these trials 
are carried out in conjunction with a ‘process evaluation’(Craig et al., 2008). A process 
evaluation is a qualitative method of understanding the process of implementing the 
intervention, to shed light on why an intervention failed or, if there is a positive result, 
to guide further implementation of the intervention. A process evaluation has been 
nested in this trial although it does not form part of this thesis and is in fact part of 
another student’s PhD thesis. The findings of that process evaluation will be of great 
importance in understanding the findings of this trial, particularly if the completed trial 
fails to show a difference.  
There were a number of safety issues considered in the design of this study, but overall 
the trial has proven to be safe. Firstly, performing BAL in critically ill patients is not 
without risk. Patients had saturations monitored and recorded during BAL and 2 hours 
post-BAL. There were pre-defined criteria for AE to be recorded in relation to the BAL. 
These criteria were the same as those used in the validation study. A total of 43 AE 
based on these criteria were reported. Only 4 patients were recorded as having an AE 
during BAL (a drop in SaO2 of >5% or an absolute SaO2 level below 90% for >5mins). 
The remaining patients met the AE criteria for increased oxygen requirements 2 hours 
after BAL (an increase in FiO2 of ≥0.1 to maintain saturations within 3% of initial 
saturations). In retrospect these criteria may not have been fit for purpose in that it 
resulted in AE being recorded although they may not be considered important clinically. 
The main weakness is that this criterion is not one that is used clinically. It is not usual 
practice to ensure that saturations remain within 3% of starting saturations, with the 
FiO2 increased accordingly to achieve this. Similarly the FiO2 is not always titrated 
down after 2 hours to starting levels. This makes interpreting these values difficult but 
overall there was not clear evidence of harm from the BAL. Five SAEs were reported 
but these were felt not be related to the trial intervention and rather were a consequence 
of the critical illness the patients were suffering from. Furthermore a DMEC had 
oversight of the trial and did not raise any concerns over trial safety. 
There was also a concern during design in relation to asking clinicians to discontinue 
antibiotics early. There was a risk that if early antibiotic discontinuation were 
inappropriate, patients would come to harm from untreated infections. Measurements 
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that were taken to detect a signal of harm were the SOFA score at days 3, 7 and 14, in 
addition to mortality and length of stay end points. There was no difference in any of 
these outcomes between the trial arms, although since antibiotic use was the same, these 
findings are not unexpected. However previous trials suggest that encouraging earlier 
discontinuation of antibiotics is not only safe, it could also be beneficial(Fagon et al., 
2000; Singh et al., 2000; Hranjec et al., 2012; de Jong et al., 2016). An additional 
design concern in asking clinicians to discontinue antibiotics related to the risk of false 
negative biomarker results. The upper limit of the 95% CI for the PTP of the biomarker, 
based on the validation study, was 9.2%. Therefore some false negative patients were 
expected and 1 false negative occurred. Antibiotics were not discontinued in this 
patient, as antibiotics were given for an intra-abdominal source of infection and the 
patient had 0 AFD at 7 days. 
If the main trial analysis finds no difference between the trial arms, consideration will 
have to be given to why the trial was ‘negative’. An important distinction will have to 
be made between whether the intervention is not effective, whether there was a failure 
of implementation (the process evaluation will help with this), or whether the trial 
design was inadequate and not the correct design to answer the questions. It is possible 
that all of these reasons are factors. In terms of effectiveness, this study has shown that 
even when inclusion criteria aimed to select out a group of patients likely to benefit 
from the intervention, the number of antibiotic days at 7 days is still high and antibiotics 
were being given for a wide range of indications. Clearly a biomarker for VAP can only 
influence antibiotics for VAP and on the basis of these results we should not think of a 
clinical moment in which the suspicion of VAP is considered in isolation, but rather of a 
moment in which a complex decision must be made around suspected infection, where 
VAP is one possibility. It may be that the biomarker was not acceptable to the clinicians 
or that they did not have confidence in the test. Antibiotic prescribing in relation to 
confirmation of VAP by semi-quantitative culture would suggest that clinicians did not 
base antibiotic use on microbiology evidence, although we cannot be sure exactly what 
microbiology evidence the clinician was using in his/her decision making. If BAL is not 
routine in the ICU and the clinician is accustomed to using positive ETA culture results 
in the decision-making process, then he/she may be less trusting of BAL biomarker 
results. In this study clinicians’ pre-test suspicion of VAP had no relation to the 
microbiological diagnosis VAP. One possibility is that if the clinician’s pre-test 
probability is high, then clinical investigations (microbiology or biomarker results) may 
have little effect on the decision to prescribe antibiotics.  
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Antibiotic use was high at baseline and at day 7 and so to influence this is a significant 
challenge. If we consider other trials that have reported significant differences in 
antibiotic use, the PRORATA trial reported 3 days difference at 30 days(Bouadma et 
al., 2010). Similarly a trial of PCT-guided early discontinuations of antibiotics in VAP 
found a difference of 3 days at 28 days(Stolz et al., 2009). Using a 7-day time period 
and using days as the smallest unit of measurement required our trial to detect a greater 
proportional change. Although using frequency distribution of AFD in the 7 days aimed 
to make for a more sensitive analysis, it may have been more appropriate to measure 
individual antibiotic doses or DDD rather than days, as more sensitive instruments to 
detect change. 
One might ask whether this was the right trial to answer the question and how might the 
trial have been changed in retrospect? At the time of planning this trial, the design was 
approached in the framework of a simple intervention that would be tested by a RCT. In 
the final stages of the trial set up and during the recruitment period the complexity of 
the intervention became much more apparent. Greater consideration should have been 
given early in the planning stage to the complexity of the intervention and how the 
results would be interpreted. The process evaluation will go some way to answer some 
of these questions, but it is unlikely to give insights from a statistical and trial design 
standpoint. There would have been a strong case for carrying out a feasibility study 
and/or a pilot study. I used AFD data from the validation study to inform the power 
calculation for the RCT. A pilot study would have allowed for more detailed AFD data 
to be collected and would have given the opportunity to consider whether this was the 
most appropriate primary outcome measure. A feasibility study would have given an 
opportunity to test the inclusion and exclusion criteria. The high rate of antibiotics used 
for non-VAP indications would suggest that our criteria were not able to select the 
population we intended to include (ie. those most likely to benefit from the biomarker). 
A feasibility study could have also given an indication of accrual rate and how the 
intervention would fit in with clinical practice. It took 9 months to randomise 60 
patients, so pilot studies and/or feasibility studies would have required significant 
increases in time and resources.  
In summary, in this subgroup analysis, no benefit in terms of antibiotic use could be 
detected in a trial of a biomarker-based VAP exclusion. It must be stressed that this 
subgroup study is underpowered to detect a difference and the completed trial dataset 
must be awaited to make firm conclusions. This analysis does however highlight the 
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considerable challenge and complexity of conducting the trial, of the intervention itself 
and, most importantly, of the clinical environment that it the trial was conducted in. If 
the final results fail to show a difference in antibiotic use between the trial arms, it will 
highlight the challenge that remains in altering antibiotic use in ICU. Calls have been 
made for novel, rapid biomarker-based diagnostics for infections(Davies, 2011). 
Through the validation study, this was achieved, but whether the test will be accepted 
and implemented into clinical use remains a far more difficult question.  
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Chapter 5. Conclusions 
The importance of addressing AMR, and in particular through novel diagnostics, has 
been stressed in a number of government reports(Davies, 2011; O’Neill, 2016). It has 
been estimated that by 2050, 10 million people could die each year from the 
consequences of AMR as resistance continues to rise, with an estimated global cost of 
100 trillion US dollars(O’Neill, 2014). It is currently estimated that AMR costs 55 
billion US dollars to the USA, although this is thought to be a conservative 
estimate(Smith and Coast, 2013). 
Patients admitted to the ICU are at considerable risk of a poor outcome in terms of 
morbidity and mortality, as dictated by their critical illness. The role of clinician is to 
strive for their recovery and to protect them from (and treat the consequences of) 
hospital-acquired complications including infections. For all of these reasons, critically 
ill patients commonly receive a treatment that is a cornerstone of our armamentarium 
against disease, namely antibiotics. As AMR increases on a global scale, the clinician is 
faced with the challenge of treating presumed infections while avoiding unnecessary 
antibiotic use. 
Clinicians are justified to a significant degree in the rapid administration of antibiotics 
in the face of suspected infection. Data show that delay in the administration of 
antibiotics in patients with sepsis is associated with worse outcome(Kumar et al., 2006; 
Ferrer et al., 2014; Garnacho-Montero et al., 2015). In fact one study found that there 
was an associated increase in mortality if the recognition of sepsis and administration of 
antibiotics were delayed(Puskarich et al., 2011), providing further incentive to give 
antibiotics at the moment of suspected infection. Furthermore, outcomes for severe 
community-acquired pneumonia are shown to be better with early administration of 
antibiotics(Gattarello et al., 2014). The other side to this argument is that administering 
antibiotics at the point of suspicion may result in the overuse of antibiotics in patients 
who do not have a disease that would respond to antibiotics. Data on the use of 
antibiotics in the ambulatory setting shows that many patients receive broad-spectrum 
antibiotics for conditions that are unlikely to benefit from antibiotic treatment(Shapiro 
et al., 2014). Furthermore global antibiotic consumption is also increasing, including 
increasing use of antibiotics that should be reserved for the most serious and resistant 
infections(Van Boeckel et al., 2014). International and national guidelines for the 
management of sepsis recommend the early initiation of antibiotics for suspected sepsis 
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and in particular for severe sepsis(Dellinger et al., 2013; NICE, 2016). The unintended 
consequence of this could be the over-prescription of antibiotics and pressures to meet 
targets have already been associated with the overuse of antibiotics(Nicks, Manthey and 
Fitch, 2009). The challenge of balancing the need to treat infections versus the need to 
conserve antibiotic use is primarily a problem of diagnostics. We do not have tests that 
can confidently rule-in or rule-out infections rapidly. 
It has been outlined in this thesis that VAP is a common infection and reason for 
antibiotic use in ICUs. It also typifies the challenge of antibiotic stewardship. Many 
non-infectious and inflammatory conditions can mimic VAP in mechanically ventilated 
patients causing fever and changes on a CXR. The ability to rule out infection based on 
culture of pathogens is significantly limited by the time taken to culture organisms from 
respiratory samples. This work has aimed to address these limitations through the multi-
centre validation of a rapid biomarker-based diagnostic test and then through testing its 
clinical effectiveness to reduced antibiotic use in a RCT. 
It was outlined in the Introduction (section 1.10.3) that many biomarkers have been 
investigated for the diagnosis of VAP. Only one of these, to my knowledge, has been 
externally validated(Laupland, Church and Gregson, 2005). In this thesis I have 
described the results of a multi-centre validation study, which have shown that IL-1 
concentrations in BAL fluid in particular, if low, can exclude VAP with confidence. 
This diagnostic performance is made more robust with the addition of IL-8. As a further 
‘validation’ of these results, the biomarker performance appears to have been consistent 
in the RCT. This has answered the call for a rapid biomarker-based diagnostic test. It 
has a high sensitivity, which means it can exclude VAP confidently, and the expectation 
of the RCT was that it would allow antibiotics to be withheld.  
This biomarker test is based on BAL and a microbiology-based definition of VAP. The 
acceptability of this strategy is uncertain in routine clinical practice. Trials to determine 
whether an invasive or clinical diagnostic strategy is superior have given conflicting 
results (see Introduction, 1.6.3)(Fagon et al., 2000; Canadian Critical Care Trials Group 
et, 2006). Furthermore a meta-analysis did not support the use of an invasive strategy 
over a clinical strategy(Berton, Kalil and Teixeira, 2012). Updated guidelines for the 
management of VAP do not recommend invasive sampling methods(Kalil et al., 2016) 
and the use of BAL is not routine practice in UK ICUs(Browne et al., 2014). This 
biomarker assay moves away from the longstanding debate over invasive sampling 
versus clinical diagnosis, in that it is using invasive sampling to obtain biomarkers at the 
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site of pulmonary inflammation. However for it to be accepted clinically, BAL must be 
accepted as a strategy for VAP diagnosis. 
Following the successful validation of the biomarker test, I carried out a RCT to 
determine whether a biomarker-based exclusion of VAP would result in reduced 
antibiotic use in patients with suspected VAP. No reduction in antibiotic use could be 
detected in the analysis included in this thesis, although it does not include the complete 
RCT dataset. This raises interesting questions as to why no difference was found. The 
possibility of using a primary outcome measure that was not sensitive enough to detect 
a change has been discussed (Results: RCT, 4.14). However it is arguable that a 
clinically relevant change should be easily detectable. The RCT results would suggest 
that clinicians did not follow the recommendation to discontinue antibiotics but they 
also did not seem to discontinue antibiotics in the face of negative BAL microbiology.  
This intervention was tested alongside normal clinical practice but an alternative 
approach would have been to embed it in an antibiotic stewardship programme (ASP). 
Recommendations and guidelines for the implementation of ASP have been 
produced(CDC, 2014; NICE, 2015). ASP have multiple elements including educational 
tools; surveillance of antibiotic prescribing and AMR; organisational approaches such 
as creating the human resources to dedicate to ASP; and appointment of a single leader 
to take accountability of driving the ASP and to implement specific interventions(CDC, 
2014). Specific interventions include persuasive interventions such as audit and 
feedback, education and reminders; and restrictive interventions such as compulsory 
order forms, expert approval and antibiotic restriction(Davey et al., 2013). Embedding a 
novel diagnostic test in an ASP could have a significant impact on the size of the effect 
of the intervention. In a study using MALDI-TOF MS to rapidly identify Gram-negative 
blood cultures, the technology was able to identify the organism much quicker than 
conventional culture(Perez et al., 2014). Importantly, the results of the test were sent to 
infectious diseases-trained pharmacists as part of an antibiotic stewardship team. 
Changes to antibiotic prescriptions were then implemented via this individual, resulting 
in a more rapid optimal antibiotic therapy with improved clinical outcomes. In contrast, 
a trial using PNA FISH technology without embedding the intervention in an ASP did 
not find an improvement in time to optimal antibiotic treatment(Cosgrove et al., 2016). 
The biomarker assay used in my studies was based on CBA and was a manual assay 
that took the technician approximately 5 hours to complete. Most laboratory tests are 
automated and it is unusual for hospital biomedical scientists to perform such a hands-
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on assay. The application of this assay for clinical purposes in this trial was of course 
experimental. Considering the manual nature of the assay, it is not surprising that there 
were a number of assays in which the internal control did not fall into the required range 
and so had to be rejected. It was impractical for the technician to simply repeat the assay 
given the time taken to perform the assay. The clinical acceptability of a new 
technology is not just based on the clinician’s view. It would be hard to view the 
application of this assay, in its current form, in the context of the workflow of a busy 
hospital laboratory. Our industry partner, BD, will have to consider the further 
development of the assay. As a minimum it would need to be automated, but maybe its 
greatest impact would be to develop it into a point of care test. 
Understanding clinical behaviours and attitudes to antibiotic stewardship, infections in 
ICU, and management of VAP, would provide valuable insights into how antibiotic use 
can be reduced. Behavioural elements have been identified as factors affecting decisions 
to prescribe antibiotics, such as the time of day that the decision is made and ‘decision 
fatigue’(Linder, 2014). Exploring the clinical environment and context of decisions in 
the ICU through an ethnographic study has the potential to identify areas where 
antibiotic stewardship could be improved. It could also inform the design of future trials 
by ensuring that interventions are implemented in clinical practice in such a way as to 
have the greatest influence on behaviours.  
The consumption of antibiotics in the ICU is known to be amongst the highest in 
hospitals(Dumartin et al., 2010). However detailed information on antibiotic 
consumption in the ICU is limited. Empiric antibiotic prescription accounts for a 
considerable proportion of antibiotics used(Candeloro et al., 2012) and the duration of 
antibiotic courses varies (for example in bacteraemia)(Havey et al., 2013; Daneman et 
al., 2016). Antibiotic-free days at 28-days as an outcome measure in trials also 
varies(Bouadma et al., 2010; Young et al., 2013). Having a deeper understanding of 
prescribing practices in the ICU in a more general sense would allow areas for antibiotic 
stewardship to be identified. 
As I have alluded to above, embedding our biomarker test in an ASP may allow for a 
greater impact of the assay. A RCT may not necessarily be the best method to evaluate 
the impact of the intervention. A before-and-after study design may be more suitable for 
an intervention that aimed to have more wide reaching changes. This could include an 
educational programme on VAP management and antibiotic stewardship; reinforcement 
of the biomarker assay and encouragement to follow the recommendation; and 
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education and reinforcement of the use of semi-quantitative culture. An alternative 
outcome measure for antibiotic use could be the total antibiotic consumption over the 
time periods studied, rather than the duration of antibiotics for individual patients. 
In summary, this work has responded to calls to deliver rapid novel diagnostic tests for 
infections. To develop a novel biomarker assay for patients with suspected VAP 
represents a significant step forward for a group of the most vulnerable and critically 
unwell patients in the hospital. Despite the potential of our test to improve antibiotic 
stewardship in an environment in which it is urgently needed, we were unable to 
demonstrate a benefit for biomarker-based antibiotic use. However striving to meet the 
goal of better antibiotic stewardship remains a priority and this biomarker should play 
an important role in meeting that goal. 
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